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ABSTRACT
I. A method for the synthesis of lanosterol (Lanosta-8,24-dien-3p-ol) is developed
such that isotopes of hydrogen can be specifically introduced into the C-32 position of the
molecule. Lanosterol labeled with tritium in this way is suitable for use in recently
developed assay methods for lanosterol-14ox-demethylase, a P-450 enzyme responsible for
the common step in the synthesis of cholesterol and ergosterol from lanosterol. This
enzyme is known to be the target of an important class of anti-fungal drugs and therefore
has been the focus of considerable industrial, clinical and scientific interest. This synthesis
is the first to preserve both of the double bonds in the lanosterol molecule and thus provide
specifically labeled samples of the natural substrate for the mammalian and yeast enzymes,
and additionally provides access to new molecules modified at the C-32 position and
posessing the proper side-chain configuration. The synthesis is based on previous
syntheses of C-32-modified dihydrolanosterol (Lanost-8-en-30-ol) and significant
improvements to several literature methods are provided.
II. The inhibitor (20R)-20-(1,5-hexadiynyl)-pregn-5-en-31,20-diol has been
shown to be a mechanism-based inactivator of the cholesterol side-chain cleavage enzyme,
P-450scc, which is responsible for the conversion of cholesterol into pregnenolone in
steroidogenic tissues. Furthermore, this inactivator has been shown to covalently bind to
the protein during the course of this inactivation. These properties have been confirmed in
the present work. Preliminary studies towards the identification of the site or sites of
covalent linkage between the steroid inactivator and the putative active-site peptide(s) are
presented. Evidence suggests that the steroid is attached to the 42 tryptic fragment of the
protein which is believed to contain the heme- and substrate-binding domain. Technical
difficulties with further progress are analyzed. Studies with related mechanism-based
inactivators having only one alkynyl group (such as (20R)-20-(1-hexynyl)-pregn-5-en-
3P,20-diol), indicate that these molecules do not covalently bind to the protein.
Speculations on the chemical differences between the inactivation modes of these two
classes of molecule are discussed.
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III. The granulocyte protein, calprotectin, is extracted from an unusual matrix stone
(a large-volume, amorphous, soft kidney stone) and identified by N-teminal peptide
sequencing and immunochemical (ELISA) methods. This protein has recently been
identified with numerous inflammatory diseases including cystic fibrosis, rheumatoid
arthritis, psoriasis, and skin cancers. Additionally, calprotectin has been found to posess
considerable antimicrobial properties versus several important human infectious strains of
fungi as well as bacteria. Struvite kidney stones, which are strongly associated with
urinary tract infection, are analyzed for calprotectin content and found to contain the protein
in considerable amounts. Speculations on the origin of this material and its significance for
the process of renal lithogenesis are discussed and proposals for future research are
outlined.
Thesis Supervisor: Dr. William H. Orme-Johnson
Title: Professor of Chemistry
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CHAPTER 1
CYTOCHROME P-450 ENZYMES:
AN OVERVIEW
11
Preface
Chapters 2 and 3 of this thesis describe research on the investigation of P-450
enzymes, specifically, lanosterol 14ax-demethylase (P-4501 4DM) and the side-chain
cleavage enzyme, cholesterol 20,22-lyase (P-450scc). The properties and biological
importance of P-450 enzymes are summarized below to provide a context for the
subsequent discussion of the experimental work. There have been many recent and
comprehensive reviews of this field, so this discussion will be brief; the relevant reviews
are cited in the text.
Cytochromes P-450: Definition and Significance
The name "P-450" is woefully uninformative, and does nothing to convey a sense
of the catalytic versatility or biological importance of this class of enzyme. The name,
deriving from "Pigment 450 nanometers," arose to signify a peculiar spectroscopic signal
that serves as a unique thumb-print for the enzyme.(38) When samples containing the
enzyme are reduced with dithionite and treated with carbon monoxide (CO), an intense
band arises at or near 450 nm compared to dithionite reduced samples. (1 2' 29) Because of
this intense signal it is a fairly straightforward matter to detect even dilute samples
containing P-450's and this has contributed to the intensity of research in this area ever
since its discovery. First noted in mammalian liver microsomes, it became apparent that the
enzyme, like the other cytochrome pigments, contains heme (i.e., an iron porphyrin).( 38 )
The heme in P-450 enzymes is non-covalently bound and differs from other heme-
containing proteins in that one of the iron ligands, perpendicular to the plane of the pyrrole
nitrogens of the heme, is cysteine thiolate. This cysteine is responsible for the unique CO-
mediated spectral signal.(4 9)
Prior to the discovery of P-450's, it was recognized that CO could inhibit the
metabolism of steroids in adrenal cortex, (43 ) and this led to the discovery that P-450's are,
in fact, the terminal oxidases of microsomal electron transport chains leading to steroid
hydroxylation.(l0) Not long afterward a second independent function was discovered,
namely the oxidation of exogenous substances in the liver.(7)
The distribution of P-450's in biological systems is exceptionally broad. In
mammalian species, P-450's are found wherever steroids are synthesized (adrenal, corpus
leuteum, placenta, testes, ovaries, etc.) and in the liver, where the catabolism of
endogenous and exogenous substances takes place, as well as in lung and intestinal
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tissue.(19) Furthermore, P-450 enzymes have been characterized in bacteria, fungi, corals,
echinoderms, plants, insects, mollusks, fish and avians.(2' 8, 18, 28, 37) There is every
reason to believe that P-450's are nearly ubiquitous in all organisms, and the comparative
study of P-450 genes (collectively characterized as a "superfamily") among species has
become a significant field of research.(13)
With the exception of the bacterial enzymes, P-450's are associated with
membranes; in mammals, those of the microsomal fraction in liver tissue and mitochondria
in steroidogenic tissues. This fact has made the characterization and study of mammalian
P-450's challenging. No membrane-bound P-450 has yet been successfully analyzed by
X-ray crystallography. Although crystals of the side-chain cleavage enzyme have been
grown, they have, thus far, been of low quality as judged by spectrophotometry which
indicates a significant portion of the protein exists in the denatured "P-420" form.(2 7)
As mentioned above, P-450 enzymes can be divided into two groups, based on the
type of molecule on which they act: endogenous or exogenous. P-450's acting on
endogenous compounds in mammals are generally biosynthetic and are primarily involved
in the formation of cholesterol and the steroid hormones (see introductions to chapters 2
and 3), although they also function in the biosynthesis of vitamin D, fatty acids,
prostaglandins, bile acids and perhaps other endogenous compounds. (1 8' 25, 44) Yeast
also possess at least two P-450's involved in the biosynthesis of the fungal steroid
ergosterol. ( 52 ) P-450's may also be involved in the specific catabolism of endogenous
compounds, although these pathways are less well understood. In plants there are many
examples of P-450 enzymes involved in the biosynthesis of natural products such as amino
acid derivatives (p-coumaric, caffeic and sinapic acids), fatty acids, flavinoids (apigenin,
pisatin, marmesin and psoralin), and terpenoids (phaseic acid, kaurenoic acid and
digitoxigenin).(8) The possible roles for P-450 in the oxidation of bacterial natural products
(especially terpenoids, which are first cyclized as hydrocarbon products which are often
further elaborated by oxidation) have not been thoroughly evaluated. These P-450's are
characterized by high substrate specificity and regioselectivity of catalytic action.
Generally, only a single, specific atom is oxidized among many chemically equivalent sites.
P-450's acting on exogenous compounds possess quite different properties.
Adapted, as they are, to the detoxification of many different exogenous chemicals, hepatic
P-450's are not specific for a particular compound, but rather, groups of compounds with
similar molecular shapes. Detoxification is arranged by making fat-soluble compounds
with low solubility in the aqueous serum and urine more water-soluble by using successive
hydroxylations, de-alkylations and other oxidative chemistry. Without this process, these
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fat-soluble chemicals could build up in the membranes and fatty cells of the body to
dangerous concentrations. It has been found that individuals express multiple hepatic
P-450's which have somewhat overlapping substrate specificities. In this way evolution
has arranged a system that can act on a general class of compounds including new
chemicals such as man-made pesticides, that no previous member of the species has ever
encountered. The only limitation to this activity is that these P-450's must not act on
natural endogenous compounds indiscriminately; these activities have surely been screened
out by natural selection. (This is in contrast to the other major mammalian defensive
mechanism, the immune system, in which a nearly infinite selection of specific agents is
screened by each individual to eliminate antibodies which react with the "self." ) The
distribution of these multiple hepatic P-450 genes is not uniform throughout a species,
there is considerable inter-individual variation in the suite of genes carried and the
regulation and expression of these genes.(19) This variability explains in part a long noted
individuality in the response of human patients to drug treatments as well as the sensitivity
of some individuals to certain chemicals at levels much lower than the norm.( 30 ) The
interaction of pharmaceuticals with various P-450's is a major concern of drug researchers
and manufacturers, as inopportune "detoxification" of the active form of a drug can reduce
the amount of time the drug stays at a useful level in the blood stream, thereby requiring
more frequent treatments or larger doses, and risking increased side-effects. (9' 26)
Alternately, determination of the biochemical mode of action of a drug may depend on
knowledge of the activity of P-450's on the compound because the form administered may
not be the active agent.
As has been realized from nearly the first report of this type of P-450, while
carcinogens and mutagens can be inactivated by P-450 enzymes, essentially non-toxic
compounds can also be "activated" to carcinogenic or mutagenic forms by the very same
enzymes. (1 4 ) Thus the study of P-450's has been intimately linked to the study of cancer
as well as chemotherapy.(16)
Bacteria seem to possess similar types of relatively broad specificity P-450's that
act on exogenous substances. Apparently, the role of these P-450's is not the
detoxification of non-polar compounds, but rather it is the first step in the use of these
compounds as sources of carbon. Bacteria seem to use P-450's as digestive enzymes
when they find themselves in environments high in hydrocarbons and low in carbon
sources that are easier to digest. Examples include the camphor and linalool hydroxylases
of Pseudomonas putida. Several species have P-450's which act on simple linear alkanes,
as do several yeast species. Generally these enzymes are not constitutively expressed, but
are induced by the conditions of the medium in which they are growing. It is possible
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however, that these enzymes have another biological role entirely and have only been
selected for such a digestive role by the manipulations of researchers growing these strains
on unusual carbon sources. (2 4 7)
The P-450 Catalytic Cycle
Much of what is known about the catalytic cycle of P-450 enzymes is based on the
studies of the camphor hydroxylase from Pseudomonas putida (P-450cam). Thanks to this
enzyme's soluble nature, it was the first of this class to by crystallized and studied by X-
ray crystallography. Many of the biophysical experiments that have been performed to
investigate the catalytic mechanisms of P-450's in general have focused on P-4 50cam
because of the insights to be gained from comparison with the available three-dimensional
structures. A schematic of the P-450cam catalytic cycle, as it is now understood, is shown
in Figure 1. In brief, the steps of the cycle are as follows: 1) substrate (S) binds to the
enzyme in its resting state where the iron is in the ferric (3+) state; 2) a protein electron
carrier (in P-450cam, putidaredoxin) reduces the heme iron to the ferrous (2+) state; 3)
Oxygen binds to the iron atom; 4) a second electron is delivered yielding a highly unstable
intermediate which 5) rearranges, splitting the oxygen-oxygen bond with the addition of
two protons and releasing one oxygen atom as water (the timing of this release is unclear);
6) the remaining oxygen bound to the iron acts on the substrate with the formal insertion of
the oxygen into a carbon-hydrogen bond, forming an alcohol; 7) product release
regenerates the resting state of the enzyme. Each of these steps is discussed in detail
below.
In the resting state of P-4 50cam the iron is low-spin ferric state and the sixth ligand
position is filled by water or a hydroxide. Binding of the substrate results in the
displacement of the sixth ligand and rearrangement of the iron ligand field from an
octahedral geometry to square pyramidal. This rearrangement has two effects: first, the
spin state changes from low-spin to high-spin, and second, the reduction potential of the
protein is raised from -300 mV to -170 mV, allowing rapid electron transfer from the
biological reductant, putidaredoxin. In effect, this acts as an electron gate, only allowing
reduction of the heme after the substrate has bound (Scheme 1).
The high-spin ferrous heme formed by this reaction then rapidly binds dioxygen
forming a low-spin, hexacoordinate complex. The ferrous dioxygen complex is somewhat
stable and has been isolated and characterized spectroscopically. Stopped-flow
spectrophotometry of the rat liver microsomal P-4 50 LM2 indicates that the initially formed
ferrous iron-dioxygen complex (k > 1000 s-1) is converted to the form observed in the
15
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Figure 1: Generallized P-450 catalytic reaction cycle;
individual steps are discussed in the text. A schematic of the iron
ligation in the resting state of the enzyme is at the center.
(after Guengerich, Crit. Rev. Biochem. Mol. Biol., 25, pp. 97-148, 1990)
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Scheme 1: Proposed heme conformational change on substrate binding
in P-450ca,, and its effect on the subsequent reduction by Putidaredoxin
steady state with a rate of 210 min-1.(20) Studies of this steady state complex by MOssbauer
spectroscopy indicate that the iron is in a state similar to that of oxyhemoglobin. (4 6 ) These
observations suggest that the steady-state electronic structure of this intermediate is best
described as a ferric superoxide complex (Scheme 2). At this stage the overall charge on
the complex is -1 (Fe = +3, 02- = -1, heme = -2, thiolate = -1). This complex is the final
one that can be isolated and studied spectroscopically because subsequent steps are
exceedingly rapid. After this stage in the mechanism, all information about the structure of
the intermediates has been gained indirectly from comparison with other heme proteins,
model compounds, and the products of P-450 catalysis.
The chemically active oxygen intermediate is generated by the addition of a second
electron and two protons into the system. Through these additions one of the oxygens of
the bound superoxide anion is converted to water and released. However, this is only
known to be true because of the overall stoichiometry of the reaction; it is not known if the
oxygen atom is converted directly to a molecule of water by protonation and elimination,
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the simplest mechanism (Scheme 3a), or by another avenue. Other possibilities include
dioxygen bond cleavage via acylation of the terminal oxygen atom by an active site
carboxylate, or formation of a cyclic peroxoiron which is the active species which forms
water during the hydroxylation chemistry (Scheme 3b and c). Ortiz de Montellano
argues(3 9) that although there is no concrete evidence to support any of these possibilities,
the acyl-intermediate hypothesis should be ruled out because no carboxylic cofactors are
required for any known P-450's, the crystal structure of substrate bound P-450cam does
not indicate any acylating functional group in the active site (41 ) and dioxygen bond cleavage
in peroxidases and metalloporphyrin models does not require any acylating group.
Furthermore, the cyclic peroxo-structure should be ruled out because model compounds
with similar structure are chemically unreactive and, because P-450's can be made to turn
over to identical products using the single oxygen atom transfer reagent iodosobenzene, the
active intermediate most likely contains only one iron-bound oxygen atom. Therefore, in
the absence of compelling evidence to the contrary, the simple protonation-elimination
scheme (3a) should be used as a working model.
What, then, is the working model for the actual oxidizing equivalent of cytochrome
P-450? Assuming that water has indeed left from the complex, we can tally up the
electrons in the complex as follows: direct removal of H20 from the doubly protonated
ferrous superoxide species would leave the proximal oxygen bearing two lone pairs and
one-half of the shared pair with iron to give 5-electrons and a positive charge; the iron
would still be ferrous with two positive charges. Adding in the heme and thiolate ligands
gives an overall neutral charge on the complex (this checks with the previous calculation of
-1 charge on the ferric superoxide intermediate since 1 electron and 2 protons have been
added while neutral water has left). This is only a formal counting and not meant to
suggest that the 5-electron oxygen atom is a stable configuration for the system. In fact, it
is only one of quite a few
18
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possible electronic configurations that must be considered. The basic configurations
include [Fe2+][0+], [Fe3+][O], [Fe4 +][O-] and [Fe5+][0 2 - ] (Scheme 4, 1-).* In
addition, there exists the possibility that one electron can be drawn in from the porphyrin
ligand to give a heme cation radical as is observed in "Compound I" of peroxidases (see
below) yielding [P+][Fe 3+][O-] and [P+][Fe 4+][O02-] (Scheme 4, 7 and ) to round out the
list.
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Scheme 4:
iron-oxygen
Possible electronic configurations for the P-450
atom complex responsible for substrate activation
* At this time it is important to discuss the various conventions in the depiction of iron oxygen
complexes. It has been common in the literature to refer to an [FeO] 3 + complex with the shorthand figure
[FeV=O]. This formalism can be confusing if one concludes from it that the oxygen, as if it were in a
carbonyl, was equally sharing two electron pairs with the iron and possessed only two lone pairs (and thus
would be at an oxidation state of 0, not -2). This use of the double bond symbol represents the donation of
two lone pairs to the metal, since, in inorganic chemistry, all usual oxygen atom ligands to metals are
"oxo" and at the -2 oxidation state. This figure has found wide use in the metalloprotein literature because
it appears to be an adequate representation of the properties of Compound I and II of peroxidases. As will
be discussed in the main text, however, it very likely is a poorer representation of the electronic properties
of the P-450 iron-oxygen complex, and it will not be used in this discussion. In its place, a single-headed
arrow will be used to represent the donation of one lone pair, while a single line always represents a shared
bond.
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Several heme-containing protein systems have iron-oxygen intermediates which are
stable enough to characterize spectroscopically and have been discussed as models for
P-450. The peroxidases are heme-containing enzymes which catalyze reduction of
peroxide to water with the accompanying oxidation of various organic substrates. The fifth
ligand in peroxidases is the imidazole nitrogen of a histidine residue instead of the cysteine
thiolate found in P-450's. Peroxidases, like P-450's, have iron-oxo intermediates, denoted
Compound I and Compound II (I is reduced to II by the addition of an electron). There is
considerable evidence from Missbauer, magnetic susceptibility, electron absorption, NMR
and X-ray absorption methods that Compound I of horseradish peroxidase is composed of
a "ferryl" iron (FeIV) and a heme n-cation radical. The oxygen, then, has a complete octet
(02-, Scheme 4, 8). EXAFS methods show the iron-oxygen bond length to be short (at
1.65A), indicating considerable double bond character. (Thus, configuration 8 might be
even more accurately represented with two dative bonds from oxygen to iron.) Compound
II is quite similar, lacking only the heme nT-cation radical. Studies of cytochrome c
peroxidase show that this enzyme differs mainly in the presence of a protein-centered
radical instead of the heme-centered radical in Compound I. The catalases have a tyrosine
fifth ligand but have very similar spectroscopic properties to the peroxidases. Although
they have no naturally occurring Compound II-like state, the Compound I-like state of
catalase is almost identical to that of the peroxidases. Finally, chloroperoxidase, which has
a thiolate fifth ligand like the P-450's (but a peroxidase-like polar heme environment), also
achieves a Compound I-type iron-oxo complex, although the electronic ground state seems
to be different from the peroxidases and catalases. (1)
The iron-oxygen complex in P-450 enzymes must be distinctly different from these
systems to explain the powerful chemical reactivity it possesses and the extremely short
lifetime of its intermediate forms. Nevertheless, the seeming uniformity of [FeO]3 +
complex structures among the three related enzyme types, including the thiolate-containing
chloroperoxidase, suggests that the difference may not be large. As will be discussed in
the next section, the overwhelming evidence concerning P-450 chemistry suggests that
radicals are involved. All of the electronic structures under consideration here have an odd
number of electrons, and thus are capable of the one-electron oxidations and proton
abstractions that characterize P-450 chemistry. The question is, which configurations place
unpaired electron density on the oxygen atom where it can initiate the chemistry?
The Compound I intermediate (e.g. Scheme 4, 8) places the radical on the
porphyrin. This is appropriate for peroxidase, for instance, since electron transfer to
organic substrates is believed to take place at the heme edge in this system. For P-450,
however, it seems unlikely that an oxygen with a full octet and bearing a -2 charge will be
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involved in radical chemistry. The hydrophobic nature of the P-450 heme pocket differs
markedly from the environment of the other oxo-iron enzyme systems; very likely this
environment favors a less electron-rich oxygen, disfavors the ionic ir-cation radical, and
high-valent iron oxidation states (note also that the total charge on the P-450 complex is
neutral, while in peroxidase it is +1). Champion has suggested that the cysteine thiolate
contributes significant extra electron density to the iron through n-bonding between the
S(sp 2) and Fe(dir) orbitals. By thus occupying the dir-orbitals, the corresponding overlap
between the oxygen lone pairs and the dn-orbitals is decreased, as is the iron-oxygen bond
order.(6) This should result in a slightly longer Fe-O distance, and theoretical calculations
have indicated that a longer distance stabilizes an oxy-radical species which lies within 0.7
kcal/mol of the Compound I-like ground state.(3 2) Champion further suggests that the
Compound I electronic configuration (e.g. Scheme 4, 8) is in equilibrium* with this low-
lying oxy-radical state ([Fe4 +][0-], seven electrons on oxygen, e.g. Scheme 4, .6) in all of
the iron-oxygen heme enzymes, the differences arising from the position of the equilibrium
constant. In peroxidase and catalase, the Compound I form is strongly favored. In
chloroperoxidase the cysteine thiolate alters this balance only slightly. But in P-450, with a
non-polar environment and a cysteine thiolate, the oxy-radical is strongly favored (Scheme
5). Of course, this remains a topic wide open for differences of opinion; in particular,
some may prefer the ferric iron-oxygen atom complex [Fe3+] [0] which would be expected
to be a stronger radical reagent because of its weaker dipole (e.g. Scheme 4, 5).
Based on the observations of stereochemical scrambling ( 45) and high intrinsic
isotope effects,(l5) it has been proposed that the initial step in aliphatic carbon atom
hydroxylation is a radical hydrogen atom abstraction to give an iron-bound hydroxyl and a
carbon-centered radical. This radical then recombines with the oxygen (dubbed the
"rebound" mechanism), generating the hydroxylated product and the ferric iron resting state
of the enzyme (Scheme 6). The rate of this radical recombination has been estimated by the
observation of partitioning between hydroxylation and radical ring opening in strained
systems whose intrinsic ring opening rates are known. This method is known as the
"radical clock." Although the ring opening of methylcyclopropane was not observed (ring
opening rate = 108 s-l), partitioning was observed in the bicyclo[2.1.0]pentane system,
indicating a recombination rate on the order of 1010 s-1.(40) There are now many examples
of reactions that could only result from the initial formation of substrate radicals, some of
which are presented below.
* The difference between discrete chemical states in equilibrium, which implies a difference in atomic
configuration and an energy barrier between the states, and resonance among electronic configurations in
this system is a point for further debate.
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(After Champion, JACS, 111, p. 3433-3434, 1989)
His H
N
R R2
X 
R1I R2
H 
:O: OH
Fe, Fe
N N N 
/S /SCys Cys
RX R2
H OH
NX N
/ Fel /
I
/SCys
Scheme 6: Radical rebound mechanism for
aliphatic hydroxylation by P-450
23
:0:
I
.,,I
Cys
I
I
P-450 Chemistry: scope of reactivity
There is a delicate balance in P-450 catalysis between the reactive oxygen-iron
center, the chemical structure of the substrates and the steric constraints of the various
enzyme active sites that results in a very wide variety of reaction types. Although the
oxygen "rebound" mechanism is adequate to describe the chemistry of a large number of
P-450 reactions, there are classes of reactions for which it is clearly incomplete. The
salient factor that binds all of the observed chemistry is the ability of the reactive species to
abstract hydrogen atoms or, if no hydrogen atom is available or the reduction potential of
the substrate is particularly high, perform one-electron oxidations. For instance, if the
binding of a substrate does not place any protons close enough to the activated oxygen,
electron transfer, which can occur over longer distances, may take place.(2 1 ) The
subsequent chemistry of these substrate-radical species is governed by several factors: the
intrinsic recombination rate (a property of the metallo-center and the distance separating it
from the substrate radical), the number of atoms over which the substrate-radical can
delocalize (a property of the substrate) and finally, the intrinsic rates of the pathways for
rearrangement of the substrate radical (a combined property of the substrate and the active
site of the protein which binds it in a particular, perhaps strained, conformation). With this
rationale in mind, the remarkable diversity of P-450 reactions presented below should seem
less surprising.
Under "basic reactions" (Scheme 7) are listed the building blocks which underlie
many P-450 reactions. The addition of oxygen to carbon is listed separately from the
heteroatomic reactions because they are believed to proceed through distinctly different
mechanistic intermediates. The typical rebound mechanism is in effect for carbon atoms,
but nitrogen hydroxylations are believed to involve a three-step sequence involving initial
]-electron oxidation followed by proton transfer and hydroxyl radical rebound. This
mechanism is suggested by the partitioning of some systems between nitrogen
hydroxylation and dealkylation (see below). In the formation of N-oxides and sulfoxides,
where no hydrogen atoms are involved, electron transfer from the heteroatom is followed
by oxygen atom transfer. Aliphatic hydroxylations are typical of the steroid hydroxylases,
while the heteroatomic oxidations have been characterized in the metabolism of heteroatom-
containing drugs and toxins such as amphetamine and pyridine. In addition to the
hydroxylamine and N-oxide forms shown in Scheme 7, P-450's can catalyze the formation
of nitrones (C=NR--O), oximes (C=NOH), nitroso- (RN=O) and nitro-compounds
(RNO2).(36)
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Olefin epoxidation is a distinct reaction type which is also found in reactions with
aromatic and acetylenic carbon atoms, forming intermediate oxarenes and oxirenes,
respectively, preceding rearrangement. Reactions of this type are believed to be initiated by
the formation of a nr-complex, but proceed through 1-electron steps to either a radical cation
or a radical o-complex, leading to products.(2 1) However, the exact nature of multiple-
bond oxidations by P-450's remains controversial. The action of P-450's on acetylenic
compounds has received much attention due to the apparent formation of electrophillic
species which act as "suicide" inactivators. These will be discussed in detail in Chapter 3
which concerns the action of such an inactivator on the side-chain cleavage enzyme.
Dehydrogenation reactions are examples of P-450 reactions in which no oxygen
atom is transferred to the product. An initial proton abstraction is followed by either a
radical [5-elimination or electron transfer to form a carbocation which eliminates via an E1 -
like mechanism. P-450-mediated desaturation of alkanes (X = H) has been suggested in
the microsomal metabolism of lindane (hexachlorocyclohexane) and testosterone, (4 0) and in
the biosynthesis of ergosterol by yeast species,( 24) and has been conclusively shown in the
metabolism of the anti-epileptic drug, valproic acid. (42 ) It is likely that many more
examples of this mode of reactivity will come to light in the future; a recent report suggests
that fatty acid desaturases may be P-450 enzymes(4) and the P-450-mediated lyase activity
in the synthesis of psoralin (Scheme 8) can be understood as an P-elimination of an
isopropyl radical.( 51 ) The P-450-mediated oxidation of alcohols to ketones or aldehydes
has also been proposed to involve desaturation in some cases. The oxidation of
epitestosterone to androstenedione, for instance, was found to proceed without the
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Scheme 8: A possible mechanism for the P-450-mediated
biosynthesis of psoralin from (+)-marmesin.
(Adapted from Hakamatsuka, Tetrahedron, 47, p. 5969-5978, 1991)
introduction of any 180 from 1802, while the oxidation of testosterone was found to
involve the gem-diol mechanism discussed below, with concomitant incorporation of 180.
The peroxidation of aliphatic carbon atoms is relatively rare, but peroxo-attack on
carbonyl carbons appears to be more common (see below). The chemistry of P-450-
supported peroxide chemistry has been reviewed.(3 5 )
The "elaborated" reactions (depicted in Scheme 9) are those in which the initial
oxidation event is believed to be one of the basic types, but further rearrangement (or
reaction of that product) disguises the underlying chemistry. One mechanism for the
oxidation of alcohols to aldehydes or ketones is merely the hydroxylation of a carbon
already bearing an alcohol; the resulting product is a gem diol, a hydrated carbonyl. The
most well-known examples of this reaction are the second step in the 14-demethylation of
lanosterol by 14(-demethylase and the second step in the 19-demethylation of
androstenedione by aromatase (see below, and references in the following two chapters).
A special case of this type of reaction is the oxidative cleavage of esters in which, instead of
OHW leaving from the tetrahedral intermediate to form water, a carboxylate anion leaves to
form an acid [R1CH 200CR 2 -- R 1CH(OH)OOCR 2 - R 1 CHO + R 2COOH].( 2 2 )
Similarly, heteroatom de-alkylation, oxidative deamination and dehalogenation are
examples of hydroxylations followed by elimination from a tetrahedral intermediate
(Scheme 9, reaction 2). These types of reactions are numerous in the area of xenobiotic
metabolism.(17)
Aromatic hydroxylation is an elaboration of oxygen insertion into double bonds.
Rearrangement of the intermediate oxarene to the phenol requires the 1,2-migration of one
of the two groups adjacent to the oxygen on the aromatic ring (Scheme 9, reaction 4, R2),
this has been called the "NIH shift" and has been observed using deuterated aromatic
compounds, as well.(3 9) The final reaction depicted is an enzymatic version of the Baeyer-
Villiger rearrangement in organic chemistry. Here, a putative heme-iron bound peroxide
acts as a peracid equivalent. Notable examples of this reaction are found in the final step of
the 14cx-demethylase sequence(ll) and (possibly) in the 17,20-lyase reaction forming
androstenedione from progesterone.( 3 3) In the case of aromatese, however, the
intermediacy of a formate ester has been ruled out.(16 2 ) Hepatic P-450's have also been
found which catalyze this reaction on cyclohexanecarboxaldehyde. ( 5 0)
The reaction sequences of 14(x-demethylase and the side chain cleavage enzyme
(the topics of Chapters 2 and 3) are shown in schematic form (in Scheme 10) as examples
of P-450's which act multiply on single substrates to effect even more elaborate chemistry.
The demethylase pathway includes hydroxylation, dehydrogenation (via the gem diol),
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Baeyer-Villiger oxidation and (x-elimination. The side-chain cleavage reaction sequence
illustrates yet another activity, glycol cleavage.
In Scheme 11, four examples of P-450-initiated radical reactions and
rearrangements are presented. Reaction la, a ring expansion, represents only one of
several ways that cyclobutylamines can react with P-450, others include hydroxylation,
ring opening and covalent modification of the heme.(3) Similar reactivity is found with
cyclopropylamines. One of the strongest proofs of an electron abstraction mechanism for
heteroatom oxidation is reaction 1 lb in which 1,4-dihydropyridines are oxidized to
pyridines with the expulsion of hydrogen and alkyl radicals.( 3 1) Reaction 1 lc shows the
proposed mechanism for the P-450-mediated rearrangement-hydroxylation of liquiritigenin
to 2,7,4'-trihydroxyisoflavanone which is subsequently dehydrated to give isoflavone, a
parent compound for many plant isoflavanoid phytoalexins having antimicrobial
activity.(23) The final reaction, ld, the biosynthesis of a gibberellin (GA12 aldehyde)
from ent-hydroxykaurenoic acid has been tentatively proposed to be P-450 mediated and
involves a ring contraction and an overall alcohol dehydrogenation.( 23)
Finally, Scheme 12 shows three examples of a novel mode of P-450 action
involving the radical rearrangement of alkyl peroxides. In reaction 12a, the hydroperoxide
(derived from lipoxygenase action on linoleic acid) is transformed into an allene oxide by
allene oxide synthase, isolated from flax seed. The reaction is formally a dismutation as
one atom of the peroxide is reduced to water, while the other is oxidized to the allene oxide.
Allene oxides are unstable and, in this case, it was detected by the isolation of its
decomposition products, an xt-ketol, a y-ketol and a cyclopentenone (tl/2 decomposition 9s
at 10 C, pH 7). Flax seed contains an allene oxide cyclase which specifically catalyzes the
conversion of this transient compound into a precursor of the plant growth regulator,
jasmonic acid. Allene oxides are also known in several species of marine invertebrates. (48 )
Similarly unusual are the reactions of thromboxane (TXA) synthase and prostacyclin (PGI)
synthase (reactions 12b), both of which act on the prostaglandin endoperoxide (PGH 2). (25 )
In all of these reactions the chemistry is initiated by the homolytic cleavage of a peroxide by
iron and the subsequent rearrangement is apparently controlled by the precise conformation
of the bound substrate. It is notable that in this class of reaction no dioxygen or reducing
equivalents are required; these are provided entirely by the substrate. Accordingly, the
rates of these reactions are significantly faster than the ordinary type of P-450 mechanisms.
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Conclusions
It is clear from the above discussion that, as a versatile catalyst, the combination of
dioxygen, heme- and thiolate-ligated iron, reducing equivalents and a conformationally
restricted hydrophobic protein binding pocket is impressve. The power of P-450 enzymes
to activate unfunctionalized carbon atoms regio- and stereospecifically is particularly
attractive to chemists interested in the development of new oxidative catalysts for organic
chemistry. The development of biomimetic catalysts with oxidative and molecular
recognition properties similar to P-450 has become a significant sub-field,( 3 4) while others
have attempted to use P-450 enzymes as organic chemical catalysts directly.(5) The
prospects for the large-scale production of fine chemicals by the use of P-450-expressing
bacteria and fungi (natural and recombinant) are considerable. In fact, the raw materials for
such applications, microbial P-450's, are one of the fastest-growing segments of the P-450
superfamily genetic list. The genetic engineering of P-450-containing microbes designed to
cleanse the environment of toxins and pollutants is also a distinct possibility.
The study of P-450 enzyme catalysis has mainly focussed on the bio-inorganic
aspects of the system in the determination of the basic chemical mechanisms. However, it
seems that the contribution of the substrate binding pocket to the course of catalysis to
particular products is critical. The information desired is: in what conformation and with
what relative orientation will a particular substrate bind to a particular P-450 enzyme? Of
course, with most P-450 enzymes presently unavailable for study by X-ray crystallography
and too large for NMR techniques, this presents a considerable challenge to researchers
interested in characterizing these interactions.
As the number of known P-450 gene sequences increases (and it is very difficult to
guess what the eventual total will be) the possibilities for determination of P-450 structure
by comparison with the soluble, crystallizable, forms and the use of computer-based
methods become more feasible (see introduction to Chapter 3). In addition, the
determination of the amino acid residues lining the active site of P-450 enzymes by
chemical means with mechanism-based inactivators should aid in this process. Finally,
genetic manipulation of P-450 sequences by various directed and combinatorial
mutagenesis methods to modulate the substrate specificity should, in the future, be an
important method in the investigation of these matters and the development of new catalytic
activities.
Considering the nearly ubiquitous distribution, variety and importance of
biochemical roles, and diversity of genetically related sequences, it seems likely that the
study of P-450's will become even more important to the fields of bioorganic chemistry,
molecular evolution, molecular recognition, pharmacology and toxicology as technical
difficulties continue to be surmounted.
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CHAPTER 2
THE SYNTHESIS OF SPECIFICALLY ISOTOPE-LABELED
LANOSTEROL FOR THE ASSAY OF
CYTOCHROME P-45014DM
(LANOSTEROL 14oc-DEMETHYLASE)
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Introduction: The study of P-450 14a-Demethylase
General Background
The motivator for this research is the P-450 enzyme, lanosterol 14-demethylase,
which is responsible for the oxidative removal of carbon 32 from the quaternary position
14 of lanosterol (see Scheme 1)*. To answer the question "Why?" requires a somewhat
broad foray into biochemistry, specifically the areas of bio-organic (or natural products)
chemistry and pharmacology. Lanosterol (and the closely related compound cycloartenol in
plants) holds a central position in the biosynthesis of steroids. The distinctive tetracyclic
ring structure of all steroids first arises in these molecules from the linear precursor,
squalene (see Figure 1). Steroids are widely distributed throughout the natural world.
They are synthesized by all animals,( 143) plants, (6 4) sponges ( 46) and fungi. (154) Some
bacteria and other unicellular organisms are also capable of steroid biosynthesis.
Organisms such as mollusks and insects obtain their steroids from their diet. Clearly, these
molecules have, from extremely ancient times, evolved indispensable roles in the
processes of life. Although the conventional wisdom of public discourse may only
recognize "steroid" as referring to certain controlled substances, these chemicals are
relevant to our daily lives, from the ubiquitous reports on cholesterol in diet and disease to
the birth control "pill" and the sex hormones testosterone and estrogen, from the anti-
inflammatory drug cortisone to anti-asthmatic breathers and other chemotherapeutics.
With very few exceptions, all steroids in nature are modified such that the methyl
group attached to carbon- 14 of lanosterol (or cycloartenol) is replaced by a hydrogen atom.
This process is mediated by 14c-demethylase. In mammals, this begins a 22-step
enzymatic cascade that results in the formation of cholesterol. Cholesterol, then, is further
* Notes on steroid nomenclature: The steroid nucleus is composed of four rings which are denoted A
through D from left to right as pictured in Scheme 1. The molecule is roughly planar, and thus a
distinction can be made between the two "faces" of the molecule. By convention, the axial methyls at C-10
and C-13 (C-19 and C-18, respectively) are said to be on the -face, and the methyl group at C-14 (C-32) is
said to be on the a-face. Proper names are based on the carbon skeleton having the same number and
configuration of carbons. Thus, a steroid lacking the 4a, 43, and 14a carbons of lanosterol would be
named based on "cholestane", while a similar molecule having an additional carbon at position 24 would be
named based on "ergostane". Double bonds are referred to either as numbers imbedded in a name preceding
"ene" or, less formally, with a "A" followed by a number preceding a common name. For instance, for a
particular isomer of lanosterol; Lanosta-7,24-dien-3[-ol or A7 -lanosterol. Solitary double bond numbers
always refer to bonds from the carbon enumerated to the next one in sequence; double bonds between
carbons not in sequence are denoted by a second number in parentheses. For instance, A7 -lanosterol refers
to a double bond between carbons 7 and 8, while A24 (2 8 )-ergosterol refers to a double bond between
carbons 24 and 28 in the side-chain.
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modified to yield all of the various steroid hormones found in these organisms. In plants
cycloartenol is generally converted into sitosterol (24xc-ethylcholest-5-enol), and in many
fungal species 24-methylene-24,25-dihydrolanosterol (or lanosterol itself in yeasts) is
converted to ergosterol (243-methylcholesta-5,7,22-trienol, see Figure 1). Fungi and algae
have considerable heterogeneity in the identity of their sterols from species to species; with
only rare exception, however, all posess 14x-demethylases. (1 5 4)
A considerable attraction to the study of this enzyme is its chemistry. Like the
cholesterol side-chain cleavage enzyme, P-450 14x-demethylase belongs to the class of
P-450's which effect complex chemical transformations. The power of P-450 enzymes to
regio- and stereospecifically hydroxylate unfunctionalized carbon atoms has been the envy
of organic chemists for decades, but the ability of these "complex" P-450's to act multiple
times on a single substrate makes them truly exceptional catalysts.
In the area of steroid biosynthesis at least six P-450's fall into this category (Figure
2), many other "simple" P-450 hydroxylases are known in this area as well. P-450scc
hydroxylates once, hydroxylates again one carbon away from the first and then performs
an oxidative glycol cleavage. (8 9 ) P-450 17 a (17,20 lyase) hydroxylates once o to a ketone
and then cleaves the bond between them.(108) Aromatase hydroxylates twice on the same
methyl carbon and then cleaves it from the steroid nucleus accompanied by aromatization of
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Scheme 1: Numbering scheme for steroids
based on the lanosterol skeleton. (Note that in
ergosterol the carbon attached at C-24 is numbered 28)
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4,4-dimethylcholesta-8,14,24-trienol
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Androstenedione
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P-450 11 (Aldosterone Synthase)
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Ergosta-7.24(28)-dienol Ergosta-7,22,24(28)-trienol
Figure 2: P-450 enzymes in Steroid Biosynthesis
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the steroid A-ring. (8 1' 140, 141) 14c-demethylase, like aromatase, hydroxylates twice on
the same carbon and cleaves it from the steroid nucleus as formate after the equivalent of a
Baeyer-Villiger oxidation (see mechanistic discussion below). P-45011 (aldosterone
synthase) is believed to hydroxylate three times, once at the 11 position and twice at the 18
position of deoxycorticosterone, to generate a hydroxy-aldehyde which cyclizes to a
hemiacetal, although the possibility remains that these activities are mediated by more than
one closely related P-450's.(11 1 ) Finally, from the biosynthesis of ergosterol in yeast, A-
22-desaturase (presumably) hydroxylates once and then catalyzes the P-elimination of that
hydroxyl group. (6 7, 165)
These reactions form a mechanistically related group that appear to elaborate on the
straightforward hydroxylation chemistry defined for P-4 50CAM (see previous chapter).
Subtle protein-mediated differences in active site structure, however, create this complexity
in oxidative chemistry. The nature of these transformations suggests that there is a great
deal to learn about how a single enzyme can control these sequential processes and exhibit
distinct mechanistic modes on different intermediate states, and how different P-450's can
exhibit such different chemical reactivities. The evolutionary efficiency exhibited in the use
of a single active-oxygen species and a single binding site to effect these multi-step, multi-
electron oxidations is truly intriguing.
P-450 14cx-demethylase is the most widely distributed P-450 of this class; a fact
which allows for comparisons between widely separated species. The enzyme has been
successfully purified from rat liver microsomes, (1 4 6) pig liver microsomes,( 13 2 ) and
Saccharomyces cerevisiae.(157' 163, 166) Because the enzyme is found in yeast, the
opportunity arises for the relatively straightforward cloning and genetic manipulation of the
enzyme. The genetic sequence of the protein has been determined from S. cerevisiae,
Candida albicans and C. tropicalis.(3 6 ' 79, 88) This has already been exploited to yield
homologous overexpression in S. cerevisiae(1 5 3) and the expression of the C. tropicalis
gene in S. cerevisiae.(3 7) Mutant cells having altered or absent demethylase activity have
been obtained using Chinese hamster ovary cells and S. cerevisiae.(38, 83) Recently, the
study of lanosterol 14cx-demethylase from human liver microsomes has begun.(12 0 ) For
these reasons, 14xt-demethylase is a particularly accessible system to investigate the
detailed issues of structure, function and mechanism of the complex P-450's.
Besides these considerations of basic science in chemistry and enzymology, this
research is motivated by the very practical prerogatives of clinical and agricultural
pharmacology. 14a-demethylase has emerged as a central player in the area of anti-fungal
drug discovery and design. The connection between the enzyme and anti-fungal drugs is
described in detail below.
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Fungi and the higher eukaryotes are similar in many ways in terms of their basic
biochemical pathways. The metabolic adaptations and structural innovations that separate
fungi from bacteria are generally conserved in all eukaryotes including mammals. This vast
biochemical gulf between mammals and bacteria are the reason why most bacterial
infections can be successfully treated by drugs (anti-bacterials); what may kill a bacterial
cell may very well have no effect on a mammal because the affected function in the
bacterium may not exist or is fundamentally different in the eukaryotic cell. Although the
effort to discover anti-bacterial agents has been long and arduous, once discovered, these
compounds have been notable for their effectiveness and lack of severe side-effects.( 5 3)
Fungal cells, on the other hand, are quite another story. Although in general the
mammalian immune system is effective at preventing fungal infection, when that system is
compromised either by disease, immune system weakness, or the mutation of an infectious
species to a new and unrecognized form, anti-fungal drugs are considerably less effective
than their anti-bacterial counterparts.(53) Discrimination between the biochemical
machinery of fungal cells and that of host cells is difficult and usually only partial, resulting
in side-effects, often of a very serious nature. Considering the most common internally
administered antifungal drugs, amphotericin B, 5-fluorocytosine, miconazole and
ketoconazole, possible side effects include chills, fever, rigors, nausea, diarrhea, pain,
convulsions, anemia, renal toxicity, liver toxicity, electrolyte imbalance, anaphylaxis and
cardiac arrhythmia. (158) What may harm a fungal cell, it seems, will often harm a human
cell as well, perhaps only less so. In recent times, with the prevalence of aggressive
chemotherapy, AIDS and the use of immunosuppressive drugs, corticosteroids and broad-
spectrum antibiotics during transplant surgery, the occurrence of systemic mycotic
infections has become a significant concern.(1 61) In fact, fungal infection has become a
major cause of death among cancer patients and transplant recipients, and the frequency of
fungal infection in patients with cancers of the blood more than doubled in the 1980's.(26)
AIDS, in particular has presented a challenge to medical science, life-threatening fungal
infections that are extremely rare in all other categories of illness are prevalent among AIDS
patients.(19) The agricultural industry, as well, desires to find anti-fungal pesticides that are
less susceptible to inducing drug-resistant strains and have lower human toxicity. Many
universities, hospitals and pharmaceutical companies have invested considerable time and
money in the effort to discover improved anti-fungal drugs and treatments. Pharmaceutical
companies such as Du Pont de Nemours, Smith Kline & French, Shionogi, Sumitomo and
Schering Plough, in particular have been at the forefront of basic research on anti-fungal
therapies.(40, 47, 52, 80, 102, 124, 130, 167)
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The anti-fungal drugs that have shown the most selectivity have been found, almost
exclusively, to affect the process of steroid biosynthesis or function.(1 03 ) Of the fungicidal
inhibitors acting on steroidogenic enzymes, a considerable number target the 14a-
demethylase. Why should this system prove to be the fungal Achilles' heel when
mammalian cells also have steroids as well as their own 14a-demethylases? As mentioned
above, the sterol biosynthesis pathways in yeast and the higher eukaryotes diverge
subsequent to lanosterol demethylation (and in filamentous fungi immediately after
lanosterol cyclization from oxidosqualene) to yield ergosterol and cholesterol. Thus, one
possible reason is that as omnivorous creatures we do not rely solely on our biosynthetic
enzymes to provide a supply of cholesterol for steroid biosynthesis; we consume a
considerable amount in our diet. Fortunately, the intermediates of cholesterol biosynthesis
between lanosterol and cholesterol do not seem to be necessary for health. Fungi living in
the environment of the human body, however, are not supplied with ergosterol or any other
metabolic precursor to it, and cannot use cholesterol for growth. (154)
Why this dichotomy between the steroid requirement of fungi and higher
eukaryotes exists is probably intimately related to the basic evolutionary schism that
separated the kingdom Animalia from the fungal world, namely multicellularity and
differentiation. ( 99) The functions of steroids in the higher eukaryotes are two-fold. They
function as hormones, carrying information between cells, tissues and organs. In general,
only those steroids beyond cholesterol in the biosynthetic pathway function in this mode.
The second function is the modification and maintenance of the physical properties of the
cell's phospholipid bilayer membranes. (91' 123) This function is shared by all eukaryotes
although ergosterol fulfills this role in fungi and cholesterol in animals. The precise three-
dimensional shape of the membrane steroid molecules have been selected for
complementarity with the shape of the membranes' constituent phospholipids. Over the
course of evolution these molecules have varied together resulting in membranes with
physical properties appropriate to their biochemical niche - the particular external
environmental conditions in which they find themselves. The surfaces of animal cells, in
contrast, do not have to come in contact with the outside environment and therefore have
evolved different physical properties than fungal cells.
Whatever the reason, interference with the fungal steroid biosynthetic pathways is
one of the few handles that we have on the problem of systemic fungal infection, and the
drugs presently available are clearly inadequate. The definition, on the molecular level, of
the origin of anti-fungal drug binding specificity and species selectivity is fundamental to
the design of improved drugs and treatments. For this reason, laboratories in academia and
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industry have increasingly focused on illuminating the structural and mechanistic properties
of the fungal steroid biosynthetic machinery such as the lanosterol 14o-demethylases.
Anti-fungal drugs and the Inhibition of 14o-Demethylase
The problem of side effects in enzyme-targeted pharmacology can be divided into
three regimes. First, an administered drug may have systemic effects unrelated to its target
enzyme; gastro-intestinal imbalance or liver and kidney toxicity, for instance, may result
from many different types of chemicals. Second, the drug designed to mimic a particular
substrate of a particular enzyme may effect other enzymes that act on similar substrates, or
closely related enzymes that act on different substrates. The more effectively a drug binds
to a particular protein target, however, the less likely there will be interferences of this
type.(2 9 ) Third, there may be specific overlap of the target enzyme in the infecting
organism with an analogous enzyme in the host organism. All three effects are relevant to
the design and development of anti-fungal drugs. Clearly, as mentioned above, there is
overlap between the 14-demethylase of fungi with that of plants and mammals, however,
much of the problem with side effects in anti-fungal drugs may result from these drugs not
discriminating between the numerous other P-450's present in mammalian tissues. For
instance, it is known that many anti-fungal drugs have broad spectrum effects on P-450
enzymes (see below).
The clinical inhibition of an enzymatic activity requires a tight binding inhibitor (that
is, one with strong complementarity of shape and electronic structure with the active site of
the enzyme). The stronger the binding of the inhibitor relative to the natural substrate of the
enzyme the lower the dosage of inhibitor will be required to completely inhibit the
enzymatic activity. Low dosage is an important factor in a potential drug because this will
lessen the severity of any side-effects. Clearly the optimal case is where the inhibitor binds
considerably more tightly than the natural substrate. Is this physically possible? It is, and
the logic behind this conclusion is developed in the following paragraphs.
In receptors and binding proteins, full advantage can be taken of the binding
interaction between a protein and its target. Consider, for example, the exquisitely strong
binding interactions of avidin for biotin or immunoglobins for their antigens. Apart from
the intrinsic dissociation rate, release of bound molecules in receptor proteins can be
initiated by an external signal causing a conformational change in the protein, if necessary.
In an enzyme, generally, the only specific signal to release the product is the relative
difference in shape between the product and the starting material or between the chemical
states of cofactors, which are often not dramatic (enzymes often bind their substrates in
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conformations approximating the transition state of the chemical process(2 3 )). Thus,
enzymes cannot bind their substrates as tightly as might be physically possible, to do so
would lower the off-rate of the product and slow down the overall rate of catalysis.( 8 5)*
Using the example of steroid-metabolizing enzymes, the interactions between
substrate and active site are believed to be mediated by a small number of discrete hydrogen
bonds and a much larger number of non-polar contacts constituting the hydrophobic effect.
For "perfect" binding (maximal energy release on binding) the active site would trace every
curve of the non-polar regions of the substrate with close contacts excluding the maximal
number of water molecules from the hydrophobic binding pocket, and all hydrogen bonds
would be at optimal distances and with optimal angular orientations. Conversely, in order
to avoid having too strong a binding constant, there must be gaps between the protein and
substrate in places, clashes causing strain in others and hydrogen bonds having less than
optimal parameters. The consequence of this state of affairs is that it should always be
possible, in principle, to find or design a molecule which will bind to an enzyme active site
considerably more tightly than the natural substrate.
The possibility for differentially inhibiting an enzyme like 14c-demethylase in
various fungi versus humans can be explained in part by divergent evolution. Evolution
will select enzyme primary sequences which fold to form an active site which is optimal for
that particular biochemical niche; the binding of the substrate will be as strong as possible
to give a high selectivity balanced against an off-rate sufficient to produce enough product
for the organism's needs. As other biochemical pathways have changed throughout the
divergence of fungi and mammals, so will have this optimal value. Furthermore, evolution
will select sequences that yield optimal values as conditions change, but there will be no
selective pressure on the precise identity of the sequences that yield this value. Thus, in
enzymes separated by as much divergence time as the fungal and mammalian 14ca-
demethylases, even though the mechanism of the enzyme may have been exquisitely
conserved and many catalytically important residues remain unchanged as well, the precise
nature of the binding interactions can be expected to vary considerably. Where in one
homolog, for example, there may be close contacts all around the 10[-methyl, strain-
causing interactions with 13fi-methyl and extra room around the 4,4-dimethyl group, in
another homolog these interactions may be quite different: as long as the binding constant is
appropriate, the details are unimportant as far as evolution is concerned. Following from
* It might be inferred from this argument that the slower an enzyme needs to go, as defined by its
biochemical niche, the tighter it will bind its substrates in order to gain in specificity. This would be
expected to be especially applicable to enzymes like 14cx-demethylase which bind discrete intermediate
states non-covalently and are relatively sluggish.
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this argument, the inhibitor which binds most tightly to a particular species' enzyme may
not bind nearly so well to that of a distantly related species.*
The fact that presently available anti-fungal drugs acting as 14tX-demethylase
inhibitors are somewhat selective in their toxicity even though both human and fungal cells
utilize this enzyme suggests that there may be considerable heterogeneity in the three-
dimensional shape of the substrate-binding cavities. Detailed comparisons between the
binding constants of these inhibitors for purified fungal and mammalian 14o-demethylases
have not yet been carried out in a systematic way. Almost exclusively these compounds,
discovered by screening methods, contain aromatic nitrogenous ligands (generally,
pyridines, diazoles and triazoles) meta-substituted with lipophilic groups of varying
structure. The nitrogen atoms of these molecules are believed to interact directly with the
heme iron resulting in a type II spectral binding shift. (12 2' 164) These compounds are
known as DeMethylation Inhibiting fungicides or DMI; examples include ketoconazole,
miconazole, itraconazole, buthiobate, fenarimol, and prochloraz (Figure 3). It is believed
that these inhibitors cause an accumulation of C-14-methylsterols in the cell membrane and,
because of the protruding axial methyl group (see side-on view of lanosterol, Scheme 2)
the cell membrane integrity is affected.( 30' 103) Recent advances in the development of anti-
fungal drugs have been extensively reviewed. (6 5' 103, 124)
* This brings up the possibility, of course, that continued drug warfare between species will cause
convergent evolution of the target enzymes with respect to their detailed active site shapes through the
growth of drug-resistant strains. Is it possible that this has already happened in mammalian fungal parasites
of archaic lineage through biological drug warfare? The discovery of unexpectedly large conservation of
detailed active site shape would imply a co-evolution mediated by natural anti-fungal enzyme inhibitors.
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Scheme 2: MM2-minimized stick-figure of lanosterol, side view.
The 32-methyl protrudes from the a-face (bottom) of the molecule.
(Hydrogen atoms omitted for clarity)
Ketoconazole
CI
N N- N I
-or
onazole
Buthiobate
OH
Fenarimol
Figure 3: Some Demethylation Inhibiting
Fungicides (DMI)
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The chemically homogeneous nature of the DMI suggests that at least part of the
selectivity of these drugs may be due to secondary effects such as differential concentration
in fungal cells relative to mammalian cells or processing of these drugs that mitigate their
effect once they reach the mammalian cell. However, no chemical or physical basis for
such secondary effects have been shown. On the other hand, drug screening and
development is by no means a random process and most work has clearly focused on the
improvement of presently available DMI compounds; this may in part explain the restricted
nature of the chemical groupings in DMIs. Enzymatic studies show that these drugs have
considerable cross-reactivity with P-450 enzymes in general, a fact which may account for
many of the observed side-effects.
In contrast to the classical technique of drug discovery, there has recently been an
increasing focus on logical drug design based on enzyme active sites target. (2 9 ) This
technique holds promise in being able to produce inhibitors that are tailored to particular
active sites thus minimizing side effects through non-specific inhibition. As noted above,
the effectiveness of the DMI fungicides makes 14ox-demethylase an attractive target for this
"engineered" approach. Unfortunately, 14-demethylases are membrane bound proteins
and have resisted attempts to acquire X-ray crystal structures. The only available crystal
structure of a P-450 enzyme is that of camphor hydroxylase which, as a bacterial enzyme
acting on a very different substrate, cannot be expected to yield much information of a
specific nature about the binding properties of lanosterol to 14-demethylase by
comparison. (l9)
Thus, researchers must resort to deduction of the structural features of the active
site indirectly, through comparative binding studies. Analysis of the numerous N-
heterocycle inhibitors (DMI's) has led to little structural information due to the very wide
variety of lipophilic groups that define the set of effective fungicides. This effort is
complicated by the fact that effectiveness against one fungal species or another is a complex
phenomenon dependent not only on enzymatic binding but also on secondary factors such
as permeability and processing; these effects have not generally been adequately controlled
in published studies. Furthermore, considering the possibility of multiple potential
conformations and binding orientations in many of the drugs it is difficult to model the
shape of the bound inhibitors. Several studies have attempted to quantify structural
parameters of these non-steroidal inhibitors and other, more simplified, model compounds
using purified or partially purified enzyme in spectroscopic studies or competitive turnover
assays.(122 , 125, 147, 161, 164) Although several generalizations about the active site of
14-demethylases have been deduced from this work, specifics are in short supply. Some
useful information has come from studies of inhibitors and probes structurally related to the
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natural substrate, lanosterol. It has been found, for instance, that the 3[3-hydroxyl group in
the A-ring is essential for orientation and processing of the substrate, presumably due to
specific hydrogen bonding interactions,(l3) that removal of more than two of the side chain
carbons results in significant loss of activity,(134) and that the enzyme will metabolize
substrates lacking the 4,4-dimethyl group. (84)
The direct approach of placing heme-ligating groups into the 14c-methyl position
of lanosterol has led to some notably strong binding constants (Table 1).(4 0 55, 102, 148,
149) For comparison, lanosterol has a Km of 165 [tM and a Kd of 6.9 gM (163). However,
the variety of potential anti-fungals accessible by this method is limited, reducing the
possibility of finding candidates that posses all of the features of useful drugs such as
solubility, permeability, oral activity and, importantly, low cost of synthesis. Bossard has
recently reported that the compound, 32-ethynyllanosterol, like the acetylene-containing
compounds discussed in Chapter 3 in regard to P450scc, is a time-dependent mechanism-
based inactivator of purified rat liver 14(x-demethylase (Table 1, final entry).( 28 ) Similarly,
the 15a-hydroxy-32-aldehyde derivative of lanosterol has been found to inactivate the
enzyme.( 52 ) The placement of the double bond at the B-C ring junction is critical for
enzyme binding and turnover, A7 compounds are metabolized considerably slower and
have poorer binding characteristics than the natural A8 substrate, A6 steroids are not turned
over by the enzyme at all.(51)
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TABLE 1
Inhibitors based on modification of Lanosterol
R= Inhibition Versus Reference
'" N IC50 = 30 nM various dermatophyte (41)fungal species
K i = 0.61 gtM Ratliver (143)
microsomes
(OH (asHA 5 IC50 = 2 nM Human hepatoma(also A15) IC50 = 2 nM cell line (96)
OH
Ki= 1.2 i'M, Purified enzyme (27)
CC-H Kinact=O. 15 min-1 from rat liver
Recent work by Wright and Honek has combined the use of small imidazole-
containing molecules to bind to the heme iron with the technique of photoaffinity labeling.
Attaching aromatic azides to the imidazole ligand with short linkers of varying lengths they
have found a molecule which, when irradiated at 313 nm, covalently labels the active site of
the 14-demethylase from Saccharomyces cerevisiae.(16 0 ) In future work the active site
residue(s) to which the probe is linked will be discovered, and very likely, new
photoaffinity probes will be found that attack different active site residues. Since these
probes have only one free imidazole nitrogen with which to bind the heme iron, modeling
of the interaction may, in a fairly straightforward manner, yield distance constraints
between these residues and the heme iron.
Since the primary structures of these P-450's are well known, the potential exists
for computer modeling of their three-dimensional structure. In fact the first attempts at this
process have begun based on secondary structure prediction, hydropathy and alignment
with the P-450Oam structure,(l 0 7) much in the same vein as those performed by S. Joardar
on P-450scc in our laboratories (see introduction to Chapter 3 of this thesis).(7 3 ) In
combination with distance constraints acquired from the photoaffinity labeling experiments
mentioned above and other techniques, a much clearer picture of the active site structures of
these and other P-450's may be forthcoming in the near future.
Effective anti-fungal drugs of the future may very well be chemical hybrids having
azole-based heme-binding groups, steroid-mimicking regions fine-tuned for exploitation of
inter-species enzyme heterogeneity and pendant groups that do not interact with the enzyme
but target the drug for differential entry into fungal cells.
Proposed Mechanism: An Historical Overview
The delineation of the enzymatic mechanism of lanosterol 14oc-demethylation has
been an active research area for over 35 years. The literature in this field has been
complicated by false starts and misleading information and made difficult by technical
complexities. Looked at in historical perspective, however, this research (along with that
on the enzymes aromatase and the side-chain cleavage enzyme) represents a monumental
effort to define the properties of a powerful, complex and highly specific oxidative
machine. The last five years have been extremely fertile in this respect, culminating in the
isolation and convincing structure determination of the final oxidative intermediate
preceding demethylation.( 52) An overview of the developments over the last three decades
is presented below.
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Acetate (methyl-labelled)
H
H - OH
HO OOH
Mevalonate
OPO 3HPO 3 2 OPO 3PO 3
Isopentenylpyrophosphate Dimethylallylpyrophosphate
OPO 3HPO 3H2
Geranylpyrophosphate
Squalene epoxide
Protosterol cation
Cholesterol
Figure 4: 14C-labelling of Lanosterol and
Cholesterol from acetate
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Lanosterol
By 1957 Cornforth and Popjak had completely determined the pattern of 14C-
incorporation into lanosterol and cholesterol by methyl- and carboxylate-carbon labeled
14 C-acetate (Figure 4).(41-43) Using this information Olson and co-workers showed that
14C-labeled lanosterol is converted to cholesterol in rat liver homogenates with the release
of at least three equivalents of radioactivity as 14 CO2, corresponding to the 4a, 4 and
14-methyl groups of lanosterol. No 14 C-formaldehyde was detected, even though
consideration was given to enzymatic conversion of formaldehyde to C0 2, perhaps because
the trapping reagent used inhibited the enzyme. Decarboxylation is direct: amino acids are
not intermediate 1-carbon carriers.( 12) Years later it was shown that the 14ch-methyl is, in
fact, released as formate, as will be discussed below.
Gautschi and Bloch showed that A 8 ,24 -4,4-dimethylcholestadienol is a 14-
demethylated intermediate by chromatographic isolation and synthesis of an authentic
standard.(56) Chromatographic techniques alone could not differentiate between the double
bond isomers. Oxidation by osmium tetroxide and lead tetraacetate, however,( 3 4 ) yielded a
ten-membered ring diketone matching that produced by oxidation of the synthesized A8
compound (Scheme 3).(57)
This isolated intermediate seemed to be one step removed from the actual
decarboxylation. Two proposals were considered for this elimination (Figure 5): a) double
bond migration to the 8(14) position and b) oxidation of the 15-position to yield an
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8,14-diene.(5, 50, 121, 127) Several groups showed that one of the hydrogen atoms at C-15
is removed in the biosynthesis of cholesterol from [2RS-3H2]-mevalonic acid and the A8,14
steroid is converted to cholesterol. It was later shown that the proton lost at the 15 position
is the 15xo-proton, and that no protons are lost from the adjacent 16-position. (4 ' 5, 32, 33,
50, 59) This information supports the C-15 oxidation mechanism for demethylation.
However, a two-step isomerization of the 8(14)-olefin to the 8(9)-olefin through the
intermediate 8,14-diene remained a possibility (Figure 5, pathway b'). (12 7 ) Considerable
uncertainty existed on this point for several years, but the issue was settled by preparation
of the putative A8 (14)-lanosterol and demonstration that it is not an efficient precursor to
cholesterol when incubated with rat liver homogenates, and that while A8 -lanosterol yields
a A8,14 intermediate, the A7 isomer yields a A7,14-diene intermediate. (1 ' 6, 152) The nature
of the oxidation at carbon-15 was alternately considered as a hydroxylation, hydrogen atom
abstraction and a hydride elimination. (4' 5, 50, 64)
In 1972 research by Alexander and co-workers showed that the original work on
the oxidation state of the released 14(x-methyl carbon atom was in error, and the carbon is
in fact released as formic acid, not carbon dioxide.(6) At around the same time it was
discovered that the process of lanosterol demethylation required oxygen, NADPH and was
inhibited by carbon monoxide (in both rat liver and yeast) and was thus very likely
mediated by P-450 enzymes.(7, 60-62, 104) These discoveries precipitated a reevaluation of
the previously proposed mechanisms, and the possibilities considered are summarized in
Figure 6.
Mechanism 6a involves base catalyzed -elimination after hydroxylation at position
15.(1, 6) The observed loss of the 15cx-proton strongly suggested that such an alcohol must
also be in the alpha orientation since all steroid hydroxylations investigated at that time (and
since) had been shown to involve retention of configuration, and therefore the reaction
must involve a syn elimination. Mechanism 6b hypothesizes an enzymatic Baeyer-Villiger
oxidation, insertion of an atom of oxygen between a carbonyl carbon and an aliphatic
carbon. In synthetic chemistry this rearrangement is preceded by the attack of a peroxide
anion on the carbonyl carbon; the enzymatic reaction would presumably be similar.
However, in organic chemistry it is observed that the hydrogen atom of aldehydes is much
more likely to migrate than the alkyl group, resulting in the formation of a carboxylate, not
a formate ester. (98 ) Thus there must be some distinct mechanistic differences between the
enzymatic and chemical reactions. Syn elimination of the resulting formate ester could be
catalyzed by an enzymatic base. Non-enzymatic elimination of this ester would be expected
to result in the energetically more favorable anti elimination. Mechanism c is similar to b in
proposing a peroxy-intermediate. As shown in the figure, elimination could be achieved
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by a radical mechanism, but also could be considered to arise from a heterolytic or even
electrocyclic mechanisms.(1 ) Mechanisms analogous to both 6b and 6c had been proposed
in relation to C-19 demethylation in the biosynthesis of estrogen.(3)
By 1978 it had been shown that all three oxidative steps require oxygen and
NADPH. The fact that the oxidation of the 32-alcohol to the aldehyde was apparently not
catalyzed by the common alcohol dehydrogenase-type mechanism suggested that the entire
demethylation may be catalyzed by a single enzyme.(1 ) Some reports, however, suggested
that more than one oxidase might be responsible for the several oxidative steps. (63 ) The
one-enzyme hypothesis was later confirmed when 14x-demethylase was purified to
homogeneity,(12, 144, 163) as well as through the discovery of demethylase-deficient strains
of yeast and Chinese hamster ovary cells.(11' 144)
A series of elegant experiments, initially using intact rat liver microsomes and later
purified lanosterol 14-demethylase, showed that several oxidized intermediates could be
accumulated in solution at the expense of demethylated products. Conditions for this
mechanistic interruption included limiting the supply of NADPH, low enzyme and high
substrate concentrations, competitive inhibition by non-steroidal inhibitors, short
incubation times and high pH. It was also found that cholesterol treatment of intact
microsomes caused intermediates to accumulate. These intermediates were conclusively
demonstrated to be the 32-aldehyde and 32-alcohol compounds predicted by the proposed
mechanisms. These experiments suggest that oxidized demethylation intermediates are
freely diffusible from the enzyme active site but, under normal turnover conditions, are not
released because of tight binding and the speed of subsequent chemical steps.( 12 9' 144-146)
Similar results were observed with the enzyme isolated from S. cerevisiae.(14' 17)
Synthesis of these intermediates and incubation of them with the purified enzyme systems
provided the relevant kinetic constants (Table 2, adapted from( 51)). The measured maximal
rates for dihydrolanosterol and the corresponding 32-alcohol and 32-aldehyde clearly
indicate kinetic competence (Vmax = 0.64, 7.00 and 20.6 nmol min-1 mg-1, respectively).
The Km of 32-hydroxylanosterol is notably lower than that of lanosterol and is
clearly part of the enzymatic strategy for avoiding premature release of the
intermediates.(14 ' 51) It should be noted also that release of the product after demethylation
is surely promoted by the planarization of carbons 14 and 15, which can be expected to
cause a distinct change in the conformation of the D-ring and thus, the disposition of the C-
18 methyl and the side-chain with respect to the rest of the steroid nucleus. Molecular
modeling of the substrate and product of lanosterol 14-demethylase indicate a distinct
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TABLE 2
Kinetic constants for several 14a-demethylase substrates
Compound || K(tM) I Vmax I Vmax/Km
Lanosterol 165 3.39 20.5
Lanost-8-en-33-ol 312 0.64 2.07
Lanost-7-en-3 -ol 338 0.09 0.26
Lanost-8-en-3 ,32-diol 56 7.00 125
3[-hydroxylanost-8-en-32-al 368 20.6 56
curvature of the molecule arises from demethylation (this effect is well represented by the
distance between carbons 18 and 19 which increases from 4.16A to 4.78A, see Scheme 4,
a and b)*
The nature of the third and final oxidative intermediate prior to demethylation
remained enigmatic for many years. Although mechanism a (Figure 6) initially seemed the
most parsimonious, it was shown that, of the two possible synthetic 15-hydroxylanost-7-
enols, only the 15/ diastereomer could be converted to cholesterol by rat liver homogenate.
Thus, either the 15[3-alcohol is only fortuitously converted to cholesterol and is not a
significant intermediate in its biosynthesis, or the activation at C-15 represented a novel
hydroxylation mechanism involving inversion of stereochemistry.(101, 136, 137)
Considering what is known about the mechanism of P-450-mediated hydroxylations, this
latter possibility seems remote. (6 6 ) Significantly later it was shown that, while both of the
15-hydroxylanosterols are, in fact, inhibitors of the demethylase, the 15x-alcohol is
extremely potent in this respect. This evidence suggests that one of the other two
mechanisms is operational; (1 06 ) however, the inference was somewhat tentative because
synthesis of the 15-hydroxy-32-aldehydes had remained elusive.
Recently, considerable light has-been shed on this process in an outstanding report
by Fischer, Trzaskos and co-workers at DuPont.( 52) Extending their initial work on the
accumulation of oxidized intermediates, it was found that by incubating the 32-aldehyde
with purified enzyme and using a slight modification of their product extraction procedure,
a third intermediate could be isolated. Infrared, 1H-NMR, EI and FAB mass spectra of the
intermediate are consistent with the 14c-formyllanosterol structure predicted by Bayer-
* Minimizations were performed using MM2 on Chem3D Plus from Cambridge Scientific Computing
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Scheme 4a: An MM2 minimized space-filling model of Lanosterol.
The 14x-methyl protrudes from the bottom face of the molecule at the center of
the drawing.
Scheme 4b: An MM2 minimized space-filling model of 4,4-
dimethylcholesta-8,24-dienol. Note the relative curvature of the steroid
nucleus (the side-chains are represented with equivalent conformations for
comparison).
Villager rearrangement (Scheme 6, mechanism b). Previously the steroid fraction had been
saponified during the extraction procedure, precluding the isolation of this ester. Re-
incubation of the HPLC purified intermediate with enzyme confirm that it is a kinetically
competent precursor to the 8,14 diene. Reducing equivalents and oxygen are not necessary
for this final elimination. In addition, the putative intermediate of mechanism a, 15ca-
hydroxy-32-aldehyde, was successfully synthesized and shown not only to not be a
competent intermediate but also to be a time-dependent inactivator of the enzyme. Another
intriguing observation was that the final elimination of the formate ester, though efficiently
catalyzed by the enzyme, was not inhibited by the competitive P-450 inhibitor ketoconazole
which binds to the heme iron or by the 15a-hydroxy-32-aldehyde. This suggests that a
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second site on the enzyme may be responsible for this transformation. A similar
suggestion has been made with respect to the final step in the mechanism of aromatase.(1 0 5)
The mechanism of the final oxidative transformation as it is now understood is
summarized in Figure 7. Although the Baeyer-Villiger rearrangement is not a general
mechanism in P-450 lyases (it has been ruled out as a mechanism in aromatase (162)), the
attack of a peroxide equivalent on carbonyls seems to represent a fundamental mechanistic
mode parallel to the radical rebound mechanism for hydroxylation and oxygen atom
insertion into multiple bonds (see discussion in Chapter 1). Aside from 14o-demethylase,
peroxide attack has been implicated in the mechanisms of aromatase, 17,20-lyase, and the
metabolism of xenobiotic aldehydes by P-450 LM2 ,(39 96 , 150) and may be involved in the
final lytic step of P-450scc.(90 )
Assays of Lanosterol 14o-demethylase
The simplest way to measure the affinity of a substrate or inhibitor for a P-450
enzyme is to monitor the spectroscopic changes that occur upon binding of the molecule.
This method is very effective for inhibitors that yield a type II binding spectrum, that is,
those like the azole antifungal drugs, which coordinate to the heme iron through a
heteroatom.(12 2 ) Type I spectral changes occur when the binding of a substrate or inhibitor
causes a change in the heme iron spin state from low-spin to high-spin resulting in a blue-
shift of the Soret maximum.(156) In difference spectra this appears as an absorption
minimum near 420 nm and a maximum around 388-390 nm with an isosbestic point at 407
nm.(110 ) This effect is generally less pronounced than the type II change. In the case of
lanosterol 14o-demethylase the effect is small, 1 gM enzyme results in only an -0.036 AU
maximal change (in the difference spectrum) even though the dissociation constant of
lanosterol is 6.9 tM. (9' 17, 163) In addition, competition experiments based on these
spectral changes can give misleading non-linear results and artifacts if full consideration is
not given to the detailed binding kinetics of the system.(10 9)
The first assay based on the turnover of lanosterol to demethylated products was
based on the mechanistic studies of Alexander and Akhtar in 1972 in which [32- 3H]-24,25-
dihydrolanost-7-ene-32,31-diol was used as a substrate for the enzyme and radioactive
water and formic acid were identified as products.(6) The radioactive products in these
assays were quantitated by freeze-drying the acidified incubation solutions and collecting
the volatiles with a liquid nitrogen trap or by bulb-to-bulb distillation. ( l' 104) If desired, the
formic acid could then be quantitated independent of the water by forming the non-volatile
formate salt under alkaline conditions and distilling again. Considering the complicated
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synthesis involved and the time required to perform this assay, subsequent researchers
found it quite cumbersome and soon turned to other methods.
Aoyama and Yoshida developed an assay in 1978 using gas chromatography.(9)
After addition of an internal standard steroid, the enzymatic incubation is saponified and
(non-radiolabeled) steroids are extracted with 9:1 petroleum ether-diethyl ether or
methylene chloride. The solvents are dried over sodium sulfate and removed by
evaporation, after which the residue dissolved in and trimethylsilylated with a small amount
of N-trimethylsilyl imidazole and then chromatographed. ( 8' 12, 17, 128, 134) Quantitation is
achieved by integration of the resulting peaks. The accuracy of this method suffers
somewhat from high and variable backgrounds due to irrelevant impurities in the protein,
cofactor and buffer preparations.
In 1984 researchers at Du Pont developed an improved assay using the newly
developed HPLC/liquid scintillation flow-through detector which has found considerable
use. (51, 52, 82, 120, 129, 145, 146, 148) By using radio-detection, problems of baseline
interference are eliminated because only metabolites of the substrate are detected. General
labeling of dihydrolanosterol is achieved by catalytic tritiation of a crude mixture of
lanosterol and dihydrolanosterol or by sodium borotritiide reduction of dihydrolanosterone.
Although the extraction procedures must still be done, no trimethylsilylation is necessary.
However, one must acquire a radio-flow type detector to take advantage of this assay.
In both of these types of chromatographic assay, if the demethylase preparation
used is not sufficiently pure, contaminating enzymatic activities may complicate the results
due to further processing of the demethylated product. For instance, in order to assay
demethylase activity in microsomal preparations, reduction of the demethylase product
A8,14 diene by a specific 14-reductase occurs rapidly with saturating amounts of
NADPH,( 11 3, 145) and cyanide must be added to inhibit the action of the 4-demethylase
enzymes.(1 2 ) Although little time is invested in the preparation of substrates for these
assays, the throughput of the assay is limited by the time it takes to perform the extractions
and chromatography steps. Estimating from procedures described in the above references
it seems that no more than 10-15 determinations can be made per chromatograph per day;
thus, these assays are very labor intensive. Although quite appropriate for the analysis of
metabolic intermediates or the products resulting from alternative substrates or inhibitors
(especially in combination with mass spectroscopy ( 9' 12, 17, 51, 52, 128, 129, 134)), these
methods are not well suited to routine assays, the screening of inhibitors, variations in
multiple parameters for kinetic studies or other uses requiring many data point
determinations.
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In a return to the earliest assay procedures, Bossard and co-workers at Smith Kline
& French Laboratories have updated the tritiated formate/water quantitation assay creating a
procedure that is both rapid and accurate.(28) The technique is straightforward. Enzyme
incubations with 32-[3 H]-dihydrolanosterol are quenched with 1% Emulgen 913 (a
detergent), 40% trichloroacetic acid (to precipitate the proteins) and 0.25% formate as a
cold carrier. After centrifugation the supernatant is passed through a Sep-Pac C 18 cartridge
(Waters Associates) with two water washes and is counted by scintillation. Samples can be
processed in large batches each taking only a few minutes. The Sep-Pac cartridges are
regenerated by washing with methanol and re-equilibration with water. This technique
eliminates both baseline noise and interference due to further processing of the
demethylated steroids. Assuming that 14-demethylase is the only enzyme acting on the
14ox-methyl and there is no enzymatic reincorporation of the released formate into a non-
polar phase, then this assay should be just as accurate in a crude system as it is in
measuring the activity of purified enzyme. For high-throughput applications this assay is
several hundred times faster than previous methods. The publication of this procedure has
placed a new importance on research towards the efficient production of 32-labeled
lanosterol substrates, as the time and effort required to produce this material is the only
significant impediment to its general utility.
Research goals
In order to investigate 14cx-demethylase the most basic requirement is the ability to
measure its presence. The choice or design of an assay is often crucial to the success of
future experimentation. It is desirable to use an assay which is easy, sensitive, accurate
and quick (determinations per hour) to perform, even if this requires a long initial period of
work, since this laboratory is committed to an extended project in this direction. As
summarized above, the major difference in assays in the case of 14ox-demethylase is
whether the substrate for the assay requires a difficult multi-step synthesis (i.e. specific
radio-labeling), a brief, simple synthesis (i.e. general radio-labeling), or even no synthesis
at all. The time required to perform a single determination of each of these assays seems to
be inversely proportional to the difficulty in preparing the substrate. The publication of the
Bossard tritium-release assay ( 28) just prior to the commencement of this project was
fortuitous, and the commitment was made to use this method along with its synthetic
challenges.
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The choice of synthetic strategy to use in the preparation of the assay substrate,
however, was also based on several longer-term research goals. Since the synthesis of
various potential inhibitors and probe molecules were contemplated, the techniques to be
initially developed needed to afford the most versatile suite of intermediates possible so as
to limit the time spent in the preparation of these other targets. Some of these
considerations are discussed below.
As has been accomplished in our laboratory in the past for the side-chain cleavage
protein, we intend to define the precise relationship between bound substrate and inhibitor
molecules and the heme plane using ESEEM and EXAFS studies.(7 4 ) Using ESEEM, the
distances between the heme iron and the deuterium atoms of specifically deuterated steroids
can be determined.( 70) It is desirable to find synthetic procedures which activate lanosterol
at several of the positions on the (x-face of the steroid which are strategically located around
the point of action of the demethylase such that the required deuterium atoms can be
introduced (Figure 8). Since the enzyme sequentially converts lanosterol into 32-hydroxy-,
32-aldehyde- (or 32,32-dihydroxy-) and 14-formyllanosterol intermediates, in order to
assess changes in the binding of these oxidized intermediates relative to the substrate it is
also desirable to use synthetic procedures that provide easy access to some or all of these
intermediates in regiospecifically deuterated forms.
Nearly all assays published to this point have used 24,25-dihydrolanosterol as the
assay substrate even though this is not the natural substrate for either the mammalian or
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Figure 8: View of the a-face of Lanosterol showing the
protons surrounding the 14x-methyl
fungal proteins. Dihydrolanosterol has a five-fold lower Vmax compared to lanosterol and
a two-fold higher Km (i.e. a ten-fold lower specificity, Vmax/Km) for the rat liver enzyme
(see Table 2).(5 1' 146) This choice, which is made to ease the synthetic burden, does not
significantly impair the assay's utility in terms of relative measurements. The synthesis of
authentic, labeled lanosterol was desirable for several reasons. First, although the synthetic
procedures would surely require modification, it seemed reasonable that the side-chain
double-bond could be preserved without undue added complexity, yielding an assay with
greater sensitivity. Second it would be beneficial to develop the synthetic techniques
necessary to control that functionality so that it could be used in the design of inhibitors and
probes. Furthermore, although in yeast species and mammals the substrate of the
demethylase is lanosterol, in filamentous fungi 24-methylene-lanosterol is the natural
substrate. It has been shown that, even in yeast, the enzyme has a preference for 24-
methylene-lanosterol compared to the enzyme from rat liver.( 10' 15, 16) The development of
the techniques for the preservation of the side-chain double bond through the synthesis of
specifically labeled lanosterol allows for the study of 24-methylene-lanosterol derivatives in
the future. Assays using the authentic substrates in each of these systems may aid in the
development of anti-fungal inhibitors that discriminate between the various enzymes by the
exploitation of this difference in side-chain preference. ( 10 3)
The synthetic work described here represents the initial phase of a larger project in
this laboratory aimed at creating selective, effective 14t-demethylase inhibitors and
understanding the molecular basis of P-450 chemistry and selectivity. A number of
proposals for future research in this laboratory based on the work presented here are given
at the end of this chapter.
Previous syntheses of Lanosterol that are Amenable to Specific
Labeling at the C-32 Position
Synthesis of Dihydrolanosterol from Cholesterol
The synthesis of lanostenol (dihydrolanosterol) from cholesterol in 1957 by the
research labs of Woodward and Barton( 15 9 ) provides the basis for the preparation of all
specifically-labeled dihydrolanosterol for the assay of lanosterol 14-demethylase found in
the literature. (1 27, 28, 104) Although several of the steps of the synthesis have been
supplanted by more efficient methods,(8 4' 115) the overall strategy remains remarkably
unchanged. In brief, the strategy, requiring ten steps, is as follows: the cholesterol alcohol
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Figure 9: Synthesis of dihydrolanosterol from cholesterol, original method by Barton with
modem modification by Parish. (a) (see Feiser, JACS, 1953,75, p.5 4 2 1); (b) t-BuOK,
t-BuOH, CH3I; (c) LiAlH4, Et20O; (d) Pyridine/Ac 2 0; (e) N-bromosuccinamide, CC14, A, hv;
collidine; (f) HCL, CHC13, -400C; NH 3, MeOH, -600 C; (g) monoperphthalic acid, Et2 O; NaOH,
EtOH, /reflux; (h) HCl, EtOH, reflux; (i) Pyridine, benzoyl chloride; (j) TMSC1, Et3N, DMF,
140°C; (k) benzyltrimethylammonium fluoride, CH 3I; (1) hydrazine hydrochloride, triethylene
glycol; NaOH, 210°C. [Barton, 1957; Bossard, 1991; Bossard, 1989; Parish, 1977]
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is converted to a conjugated ketone for the introduction of the geminal methyl groups at C-4
on the steroid A-ring; a second double bond in the B-ring is formed and the double bonds
are isomerized to the A7,14 position where they are oxidized-isomerized to form another
conjugated ketone which is used to introduce the 14-methyl; the ketone is then removed
by Wolff-Kishner reduction and the double bond is isomerized to the proper A 8-position
(Figure 9).
In recent preparations for use in enzymatic studies, the label is introduced in a
straightforward manner as 3H methyl iodide and the overall yield is -2%.(28) Several
disadvantages of this synthetic strategy are evident, however. If one desires to use
authentic lanosterol (A 8,24 ), the only possible way to do so is to build up the side chain
from pregnenolone or progesterone.* This modification would require additional steps to
protect the shortened or completed side-chain from the various reagents used. A more
pressing concern is the lack of lanosterol-like intermediates in the synthesis that could be
used as starting materials for inhibitors or structural probes. Since the 14ic-methyl group is
introduced at the end of the synthesis, any variations (other than the introduction of
functionality at C-15 or at the 14-methyl position itself(1 3 9)) are limited by the requirement
of being compatible with the remainder of the synthesis. A minor drawback is the fact that
the introduction of the label is not the last step; the radioactivity must be handled through
two synthetic steps as well as the purification of the mixture of double bond isomers (A8,24
from A7,24 ).
A recently published variation on this strategy(1 8) proceeds via epoxidation of the 3-
hydroxylanost-14-ene isomer (as opposed to the 7,14 diene) which can be prepared from
dihydrolanosterol in -25% yield in 9 steps (4 1) . Overall, this variation is more complex (14
steps) but somewhat higher yielding at -4.3%.
Synthesis of 32-Hydroxylanosterol from Lanosterol
A second strategy is based on the work of numerous researchers interested in the
mechanism of 14(x-demethylase and specifically the 32-oxidized intermediates of
lanosterol. Dihydro-analogs of these intermediates (32-hydroxy- and 32-oxo-lanost-8-
enol) have been synthesized and appeared to be suitable precursors for the synthesis of
specifically-labeled lanosterol via reduction of the functional group at C-32 with the
introduction of tritium (3 H). The basic strategy is the oxidative activation of the allylic C-7
position of lanosterol to form a 7tc-hydroxylanostane derivative. The axial 7x-hydroxyl is
* Cholenic acid, a starting material lacking only the terminal isopropyl carbons, is prohibitively expensive
at $125/gram as is 25-hydroxycholesterol at $1,250/gram (Steraloids, 1992 catalog).
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positioned to be in close proximity to the axial 14c-methyl (a bond formed between the
hydroxyl oxygen and one of the methyl protons would form a six-membered ring, Scheme
4). From this vantage the 7a-hydroxyl is used to effect a through-space radical oxidation
of the otherwise inaccessible neopentyl methyl (details of these techniques are presented
below). It is required that the A8 double bond of lanosterol be reduced to carry out these
oxidations. Otherwise, with the double bond in place, the angle defined by carbons 7, 8,
and 14 expands several degrees placing the hydroxyl and methyl groups too far away from
each other to effectively form a bond. (68' 131)
There are several advantages to this strategy over the cholesterol-based approach.
Being based on lanosterol, the possibility of retaining the natural A24 unsaturation in the
final product requires no extra synthetic effort, although extra steps may be necessary to
preserve the olefin throughout the synthesis. Almost all of the synthetic intermediates of
this route may be used as bases for the construction of lanosterol-like inhibitors and
structural probes. Since the 32-hydroxy group is used as a handle for the introduction of
the radiolabel, this transformation can be postponed until the very last step in the synthesis,
obviating the need for multiple radiochemical transformations. Although no procedures for
the reduction of 32-oxidized lanostenols to lanosterol have been published, many methods
exist for this functional group transformation. (9 8 ) For these reasons the lanosterol-based
route was chosen for this project.
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Scheme 4: Conformation of 7oc-hydroxylanostane showing close
contact of hydroxyl alcohol and 14c-methyl protons
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Synthetic strategy
Methods of Synthesizing 7-Hydroxylanostanols
The earliest synthesis of this lansoterol derivative was achieved via a low-yielding
allylic oxidation of the tetrasubstituted A8 bond to the conjugated 7-ketone with chromic
acid.(2 5, 35) This was subsequently reduced by lithium in ammonia followed by catalytic
hydrogenation in low yield.(22 ) This method was replaced in 1965 by one incorporating
the isomerization of A8 lanosterol to the A7 isomer (100) followed by epoxidation with meta-
chloroperoxybenzoic acid and reductive ring opening with lithium metal in ethylamine.(54)
A more recent version of this route resulted in a 6.2% yield.(1 14 )
In 1977, Sonoda published an improved method based on the 7-keto-8-ene. (13 5 )
Using peroxide and sulfuric acid to make the ketone,(1 18) it was found that the 7a-alcohol
could be produced directly via catalytic hydrogenation (overall yield, 18%). This method
suffers, however, for our application because the catalytic hydrogenation will reduce the
side chain double bond as well. Conversion of the double bond to the dibromide does not
protect it from this reduction (see Synthetic Tactics section, below).
It was our goal, therefore, to develop a new method based on stepwise dissolving
metal and hydride reductions, neither of which should affect the side-chain double bond
(see Tactics section below). This endeavor has resulted in a procedure that is far superior
to that reported by previous researchers; by using lithium in ammonia-toluene followed by
lithium tri(t-butoxy)aluminohydride we have produced the 7oa-alcohol in 65% yield from
the 7-keto-8-ene (which would correspond to -45.5% from dihydrolanosterol for
comparison).
Methods of Activating the 32-Methyl Position
The activation of the angular methyl groups of steroids and like compounds via
radical chemistry has wide application in chemistry and has been especially useful in the
study of enzymes in the steroid biosynthetic pathway such as aromatase and aldosterone
synthase.(21 ' 69) The classical method was pioneered by Barton and co-workers in the
early 1960's.(20) Using nitrite esters of alcohols in a 1,3-diaxial relationship with a methyl
group, it was found that photolysis generated the corresponding oxime. Mechanistic
studies suggest the intermediacy of alkoxy and carbon-based radicals.(2)
This method was applied to the synthesis of 32-oxygenated lanostanol derivatives
by Bentley, McGhie and Barton in 1965.(24) The 7-hydroxylanostane was converted to
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the corresponding nitrite with nitrosyl chloride which, when photolyzed in benzene,
yielded the 7oc-hydroxy-32-oxime. The 7oc- and oxime hydroxyl groups were eliminated
via their methane sulfonates yielding the 14o-nitrilo-7-ene which can be reduced to the
corresponding 32-aldehyde or alcohol.(24 ) (Scheme 5)
This method has been used to efficiently synthesize inhibitor and probe molecules
functionalized at C-32 and containing the A7 double bond. (4 0' 148, 149) However, use of
this method for the synthesis of A8 lanostenols requires extra steps to isomerize the double
bond. Directing the isomerization of this double bond is somewhat of a hit-or-miss
process; for instance, Cooper found that neither the 14(x-nitrile or 32-alcohol would
isomerize to the A8 isomer, while the 32-amine isomerized completely at pH 4.5.(40! It is
possible to create a 70/30 mixture of A8/A 7 from dihydrolanosterol using HCl in
chloroform. (1 00 ) Furthermore, it is only possible to isomerize the A7/A 8 system of
lanosterol once the A24 olefin is protected as the dibromide. (58 ) Separation of the resulting
mixture of A7- and A8-lanosterol isomers requires high-performance techniques such as
HPLC or gas chromatography.
A second method (published, incidentally, side-by-side with Bentley's
communication in 1965) has become much more widely used due to its simplicity and
higher yield.( 54' 114, 135) Lead tetraacetate is used in place of the nitrite to generate an
alkoxy radical. After hydrogen abstraction from the nearby 14-methyl and trapping by
the lead triacetate, the hydroxyl group attacks the carbon displacing the lead and forming a
tetrahydrofuran ether ring (Scheme 6).(68) This ether is converted by acetolytic cleavage
with refluxing pyridine hydrochloride in acetic anhydride to a mixture of 32-
hydroxylanostadienes consisting of 22% A8 and 38% A7. Because of the simplicity of this
method it was selected for use in this work.
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Scheme 5: Nitrite photolysis activation of C-32
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Very recently a method of generating lanost-7-en-32-al using the hypoiodite
method (6 8) has been reported. (1 33) However, despite generating the aldehyde in only two
steps from the 7a-alcohol, the overall yield of this transformation is low (-10%) and the
conditions of the hypoiodite method are incompatible with an unprotected or dibromide-
protected side-chain double bond.
Strategies for Reduction of 32-hydroxylanosterol to Lanosterol
Although there are no published procedures for the conversion of 32-
hydroxylanosterol to lanosterol many synthetic routes are known for this type of
transformation. (98) The factors to consider in the choice of method in this case are varied.
Although residing on a primary carbon which protrudes noticeably from the steroid a-face
in stick-figure models of 32-hydroxylanosterol (Scheme 2), the position is neo-pentyl and
quite hindered as can be seen from space filling models (Scheme 4a and Figure 8). For this
reason, SN2 substitutions are expected to be difficult. Similarly, reactions having
considerable cationic character in the transition state may be slow (primary carbon) or lead
to rearrangement (since it is to a quaternary carbon and homoallylic). The method
chosen needs to be compatible with the side chain double bond. Thus, strongly acidic,
electrophilic or free radical reagents should be avoided. In order to introduce tritium at the
32-position for the enzymatic assay, the tritium source should be inexpensive and in as little
excess as possible. Furthermore, the labeling with tritium should be specific; no other
protons in the steroid can be equilibrated with the tritium source. Of course, high yield is at
a premium as this reaction is at the end of rather lengthy synthesis.
Although at a neopentyl position there are some nucleophilic substitution reactions
which might be expected to proceed productively. Hydride reagents, in particular, may be
able to access the proper position to displace a suitable leaving group. Most often used are
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Scheme 6: Lead tetraacetate activation of C-32
sulfinate esters such as methanesulfonyl (mesyl), toluenesulfonyl (tosyl) and
trifluoromethanesulfonyl (triflyl). It is possible that these reagents may be effective in
polar aprotic solvents such as hexamethylphosphoramide (HMPA) or dimethylsulfoxide
(DMSO). Unfortunately, sodium borotritiide, while a relatively inexpensive source of
tritium, is probably too mild a reagent for this transformation, very likely requiring a large
excess if it is to be successful at all. Lithium aluminum tritiide, on the other hand, is a
more expensive source of tritium.
Even though radical-forming reagents may react with the side-chain double bond,
the action of tri-alkyl tin hydrides on alkyl bromides and iodides have been reported to be
significantly faster than the addition to and reduction of double bonds. (8 7 ) Tritium can be
supplied easily and inexpensively by reducing tri(n-butyl)tin chloride in situ with sodium
borotritiide.( 86 ' 87) The challenge, then, is the conversion of the alcohol to either of these
halides. Direct conversion of the alcohol to the halide, using HX or PBr3 for instance,
generally will result in considerable rearrangement of the neopentyl carbon. Several less
common reagents have been reported to support halide formation with minimal
rearrangement including NaX, KX or NH4X in polyhydrogen fluoride-pyridine solution,
(RO) 3PRX and R 3PX 2. (98 ) The substitution of sulfinate esters by nucleophiles such as
iodide and bromide ion has been effected at neopentyl positions using HMPA.(1 38 )
A most promising method is the reduction of the corresponding 32-aldehyde by a
modification of the Wolff-Kishner method. The alcohol can be oxidized to the aldehyde by
the mild Swern oxidation using DMSO and oxalylchloride at -600C.(92, 97) The aldehyde
can then be converted to the tosylhydrazone and reduced by one of several methods. (3 1' 71,
76, 77) In one method, using catecholborane, tritium can be supplied in the water used to
decompose the catecholborane-tosylhydrazone complex (Scheme 7).(78) In another
variation, sodium borohydride in methanol or lithium aluminum hydride in dioxane are
used; these two reductions proceed by quite distinct mechanisms.( 14 2 ) In this way, since
one of the hydrogens added to the carbon comes from the solvent (or quench solution) and
the other from the reagent, two equivalents of tritium can be added at once.
A fourth technique, particularly well-suited to hindered alcohols, is the dissolving
metal reduction of phosphorodiamidates. ( 72 ) The phosphorodiamidate is easily formed by
the reaction of N,N-dimethylphosphoramidodichloridate (DMPADC) with the n-
butyllithium- or lithium diisopropylamide-generated anion of the alcohol. The resulting
monochloride is converted to the N,N,N',N'-tetramethylphosphorodiamidate (TMPDA) by
the addition of dimethylamine prior to work-up of the reaction. (9 4 ) The TMPDA is then
reduced by lithium in ammonia, methyamine or ethylamine.( 72) This method is much less
likely to be affected by steric factors, (consider, for instance, the reduction of the highly
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hindered intermediate in the synthesis of palauolide by Piers and Wai(l 17)), but has the
drawback of having no direct way of introducing tritium at high specific activity. The
availability of tritiated ammonia, methyl- or ethylamine is poor and their use would be
extremely wasteful of the isotope. One way around this situation is to first introduce the
tritium by a two-step oxidation-reduction path via the aldehyde using, for instance, Swern
oxidation followed by reduction with tritiated sodium borohydride.
Protecting groups
Several possibilities exist for the protection of the side-chain double bond through
the course of the synthesis. The most basic, and the one used in this work, is to protect the
double bond as the dibromide (75' 93) through the oxidation at position C-7 and then to
avoid using techniques which would adversely affect the unprotected double bond
subsequently (Figure 10). Other possibilities exist, however, and are worthy of note here.
Ozonolysis of the side chain is possible in the presence of the A8 olefin due to the
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hindered nature of that ring-juncture.(1 16) This leads to 25,26,27-trisnor-24-lanosteroic
acid which can then be esterified or reduced to the alcohol and protected. Lanosterol could
be reformed at the end of the synthesis by reduction or oxidation to the aldehyde and
elaboration of the side-chain terminus by Wittig reaction with isopropyl ylide.
Epoxidation of the side chain double bond has been carried out followed by boron
trifluoride-catalyzed rearrangement to 24-ketolanosterol.(12 6) This ketone can be protected
by standard methods and then reduced to the A22 olefin by the Shapiro reaction (conversion
of the ketone to the tosylhydrazone and reduction with two equivalents of alkyllithium).
This olefin could then be isomerized to the more hindered A24 position with borane. (It is
interesting to note that this 24-ketone is an excellent precursor to the substrate of the fungal
14-demethylase, 24-methylenelanosterol, via a Wittig reaction with methyl ylide.)
Alternatively, the epoxide could be hydrolyzed to the diol (or the olefin oxidized to
the diol directly) and protected. Several methods exist for the dihydroxy elimination of
vicinal diols to reform the olefin. (98 )
The double bond can be converted to the 25-hydroxylanost-8-enol by
hydroxymercuration or simply by treatment with aqueous acid. The alcohol can be reverted
to the olefin via elimination of the corresponding bromide (the more hindered A24 olefin
should result considering Zaitsev's rule).
As for the protection of the 3[3-alcohol, the acetate group proved to be adequate for
the needs of this synthesis. Although removed during reduction of the C-7 ketone as well
as during deprotection of the 32-alcohol it does resist side-reactions during peroxide
oxidation, lithium-ammonia reduction, and acetolytic ether cleavage. As will be discussed
below, it was convenient to switch to a silyl ether for the last few steps of the synthesis in
order to efficiently use some 3,32-diol which was protected as the 32-acetate (the diol is a
minor product of the selective deprotection of the 3,32-diacetate). This change had no
effect on the synthetic strategy
Synthetic Tactics
The chemical compounds involved in the following synthesis are numbered
according to Scheme 8. Due to the variations in side-chain structure, protecting groups,
double bond location, functional group orientation and isotopic labeling, the following
system has been adopted: only the basic steroid forms are numbered, the above variations
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o-4: R3 = alpha-alcohol
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Scheme 8: Numbering scheme for molecules mentioned in this chapter.
(Prefixes indicate side-chain structure, oc/3 orientation and double bond
position, suffixes indicate protecting groups. For instance, A 7-6d
corresponds to 3 3,32-dihydroxylanosta-7,24-dienyl diacetate)
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DH-I: R2 = *-'e
DB-i: R2 =
Protecting Groups
a - no protecting groups
b - 3-acetate
c - 7- or 32-acetate
d - diacetate
e - 3 P-TBDMS ether
- |
R4-
R4
DH-la
a,b
DB-lb
c
d, e, f
9g
5b
or e)
DOH
k
D-lle
Figure 10: Synthesis of 32-[D]-Lanosterol from a commercial mixture of lanosterol and
dihydrolanosterol. (a) Br 2, NaOAc, AcOH, Et20O; (b) Pyridine, Ac 20; separation of dihydro-
from dibromo-compounds; (c) AcOH, H 2SO4, H 2 02 ; (d) Zn, AcOH, Et20; (e) Li,
NH3-Toluene (1:1); (f) Li(t-BuO)3 AlH, Et2O; LiAlH4, Et20; Pyridine, Ac2 0; (g) Pb(OAc) 4,
Benzene, Toluene; (h) Pyridine-HC1, Ac20; LiAlH 4, Et 2O; (also Pyridine, Ac 20 or
TBDMS-triflate, CH 2C12, Pyridine, see text); Purification of A7 from A8 isomers; (i) DMSO,
Oxalyl chloride, CH 2C12; (j) NaBD 4, EtOH, (k) LDA, 1,2-DME, TMEDA; DMPADC
(dimethylphosphoramidodichloridate); dimethylamine; (1) Li, MeNH 2.
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are indicated by prefixes (DH and DB for dihydro- and dibromo- side-chains, a and for
alcohol orientations and D for deuterium labeling) and suffixes (protecting groups, see
Scheme 8).
Preparation of pure starting material and use of protecting groups
Lanosterol is isolated in considerable quantity from wool-fat, the steroid fraction of
which contains lanosterol (la), dihydrolanosterol (DH-la), agnosterol and gamma-
lanosterol. Presently, lanosterol can be purchased from Sigma as mainly a 3:2 mixture of
lanosterol and dihydrolanosterol. The separation of this mixture is quite difficult (see, for
instance, early work by Ruzicka (151) and earlier papers). Faced with this problem, many
researchers have converted the mixture to pure dihydrolanosterol by catalytic
hydrogenation. (100 ) Others, who required only small amounts of pure lanosterol have used
preparative gas chromatography and preparative HPLC. (12' 145) Both of these methods are
appropriate for applications where unmodified lanosterol of dihydrolanosterol are used as
the assay substrates (small amounts of material need to be prepared periodically, whenever
assays need to be done). For use as synthetic starting materials these methods are generally
inappropriate because a large amount of material needs to be prepared very infrequently;
ideally, this would only have to be done once to provide enough for the whole synthesis.
The lanosterol mixture obtained from Sigma was considerably more pure than that
which earlier researchers used, so separation of the isomers by recrystallization was
attempted. Recrystallization from methanol and methanol/ethyl acetate mixtures under
various conditions failed to discriminate between lanosterol (la) and dihydrolanosterol
(DH-la). Purification of the isomers by silica gel chromatography could be effected by
multiple elutions on analytical thin-layer chromatography plates. Column chromatography
using very low polarity solvent mixtures (like 100:1 hexanes ethyl acetate) could partially
separate the material but the excessive amount of solvents necessary were deemed
impractical.*
Two methods exist in the literature for the purification of lanosterol (la) via
reversible derivatization of the side-chain double bond. In the first, 24-bromolanosterol is
* Near the end of the work presented in this chapter the t-butyldimethylsilyl (TBDMS) ether of lanosterol
(le) was prepared for comparison with that synthesized by reduction of the 32-TMPDA ester (see forward).
This extremely non-polar derivative was found to separate from the dihydro-isomer (DH-le) by up to 0.12
Rf units on analytical thin-layer chromatography in hydrocarbons such as pentane, heptane, isopentane and
cyclohexane. Although the Rf's in these solvents were higher than is generally optimal for column
chromatography (-0.5), the use of large silica columns may provide a simple method for large scale
purification of lanosterol.
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formed, (4 5) separated from the crude mixture and then the bromine is removed with lithium
in tetrahydrofuran to regenerate lanosterol. ( 9 5) This methodology may be useful in the
preparation of 24-methylene lanosterol, the natural substrate of the 14-demethylase in
filamentous fungi.
The second method uses bromine to generate 24,25-dibromolanosterol (DB-la)
which is separated from the crude mixture, crystallized as the acetate (DB-lb), saponified,
and debrominated with zinc to regenerate lanosterol (DB-la).( 5 8' 75) This method was
judged to be more applicable to our needs as the protected molecule, dibromolanosterol
acetate, should be suitable as a starting material for the synthesis of 32-[ 3H]-lanosterol. As
has been summarized above, this scheme calls for the oxidation of the A8 double bond of
lanosterol to a conjugated ketone, and the reduction of that group to an alcohol. It was
reasoned that the vicinal dibromide group would be resistant to the oxidation by
peroxyacetic acid, and might be sufficiently resistant to reduction by hydrogen over
platinum to serve as a protecting group for the double bond through these transformations.
In a test experiment it was found that a slight excess of bromine over lanosterol
yielded the 24-R and 24-S diastereomers of dibromolanosterol in a 1:1 ratio by HPLC
using a C-18 reverse phase column with methanol as the mobile phase. All of the
lanosterol was consumed and none of the A8 double bond reacted. Purification of the
product by recrystallization was achieved more easily after formation of the acetate with
pyridine/acetic anhydride. It should be noted that chromatography of these dibromides is
somewhat complicated by the diastereomerism, since the mobility of these isomers is
different enough to significantly broaden any eluted bands.
Activation of C-7 and C-32 positions
Allylic oxidation at C-7
The conversion of lanost-8-enes to lanost-8-en-7-ones has been traditionally carried
out by oxidation with chromic acid in poor yield. Since 1970 however, an improved
method using dilute peroxide and sulfuric acid has been in wide use. (1 18) This method
gives yields of 60-80%.
In thinking about whether this reaction would be compatible with the dibromide
protecting group, a working model for the mechanism of this reaction was developed
(Figure 11). This mechanism is based on several observations: first, peracetic acid, an
epoxidizing agent, is formed by the mixture of sulfuric acid, acetic acid and peroxide;
second, the acidic conditions will allow partial isomeriziation of the A8 double bond to the
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Figure 11: Proposed mechanism of allylic oxidation by peroxide and
sulfuric acid on lanosteryl acetates
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A7 and A9( 1 1) positions; and third, the C-7 position is considerably less hindered than the
C-ll position.
In carrying out the reaction using the conditions described by Pinhey (acetic acid as
solvent, 0.3% sulfuric acid, 1% peroxide, room temperature, 17 hours) very poor
conversion to product was observed. Even after 46 hours the reaction was not complete,
and that which had reacted was distributed over 10 product compounds. Addition of ethyl
acetate to improve the solubility of the starting material and increased oxidant concentration
were not found to improve the situation. Heating the solution, however, and lowering the
reaction time greatly simplified the product distribution and drove the reaction nearly to
completion. Apparently, the side reactions involving degradation of the dibromide are less
sensitive to rate enhancement with increasing temperature. The optimal conditions were
found to be 70 C for 1 hour, yielding nearly 50% desired product. To do the reaction on
large scales, however, a more concentrated reaction mixture must be used to obtain
reasonable volumes. This modification reduced the yield to around 35%. (This figure
may, however, be improved by further optimization.)
Recently it has come to our attention that an alternative oxidation may be superior in
this case. Paryzek reports an interesting allylic oxidation of lanosterol (la) to 7-keto-
lanosterol (2a) in 57% yield using ozone in polar solvents such as ethyl acetate (the 7a,8tx-
epoxide is also formed in 22% yield).( 16) Although this yield is lower than the 60-80%
reported for peracetic acid oxidation of dihydrolanosterol, it is better than the yield obtained
here with dibromolanosterol. Furthermore, the workup of this reaction is considerably
simpler and purification of the product should be easier than with the peracetic acid
reaction. The dibromide protecting group should be quite stable under these conditions.
Reduction of the unsaturated ketone
The method of Sonoda (hydrogenation over platinum (135 )) for the formation of the
7c-alcohol (o-4) directly from the 24,25-dibromo-7-oxo-lanosterol acetate (DB-2b) was
attempted first. As a test of the method the reaction was carried out on a sample of 7-oxo-
dihydrolanosterol acetate (DH-2b) and, as reported, 7ca-hydroxylanostane (DH-cx-
4a)was obtained in -20% yield. When this reaction was attempted with the dibromo-
protected compound (DB-2b), however, it was found that the bromines were reduced
significantly faster than the conjugated ketone, and no brominated compounds could be
recovered.
The dibromide protecting group is incompatible with reduction by lithium in
ammonia, but the unprotected double-bond is insensitive to this treatment. Therefore, the
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dibromide was removed by treatment with zinc/acetic acid in diethyl ether. Initially,
standard conditions were used for the dissolving metal reduction: the steroid (2b) was
dissolved in diethyl ether and t-butyl alcohol was added as a proton source. This was then
added to an excess of lithium in liquid ammonia. The reaction was quenched with aqueous
ammonium chloride. This procedure resulted in a very complex mixture of products from
which the desired saturated ketone (3) could be isolated in only about 20% yield. Probably
the presence of t-butyl alcohol caused over-reduction of the ketone to the alcohol by
protonation of the initially formed, and otherwise stable, lithium enolate. Under such
equilibrating conditions the equatorial 3-alcohol (-4) will be formed. This can also result
from the addition of water in the quenching solution. (A thorough discussion of lithium-
ammonia reductions of steroidal ketones can be found in Fried(48 ))
Changing the conditions to include toluene (to aid in the solubilization of the steroid
in the ammonia), omit t-butyl alcohol and quench the reaction with ethylene dibromide to
prevent over-reaction caused by premature protonation in the presence of excess lithium,
resulted in a considerably cleaner reaction. It was found that reaction for considerable
periods of time with excess lithium would not fully reduce the 313-acetate to the
corresponding alcohol. Furthermore, the desired products (acetate and alcohol) were
contaminated in a 1:1 ratio with two side products which were shown by chemical and
spectroscopic techniques to be most consistent with the -hydroxy ketone, 3,8f3-
dihydroxy-7-oxolanost-24-enol and its corresponding 3-acetate. This assignment of
structure is quite surprising, and possibly unprecedented in lithium-ammonia reductions.
Due to the unususal nature of the assignment, a detailed discussion of the supporting
evidence is presented in the Appendix to this chapter. The possibility that this anomalous
product was due to trace water impurity was eliminated by using freshly distilled toluene
and running the reaction under argon. It seems quite likely that the oxygen is introduced
either in the work-up of the reaction, from 02 dissolved in the toluene, or even from
peroxides in the ether, since there is no other source of oxygen in the reaction itself
(besides that small amount from any cleaved acetates). The mechanistic origin of this
compound remains a mystery since it is generally believed that reduction of conjugated
ketones results in the lithium enolate of the ketone prior to quenching with a proton source,
and in any case, the position alpha to a ketone should be electron-rich, requiring an
electrophilic oxygen source.
Whatever the mechanistic cause, the practical solution to the problem involved the
relative solubility of the steroids in the ammonia and toluene phases of the reaction.
Fortuitously, it was found that running the reaction in 1:1 ammonia-toluene and completely
emulsifying the two immiscible phases with vigorous stirring (overhead stirring at
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maximum speed in a baffled flask) completely eliminated the production of the side
product.
Reduction of the ketone at position 7 with lithium aluminum hydride resulted in an
unfavorable 3:1 mixture of the 71- and 7a-alcohols (-4, -4). This result is consistent
with previous reports in the lanosterol literature as well as the general trend for steroidal 7-
ketones. Wheeler, for instance, reports that hydride reduction of 7-keto-cholestanes results
in -70% 13-alcohols whether the reductant is LAH, NaBH 4 or the hindered reagent lithium
tri(t-butoxide)aluminohydride. (155 ) Analysis of MM2-minimized models of 7-ketolanost-
24-enol (3a, Scheme 9) indicated that the primary steric block to the approach of reagents
to the j3-face are the two angular protons at C-8 and C-6 adjacent to the carbonyl. The two
nearby 3-methyls (C-18 and C-19) appear to be too far away to have much of an effect.
The (a-face, on the other hand, has two angular protons which are two carbons removed
from the carbonyl at C-9 and C-5. In this respect it is relatively uncrowded, and seems to
explain the preference of hydride reduction in the cholestane series. In lanostanes,
however, the presence of the angular 14x-methyl should come into play by blocking the
approach of more hindered reagents, although the smaller lithium aluminum hydride seems
to be unaffected by it. Using lithium tri(t-butoxy)aluminohydride, the 7c-alcohol (-4)
was formed in a 3.75:1 ratio (79% to 21%). When this reagent was used on the crude
product of the lithium/ammonia reduction, the residual acetate at C-3 was undisturbed
yielding a mixture of 31-alcohols and acetates. To complete the reaction then, an aliquot of
lithium aluminum hydride was added prior to work-up to yield only the mixture of 313,7a
and 31,71 alcohols.
The yield of 7x-alcohol (oc-4) from these combined reduction steps is 65%.
Another 17% is 713-alcohol (13-4) which can, without much difficulty, be converted into the
proper isomer. This compares quite favorably with the 26% yield of the literature
preparation using catalytic hydrogenation.(135)
Reprotection of the 33-alcohol in the presence of the 7ax- and 713-alcohols is easily
achieved by acetylation with acetic anhydride in pyridine. The two equatorial alcohols, 313
and 7, react much more rapidly than the axial 7-alcohol. This has the effect of
selectively protecting the 31-alcohol while simultaneously purifying the 7x-alcohol from
the 71-alcohol. For instance, when a mixture containing 79% 7-alcohol (-4a) is
allowed to react until 90% of the starting diols are consumed (4 hours with 25 alcohol-
equivalents of acetic anhydride in 1:2 anhydride-pyridine) the 7-hydroxy-3-acetate that is
isolated in 43% yield is entirely the 7a isomer (a-4b), while the 3,7-diacetate is found to
be 40% 7oa (a-4d, 34% yield). By modeling the reaction as two independent first-order
reactions and using the data from several trials, the optimal reaction time for maximizing the
production of the 7cx-monoacetate (a-4b) from a 79% 7a mixture of diols was found to be
roughly 4.4 hours.
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oc-face
Scheme 9: MM2-minimized space-filling models of 7-oxolanost-24-enol (3a),
comparison of a and -faces. Notice the partial occlusion of the carbonyl by the
14a-methyl group. In both representations the carbonyl and its alpha carbons are
constrained to the plane of the paper.
Formation of 32-alcohol
When the lead tetraacetate cyclization of 3P-acetoxylanost-24-en-7a-ol (a-4b) is
carried out under the conditions specified by Parish( 11 4) for the saturated compound (i.e.
24-hours refluxing benzene, 5.5 equiv. lead tetraacetate) a very poor yield (14%) of 7a-32
cyclic ether (5b) is formed. NMR of the various side-products all indicate that although the
desired tetrahydrofuran ring is in evidence in all products, the side-chain double bond has
been oxidized in various ways. Clearly, these results indicate that the degradation of the
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side-chain is a slower process than the cyclization and, therefore, reducing the reaction time
should improve the situation. It was found that reaction for only 2.5 hours resulted in a
59% yield of the desired product. 20% of the starting material was reclaimed unchanged;
10% was isolated as 7-oxolanost-24-enyl-3[f-acetate (3b), while only 11% was lost to
side-chain degradation. Acetolytic cleavage of this ether by pyridine hydrochloride and
acetic anhydride proceeded exactly as reported by Parish and Schroepfer,(114) yielding a
mixture of A6, A7 and A8 diacetates (6d, 1:6:3 ratio).
The diacetates formed at this stage are conveniently cleaved to a mixture of 3[-
monoacetates and diols by partial reduction with lithium aluminum hydride. The primary
32-acetate is cleaved significantly faster than the secondary 33-acetate such that only trace
amounts of 3f3-hydroxy-32-acetates are formed.
At this stage, the separation of the double bond isomers is most easily performed
using chromatographic techniques. Apparently the disposition of the 32-alcohol is affected
by the position of the double bond in the C-ring, because the isomers show small but
significant mobility differences on polar chromatography media (much better than that
displayed by A 8 -lanosterol (la) and A7 -lanosterol, for instance. Sonoda achieved
separation of the diols using a Waters -Bondpak-NH2 HPLC column in 1:1 chloroform-
hexane, while Parish used a combination of silica MPLC chromatography (1:3 EtOAc-
Toluene) and silica flash chromatography (97:2.5:0.5 chloroform-ether-acetic acid).(ll 14
135) It was found in the present study that separation of the 33-monoacetates was relatively
straightforward using Chromatatron radial thin layer chromatography (Harrison Research
Co.) in 8:1 hexane-EtOAc.
The diols formed by over-reduction are easily reconverted to the diacetates for
repetition of the above procedure, however, at this stage the 32-alcohol can be selectively
protected as the acetate (6c) by treatment with acetic anhydride in pyridine with monitoring
by TLC (Yield 65%). The 3(-alcohol can then be quantitatively protected as the TBDMS
ether (6f) using TBDMS triflate in methylene chloride with pyridine as base.
Saponification with 1 N NaOH in THF/Methanol gives the isomeric 3,32-
dihydroxylanostadienyl-33-TBDMS ethers (6e) in excellent yield. The double bond
isomers in this case are separated by silica flash chromatography in 5:2 cyclohexane-
chloroform.
Since the isomers are easily separated at this stage, the possibility of converting the
A7 isomer (A 7 -6e) into the A8 isomer (A8 -6e) was explored. The standard method for
this isomerization in 24,25-dihydrolanosterol (DH-la) uses HC1 gas passed through a
solution of the steroid in chloroform (100). Treatment of the A7 -32-alcohol (A7-6e) in this
manner resulted in numerous compounds by TLC. By cooling the solution to -30 C in a
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bromobenzene/liquid nitrogen bath a cleaner reaction was observed that by TLC appeared
to result in a 60/40 A8/A 7 ratio. Analysis by NMR, however, showed that although the
desired double bond isomerization had taken place, the side chain olefin was extensively
modified. This trial does, however, indicate that the presence of the 32-hydroxyl is no
impediment to the desired isomerization. A search of the literature showed a report of the
isomerization of A 7 -lanosterol (DH-la) by first protecting the side-chain double bond
again as the dibromide (DB-la) (5 8 ). Thus, by a three step procedure, the A7 isomers
should be convertible to usable A8 products.
Reduction of the 32-alcohol (6) to Lanosterol (1) with the Introduction
of Isotopes at the C-32 Position
The primary goal in this section was to show that the reduction of 32-hydroxy
lanosterol to lanosterol is possible. Throughout attempts towards this goal, the work was
carried out on only milligrams of material at a time, because that was all that was available.
Because this conversion was expected to be problematic, our strategy was to utilize the A6
and A7 isomers of the alcohol whenever possible to test the reactions in order to preserve
the proper A8 isomer for those conditions which looked promising. Of course, this may
have precluded some methods for which these "test isomers" were unsuitable while the
proper isomer may have been more successful. Furthermore, we did not have the luxury
of being able to extensively vary the reaction conditions of each method in order to tease
out the desired products out of seemingly unfavorable results. Four basic methods were
attempted. The first three were deemed unsuccessful due to either rearrangement or steric
hindrance. The fourth method, however, was quite successful (and the discovery of which
coincided with the exhaustion of our last batch of 32-hydroxylanosterol).
Hydride reduction of Sulfonate Esters
The tosylate of A6 -32-hydroxylanosteryl-33-acetate (A 6 -8b) was reacted with
lithium aluminum hydride in THF for 3.5 days and yielded three major products and
several minor ones. The only product with an Rf near that of lanosterol was shown by
NMR to have undergone some kind of rearrangement. It is possible that reaction in HMPA
or some other polar aprotic solvent might yield an unrearranged product, but this was not
attempted.
85
Iodide substitution of Mesvylate
The mesylate of A7 -32-hydroxylanosteryl-33-acetate (A7-7b) (44) was treated with
sodium iodide in HMPA and heated to 100 C for 4.5 hours. (13 8) Repeated thin layer
chromatography under optimized conditions revealed that the initially identified product
spot was, in fact, composed of five compounds, two of which correspond to solvolysis
products of the mesylate. The solvolysis products appear to contain three double bonds by
NMR and mass-spectroscopy, and probably resulted from D-ring expansion. One of the
products contains a cyclopropane ring (presumably by formation of a bond between
carbons 8 ands 32) as evidenced by a pair of doublets in the H 1-NMR between 0 and 1
ppm. The last two products contain iodine, but lack the vinyl resonance from C-7 in the
NMR, and probably result from iodine trapping of rearranged cations. Figure 12 shows
some of the possible rearrangement products and their mechanisms of formation; many
other possibilities exist. It is possible that reducion of the temperature, shorter reaction
times or the use of the smaller bromide ion instead of iodide might yield the desired
product, but this was not attempted here.
Reduction of 32-Tosylhydrazone
The 32-aldehyde (9) was easily formed from the corresponding alcohol via the
Swern oxidation(92 97) using DMSO and oxalyl chloride with yields in excess of 95%.
The tosylhydrazone (10) was formed by refluxing the aldehyde with toluene
sulfonhydrazide in ethanol for several hours. Recovery of the product was difficult if too
much reagent had been used, but yields approached 85%.
Reduction of the tosylhydrazone (10) using excess sodium borohydride in
refluxing methanol after the method of Caglioti,(3 1 ) yielded what appeared to be a mixture
of lanosterol (la) and lanosteryl acetate (lb) by TLC. After workup, reduction of the
acetate with LAH, and purification of the product, TLC showed a mixture of a UV-
transparent spot which co-eluted with lanosterol and a more polar UV-absorbing spot in a
1:1 ratio. NMR of the less polar compound, unfortunately, does not match with authentic
lanosterol. The identitiy of this product has not yet been determined.
Reduction of the tosylhydrazone (10) with catecholborane by the method of
Kabalka (-10 C, 20 minutes, followed by quenching with sodium acetate trihydrate)
resulted in no reaction. (7 6' 78) Increasing the length of reaction, amount of reagent and
temperature had no effect (the reagent was shown to be pure by comparison of the NMR
with published standards, the solvents were confirmed to be dry, and the starting material
was shown to have the proper structure after recovery from the reaction mixture). Initial
modeling of the starting material and reagent using the HyperChem package (AutoDesk,
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Figure 12: Some possible rearrangement products of the C-32 cation
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Inc.) seemed to indicate that there was little steric impediment to the approach of the
boronand its attached hydrogen into position alongside the carbon-nitrogen bond which is
initially reduced (Scheme 7). After the negative result, the molecule was reexamined using
a plastic CPK-type model. This model clearly illustrated that the rehybridization of the
proximal nitrogen to sp3 in the intermediate catecholborane adduct hinders the formation of
that adduct because of clash between the catechol group and the steroid nucleus.
Reduction of TMPDA
Conversion of the A 7 -alcohol (A 7 -6e) to the corresponding tetramethyl-
phosphonodiamidate (TMPDA, A7 -lle) was carried out by the method of Liu (94 ) using
dimethylphosphoramidic dichloride (DMPADC) after formation of the lithium alkoxide of
the alcohol with LDA. The reaction was quite clean and gave a 79% yield. Reduction of
the TMPDA with lithium in methylamine (without a proton source to inhibit reduction of
the double bonds(l 17)) gave three products in 6:3:1 ratio. The most abundant product was
consistent with the desired compound, A7-lanosterol-TBDMS ether (A 7-le), however this
could not be confirmed for lack of an authentic standard. The second most abundant
product appears to contain a cyclopropane ring by NMR as well as, perhaps, a A6 olefin.
Both of these compounds show the expected weight of desired product by mass
spectroscopy.
Reaction of the A8 -alcohol (A8-6e) with DMPADC was problematic, giving only a
12% yield under the standard conditions; using excess reagent only reduced this yield. The
consumption of the starting material is accompanied by the formation of a considerably less
polar side-product which is unidentifiable by NMR, but presumably results from a
rearrangement-elimination of the intermediate monochlorophosphoramidate. This reactivity
difference between the two double bond isomers is surprising. Varying the conditions will
probably improve the yields, but lack of material has precluded such a study at this time.
Reduction of the TMPDA (A 8 -lle) with lithium in methylamine, however, resulted in the
clean production of a single product (>95% yield by TLC). This product co-spotted with
authentic lanosterol-TBDMS ether in several solvent systems, showed identical 1H and
13 C-NMR's, and gave the same retention time and fragmentation patterns by GC-MS.
In order to introduce tritium at the C-32 position the alcohol can be oxidized to the
aldehyde and reduced with tritiated sodium borohydride. As a model for this process, the
aldehyde (A 8-9e, see above) was reduced with sodium borodeuteride. NMR shows
>60% incorporation of deuterium into the 32 position.
1H-NMR of these compounds indicates that there has been no degradation or
isomerization of the side-chain double bond throughout these transformations.
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Conclusions: Comparison of yield and complexity with dihydro-
syntheses
The synthesis described above formally represents the first synthesis of lanosterol
isotopically labeled at the 14c-methyl position. The conversion of 32-hydroxylanosterol
(6a) to lanosterol (la), described in the previous section, provides a second independent
route to these labeled lanosterols in parallel to the route from cholesterol to 24,25-
dihydrolanosterol (DH-la, Figure 9). Furthermore, this work demonstrates the feasibility
of preserving the side-chain olefin of lanosterol through a complex series of synthetic
transformations.
Compared to the corresponding synthesis of 32-hydroxydihydrolanosterol (DH-
6), although no comprehensive effort was made to optimize yields for all steps,
preservation of the double bond clearly results in some loss of overall yield. These
additional losses arise mainly during the preparation and purification of dibromolanosteryl
acetate (DB-lb), and the oxidation of this compound to the 7-keto derivative (DB-2b).
As mentioned above, the purification of lanosterol may be improved in the future by
chromatographic separation of the silyl ethers, and the allylic oxidation may be improved
by using an ozonolysis methodology.( 16) The lead tetraacetate activation of the C-32
position resulted in some losses due to double bond reactivity, but by lowering the reaction
time, this was mainly eliminated. This results more in a loss of research time than yield, as
the incompletely reacted mixture must be purified and the remaining starting material re-
oxidized. Although the penultimate reaction synthesizing the TMPDA derivative of 32-
hydroxylanosterol is problematic at this time, further investigations will likely alleviate this
difficulty.
The predictable failure of the hydrogenation of the dibromo-7-ketolanosterol (DB-
2) to selectively reduce the (hindered) conjugated ketone in the presence of the dibromide
was fortuitous as it prompted us to investigate the two-step reduction path using lithium-
ammonia and lithium tri(t-butyl)aluminohydride. This new reduction method is far
superior to previously published methods in yielding 7ca-alcohols and is applicable to both
lanosterol- and dihydrolanosterol-based syntheses.
Overall, this synthesis compares favorably in terms of yield and complexity with
the cholesterol based synthesis, and may, in time, prove to be a superior method for the
synthesis of labeled dihydrolanosterols. Presently it remains the sole method for obtaining
specifically-labeled lanosterol.
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Materials, Methods and Data
Materials and Equipment
All chemicals were purchased from Aldrich chemical company, were of the highest
grade available and were used without further purification unless noted otherwise. All
NMR's were taken in deuterochloroform with tetramethylsilane as an internal standard
unless otherwise noted. Spectra were acquired on the MIT Chemistry department's Varian
XL-series and Unity 300 MHz spectrophotometers. Mass spectra were taken using either a
Finnegan System 8200 quadrupole mass spectrometer in electronic ioniozation mode or an
Hewlett Packard 5890-series gas chromatograph with HP-1 100% dimethylpolysiloxane
(gum) column equipped with a Hewlett Packard 5971-series mass selective detector.
Infrared spectra were acquired using a Perkin Elmer 1600 series FT-IR spectrophotometer
with samples as thin films on NaCl plates. Melting Points were determined in sealed tubes
using a Hoover Mel-Temp apparatus.
Synthetic Preparations
Lanosteryl and Dihydrolanosteryl Acetates (lb, DH-lb). A mixture of
lanosterol (la, 62%) and dihydrolanosterol (DH-la, 38%) purchased from Sigma (40 g,
92 mmol) was added to a 2 liter round-bottom flask. 800 mL of freshly distilled pyridine
and 150 mL fresh acetic anhydride were added. The solution was allowed to stir
overnight. The solution volume was reduced by distillation of the volatile solvents under
reduced pressure. The remaining solution was dissolved in methylene chloride and
extracted with 2 N HCl, distilled water and saturated brine. The organic phase was dried
over magnesium sulfate, filtered and concentrated under reduced pressure. When the
volume of methylene chloride reached approximately 400 mL, 400 mL of methanol were
added. Evaporation of the solvents continued until cooling resulted in crystal formation.
Two batches of recrystallized product yielded 36.5 g (83% yield). This material was
relatively enriched in lanosterol acetate (68%) compared to dihydrolanosterol acetate as
assayed by integration of the 24-vinyl proton relative to the 3ac-acetoxy proton (see below).
The mother liquor was reserved for further purification during future preparations
(accounting for this process, the overall yield is approximately 90%). 13C-NMR (CDC13):
6 15.78 (C-18), 16.53 (C-30), 17.63 (C-27, lb), 18.12 (C-6), 18.63 (C-21, lb), 18.74
(C-21, DH-lb), 19.20 (C-19), 21.00 (C-ll), 21.33 (C-3", Ac-CH3), 22.55 (C-26,
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DH-lb), 22.86 (C-27, DH-lb), 24.18 (C-2; C-23, DH-lb), 24.24 (C-32), 24.94 (C-
23, lb), 25.73 (C-26, lb), 26.39 (C-7), 27.91 (C-31), 28.00 (C-25, DH-lb), 28.20 (C-
16), 30.82 (C-15), 30.99 (C-12), 35.29 (C-1), 36.26 (C-20, lb), 36.37 (C-22, lb),
36.47 (C-20, DH-lb; C-22, DH-lb), 36.89 (C-10), 37.80 (C-4), 39.54 (C-24, DH-
lb), 44.46 (C-13), 49.82 (C-14), 50.40 (C-17, lb) 50.49 (C-5; C-17, DH-lb), 80.91
(C-3), 125.24 (C-24, lb), 130.85 (C-25, lb), 134.22 (C-9), 134.48 (C-8), 170.97 (C-
3', Ac-C=O). 1 3C-NMR assignments are based on the data published in (49)
24,25-Dibromolanosteryl acetate (DB-lb).
36.5 g of a mixture of lanosteryl acetate (lb, 68%, 24.82 g, 52.87 mmol, 1 equiv.) and
dihydrolanosteryl acetate (DH-lb, 32%) was dissolved in 640 mL anhydrous diethyl ether
in a 1 liter round-bottom flask. The solution was chilled to 0 C in an ice water bath. 5.5 g
of sodium acetate (69.98 mmol, 1.32 equiv.) was dissolved in about 200 mL of acetic acid.
To this acetate solution was added 3.0 mL of bromine (58.32 mmol, 1.1 equiv.). This
solution was added to the reaction flask slowly with a dropping addition funnel over 2
hours. When the stirred solution remained yellow for more than one minute the excess
reagent was quenched with several drops of cyclohexene. The mixture was washed with
bicarbonate until the ether layer tested neutral with pH paper and then washed with distilled
water. The combined organic layers were dried over magnesium sulfate , filtered and
concentrated. The crude product was recrystallized repeatedly from methanol/methylene
chloride yielding 11.72 g of >97% pure DB-lb (44% yield). The mother liquors were
combined with those from other preparations and recrystallized. The overall yield is
estimated at 70%.
7-oxo-24,25-dibromolanosteryl acetate (DB-2b). 15.8 g. of
dibromolanosteryl acetate (DB-lb, 25.2 mmol, 25 mM) was placed in a 2-liter round-
bottom flask affixed with a reflux condenser and dissolved in 965 mL of acetic acid. The
solution was heated to -70 C until all of the dibromide dissolved. The flask was flushed
with argon and 4 mL of sulfuric acid (3 equiv., 0.4% final concentration) in 5 mL of acetic
acid were added slowly through an addition funnel over 20 minutes. When this addition
was complete, 33.4 mL of 30% hydrogen peroxide (13 equiv., 1% final concentration),
was added all at once. The reaction was stirred at -70 C for one hour and then poured into
1 liter of ice water. The resulting precipitate was filtered and washed with methanol. The
crude product was recrystallized from methanol and methylene chloride to yield 6.51 g of
product. The mother liquor was chromatographed on alumina using a step-gradient of
heptane, 50:1 heptane/EtOAc, 25:1 heptane/EtOAc, 9:1 heptane/EtOAc, and 100% EtOAc.
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This yielded fractions which were recrystallized to yield 1.2 g of product. Final yield, 7.7
g, 49%.
DB-2b: 1 H-NMR (CDC13): 6 4.46 (dd, Jl=4.6Hz, J2 =11.2Hz, C-3, 1-H), 4.11
(dd, Jl=1.2Hz, J2 =11.1, C-24 {one diastereomer), 0.4-H), 4.06 (dm, J=9.3Hz, C-24
{one diastereomer), 0.6-H), 2.00 (s, acetate, 3-H), 1.93 and 1.92 (s, C-26 two
diastereomers), 3-H), 1.76 and 1.75 (s, C-27 (two diastereomers}, 3-H), 1.34 (s, C-19,
3-H), 0.91 (d, C-21, 3-H), 0.90 (s, C-30, 3-H), 0.87 (s, C-32, 3-H), 0.83 (s, C-31, 3-
H), 0.62 and 0.61 (s, C-18 (two diastereomers), 3-H).
7-oxolanosteryl-3[ -acetate (2b). 18.3 g of 7-oxo-24,25-
dibromomolanosterol acetate (DB-2b, 28.5 mmol) was added to a 3 liter round-bottom
flask along with 2 liters of anhydrous diethyl ether. The mixture was stirred with an
overhead stirring blade. The ether was heated to reflux and 25 mL of acetic acid were
added (420 mmol, 14.7 equiv.) followed by 4.66 g of zinc dust (71.2 mmol, 2.5 equiv.)
added cautiously. The solution was allowed to stir at reflux until all of the dibromide had
dissolved and TLC showed complete reaction (approximately one hour). The solution was
allowed to cool and was filtered to remove the zinc dust. The ether was evaporated under a
stream of air to about 300 mL. 1 liter of methanol was added to precipitate the steroid
which was filtered and washed with methanol. The filtrate was evaporated further to yield
additional steroid. The total yield of this reaction was 80%.
2b: 1H-NMR (CDC13): 6 5.09 (tt, C-24, 1-H), 4.51 (dd, C-3, -H), 2.36 (m, C-
8, 1-H), 2.29 (d-br, C-6, 2-H), 2.06 (s, acetate, 3-H), 1.68 (s, C-26, 3-H), 1.60 (s, C-
27, 3-H), 1.19 (s, C-19, 3-H), 0.96 (s, 3-H), 0.92 (d, C-21, 3-H), 0.91 (s, 3-H), 0.88
(s, 3-H), 0.65 (s, C-18, 3-H).
3P-hydroxy-7-oxolanost-24-ene (3a). 13.6 g of 7-oxolanosteryl acetate
(2b, 28.2 mmol) was dissolved in 500 mL of dry toluene. A 2 liter baffled round-bottom
flask was placed in a 10 liter bucket and equipped with an overhead stirrer, dewar
condenser, gas inlet and dropping addition funnel. The apparatus was cooled to -78 C in a
dry-ice/acetone bath and approximately 500 mL of anhydrous ammonia was condensed into
the flask. 2.5 g of lithium metal (360 mmol, 12.8 equiv.) were added to the ammonia in
small pieces. When the metal had dissolved (deep royal blue solution), the steroid solution
was added over 10 minutes through the addition funnel. The reaction mixture was stirred
vigorously for three hours and then quenched by the addition of 10 mL dibromoethane. 10
mL of acetic acid in 20 mL of methanol were added over 30 minutes and the ammonia was
evaporated under a stream of argon over the next 24 hours. The remaining solution was
92
partitioned between water and methylene chloride. The aqueous phase was extracted three
times with methylene chloride and the combined organic phases were washed with water
and brine, dried over sodium sulfate and evaporated to yield the crude product (13.1 g,
96% crude yield), a white solid. TLC shows primarily the desired product contaminated
somewhat with 3[3-acetoxy-7-oxolanost-24-ene (3b).
3a: 1H-NMR (CDC13): 6 5.09 (tt, C-24, 1-H), 3.25 (dd, C-3, 1-H), 2.36 (m, C-8,
1-H), 2.29 (d-br, C-6, 2-H), 1.68 (s, C-26, 3-H), 1.60 (s, C-27, 3-H), 1.08 (s, C-19, 3-
H), 0.95 (s, 3-H), 0.90 (s, 3-H), 0.88 (d, C-21, 3-H), 0.83 (s, 3-H), 0.75 (s, C-18, 3-
H). 1 3C-NMR (CDCl3): 6 13.08 (C-19), 14.70 (C-18), 15.01 (C-31), 17.10 (C-32),
17.58 (C-27), 18.61 (C-21), 20.46 (C-ll), 24.84 (C-23), 25.66 (C-26), 27.39 (C-2),
27.68 (C-30), 28.21 (C-16), 31.67 (C-12), 33.77 (C-15), 35.74 (C-20), 36.60 (C-10),
36.40 (C-22), 36.95 (C-1), 39.00 (C-4), 39.76 (C-6), 45.83 (C-13), 46.34 (C-14), 48.68
(C-9), 49.59 (C-17), 53.11 (C-5 and C-8), 78.50 (C-3), 125.08 (C-24), 130.82 (C-25),
211.65 (C-7).
3b: 1H-NMR (CDCl3): 6 5.09 (tt, C-24, 1-H), 4.49 (dd, C-3, 1-H), 2.37 (m, C-
8, -H), 2.29 (d-br, C-6, 2-H), 2.05 (s, acetate, 3-H), 1.68 (s, C-26, 3-H), 1.60 (s, C-
27, 3-H), 1.11 (s, C-19, 3-H), 0.91 (d, C-21, 3-H), 0.90 (s, 6-H), 0.83 (s, 3-H), 0.76
(s, C-18, 3-H). 13 C-NMR (CDC13): 6 13.10 (C-19), 14.70 (C-18), 15.97 (C-31), 16.97
(C-32), 17.58, (C-27), 18.60 (C-21), 20.47 (C-ll), 23.80 (C-2), 24.83 (C-23), 25.65
(C-26), 27.49 (C-30), 28.19 (C-16), 31.63 (C-12), 33.78 (C-15), 35.74 (C-20), 36.47
(C-10), 36.39 (C-22), 36.60 (C-1), 37.82 (C-4), 39.52 (C-6), 45.82 (C-13), 46.34 (C-
14), 48.55 (C-9), 49.56 (C-17), 53.10 (C-5 and C-8), 80.17 (C-3), 125.08 (C-24),
130.82 (C-25), 211.16 (C-7).
3 o,7c-dihydroxylanost-24-ene (-4a) and 3,7[-dihydroxylanost-24-
ene (-4a). 13.1 g of crude 3-hydroxy and 3-acetoxy-7-oxolanost-24-ene (-29
mmol) was transferred to a 1 liter round-bottom flask and dissolved in 600 mL anhydrous
diethyl ether. 23 g. of lithium tri(t-butoxy)aluminohydride (90.4 mmol, 3.1 equiv.) was
added to the solution which was allowed to stir over night. TLC showed that reduction of
the 7-keto group was complete by this time. To convert all of the product to the 3-
hydroxy species, lithium aluminum hydride was added and the solution allowed to stir
until TLC showed a single product. The reaction was quenched by the addition of 10%
aqueous ammonium chloride. The solution was filtered to remove the reagents, the filter
cake washed with ether, and the combined filtrates dried over sodium sulfate. Evaporation
of the ether yielded 10.7 g of product (82% yield from compound 2b) which was found to
be 79% c (cc-4a) at the 7-position by proton NMR.
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c-4a: 1H-NMR (CDC13): 6 5.09 (tt, C-24, -H), 4.06 (s-br, C-7, I-H), 3.26 (dd,
C-3, -H), 1.68 (s, C-26, 3-H), 1.60 (s, C-27, 3-H), 1.08 (s, C-19, 3-H), 0.96 (s, 3-H),
0.92 (s, 3-H), 0.87 (d, C-21, 3-H), .80 (s, 3-H), 0.74 (s, C-18, 3-H).
1-4a: 1H-NMR (CDC13): 6 5.09 (tt, C-24, 1-H), 3.58 (dt, J 1=4.8Hz, J2=10.2Hz,
C-7, I-H), 3.19 (dd, C-3, 1-H), 1.68 (s, C-26, 3-H), 1.60 (s, C-27, 3-H), 0.97 (s, C-19,
3-H), 0.92 (s, 3-H), 0.90 (d, C-21, 3-H), 0.88 (s, 3-H), .81 (s, 3-H), 0.78 (s, C-18, 3-
H).
7a-hydroxylanost-24-enyl-3b-acetate (a-4b). 164 mg of 3,7-
dihydroxylanostenes (a-4a, 79% and 1-4a, 21%; 0.368 mmol, 2 equivalents of alcohols)
was dissolved in 3.5 mL of dry pyridine and 1.75 mL of fresh acetic anhydride (18.54
mmol, 50 equiv.). The solution was stirred at room temperature for four hours. The
reaction mixture was poured into 300 mL diethyl ether and was washed with distilled
water, cold 2 N HC1, and saturated bicarbonate. The combined organic layers were dried
over sodium sulfate, filtered and evaporated to dryness. The crude product was purified
using a 2 mm chromatotron rotor and yielded the following results: 60 mg 3,7-diacetates
(a-4d and -4d, 33.6% yield, 60% 7 by NMR), 78 mg 7-hydroxy-3-acetate (-4b,
43.4% yield, 100% 7oa by NMR), 5 mg 3-hydroxy-7-acetate (-4c, 2.8% yield, 100% 7,3
by NMR) and 18 mg 3,7-diol (x-4a, 10% yield, 100% 7a by NMR). Total yield: 89.8%.
Yield as 7oa products: 66.8%.
a-4b: 1H-NMR (CDC13 ): 6 5.09 (tt, C-24, 1-H), 4.06 (s-br, C-7, 1-H), 3.26 (dd,
C-3, -H), 1.68 (s, C-26, 3-H), 1.60 (s, C-27, 3-H), 1.08 (s, C-19, 3-H), 0.96 (s, 3-H),
0.92 (s, 3-H), 0.87 (d, C-21, 3-H), .80 (s, 3-H), 0.74 (s, C-18, 3-H).
13-4c: 1H-NMR (CDC13): 6 5.09 (tt, C-24, 1-H), 4.86 (dt, Jl=5.lHz, J2=10.8Hz,
C-7, -H), 3.21 (dd, C-3, -H), 2.00 (s, 7'-acetate, 3-H), 1.68 (s, C-26, 3-H), 1.60 (s,
C-27, 3-H), 0.96 (s, C-19, 3-H), 0.94 (s, 3-H), 0.89 (d, C-21, 3-H), 0.83 (s, 3-H), 0.80
(s, 3-H), 0.79 (s, C-18, 3-H).
,3-4d: 1H-NMR (CDCl3): 6 5.09 (tt, C-24, 1-H), 4.86 (dt, Jl=5.lHz, J2 =10.8Hz,
C-7, 1-H), 4.47 (dd, C-3, 1-H), 2.04 (s, 3'-acetate, 3-H), 2.00 (s, 7'-acetate, 3-H), 1.68
(s, C-26, 3-H), 1.60 (s, C-27, 3-H), 0.97 (s, C-19, 3-H), 0.89 (d, C-21, 3-H), 0.87 (s,
3-H), 0.85 (s, 3-H), .83 (s, 3-H), 0.79 (s, C-18, 3-H).
7ot,32-oxolanost-24-enyl-3,-acetate (5b). 7.45 g of 7c-hydroxylanost-
24-enyl-3b-acetate (-4b15.3 mmol) were added to 2 liters of benzene and 500 mL of
toluene in a 3 liter round-bottom flask. The mixture was heated to reflux and 250 mL of
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benzene was distilled off to remove any residual water. The reaction was kept under an
atmosphere of argon at all times. 34.82 g of lead tetraacetate (78.5 mmol, 5.1 equiv.) was
added to the solution and the reaction was refluxed for 2.5 hours. The solution was
allowed to cool for one hour more, and then 500 mL of 20% potassium iodide was added
to quench the reaction. This caused the precipitation of a yellow solid which was
redissolved by addition of 400ml of saturated sodium thiosulfate. The organic and aqueous
layers were separated after shaking in a separatory funnel. The aqueous phase was
extracted three times with ether, and the combined organics washed twice with distilled
water. The organic phase was dried over sodium sulfate, filtered and concentrated under
reduced pressure. The concentrated solution of steroids in toluene was diluted with 10:1:1
hexanes/ethyl acetate/methylene chloride and loaded onto a flash silica column equilibrated
in that solvent mixture. The column was eluted with 8:1:1 and then 5:1:1. Fractions
containing mainly the desired product were recrystallized from methanol/methylene
chloride. Side fractions and mother liquors were repurified by column chromatography
and recrystallization. Final yields were 4.39 g, 59% yield of desired product (5b), -20%
yield of unreacted starting material (a-4b), and -10% yield of 7-oxolanost-24-enyl acetate
(3b).
5b: 1H-NMR (CDC13): 6 5.08 (tt, J1=3Hz, J 2=7.5Hz, C-24, l-H), 4.49 (dd,
J1=5.4Hz, J2 =11.7Hz, C-3, -H), 4.17 (s-br, C-7, l-H), 3.97 (d, J=7.8Hz, C-32, l-H),
3.33 (d, J=6.9Hz, C-32, I-H), 2.04 (s, acetate, 3-H), 1.68 (s, C-26, 3-H), 1.60 (s, C-27,
3-H), 0.91 (d, J=6.9Hz, C-21, 3-H), .87 (s, C-19, 3-H), 0.86 (s, 3-H), 0.83 (s, 3-H),
0.81 (s, C-18, 3-H)
3[3,32-dihydroxylanostadienyl diacetates (A 6 -6d, A7 -6d, A8 -6d). 0.5 g
of 7,32-oxolanost-24-enyl acetate (5b, 1.03 mmol) was added to a 250 mL round bottom
flask and dissolved in 90 mL acetic anhydride. To this was added 1 g of pyridinium
hydrochloride (8.6 mmol, 8.3 equiv.) and the mixture was heated to reflux under an
atmosphere of nitrogen and allowed to react overnight. The reaction was quenched by
pouring over water-ice and allowed to stand 1.5 hours until the ice had completely melted.
The resulting precipitate was filtered and dissolved in methylene chloride. TLC showed the
product as a single broad spot consisting of the A 8 (A8 -6d), A7 (A 7-6d) and A6 (A 6-6d)
dienyl diacetates.
3,32-dihydroxylanostadienyl-3f-acetates (A 6 -6b, A 7-6b, A 8 -6b) and
3f[,32-dihydroxylanostadienes (A 6 -6a, A 7 -6a, A 8 -6a). The crude dienyl
diacetates mixture (A6 -6d, A7-6d, A8-6d) was dissolved in 100 mL dry diethyl ether in
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a 250 mL round-bottom flask. Small aliquots of lithium aluminum hydride (LAH) were
added and the progress of the reaction was followed by TLC. The reaction was allowed to
proceed until the amount of 3-monoacetates was maximized. The LAH was quenched by
the addition of 10% aqueous ammonium chloride followed by ether/water extraction. The
combined ether layers were dried over sodium sulfate and separated on a 2mm
chromotatron rotor by the following procedure. As the solubility of the material was poor
in the most efficient solvent mixture, the material was loaded onto a semi-dry rotor in
10: 1:1 hexanes/ethyl acetate/methylene chloride spiked with approximately 50% methylene
chloride to make a concentrated solution. The rotor was then allowed to spin completely
dry under nitrogen gas. The compounds were eluted in a step-gradient of 10:1:1, 5:1:1,
and 100% ethyl acetate.
In a typical preparation: 6% 7,32-oxolanost-24-enyl acetate (5b), 5% 3,32-
dihydroxylanosta-6,24-dienyl-33-acetate (A 6 -6b), 18% a 1:1 mixture of 3,32-
dihydroxylanosta-8,24-dienyl-3[-acetate (A 8 -6d) and 3,32-dihydroxylanosta-7,24-
dienyl-3[-acetate (A7 -6d), 20% a mixture of 31,32-dihydroxylanosta-6,24-diene (A 6-6a)
and 7,32-oxolanost-24-ene (5a), 33% a 2:3 mixture of 313,32-dihydroxylanosta-8,24-diene
(A 8-6a) and 3f3,32-dihydroxylanosta-7,24-diene (A 7 -6a). Total yield: 82%. Yield of A8
and A7 products: 51%. Yield of reclaimed starting material: 15%.
The 1:1 mixture of A8 and A7 monoacetates was separated on a chromatatron rotor
using 8:1 hexanes/EtOAc. A small percentage of methylene chloride was used in the
loading mixture to provide a concentrated initial band.
A 8 -6b: 1 H-NMR (CDC13): 6 5.08 (t-br, J=6.9Hz, C-24, 1-H), 4.49 (dd,
Jl=4.8Hz, J2 =11.7Hz, C-3, 1-H), 3.62 (d, J=1l.lHz, C-32, 1-H), 3.22 (d, J=ll.lHz,
C-32, 1-H), 2.05 (s, acetate, 3-H), 1.68 (s, C-26, 3-H), 1.60 (s, C-27, 3-H), 1.06 (s, C-
19, 3-H), 0.91 (d, J=6.3Hz, C-21, 3-H), 0.90 (s, 3-H), 0.89 (s, 3-H), 0.70 (s, C-18, 3-
H).
A7-6b: 1H-NMR (CDC13): 6 5.36 (m, C-7, -H), 5.09 (t-br, J=6.9Hz, C-24, 1-
H), 4.49 (dd, J=4.8Hz, J 2=11.7Hz, C-3, -H), 3.63 (dd, J 1=1.5Hz, J2 =10.2Hz, C-32,
1-H), 3.23 (d, J=10.5Hz, C-32, 1-H), 2.05 (s, acetate, 3-H), 1.68 (s, C-26, 3-H), 1.60
(s, C-27, 3-H), 0.97 (s, C-19, 3-H), 0.93 (s, 3-H), 0.90 (d, J=5.7Hz, C-21, 3-H), 0.87
(s, 3-H), 0.72 (s, C-18, 3-H).
A6-6b: 1 H-NMR (CDC13): 6 5.82 (dt, J 1=3Hz, J2=10.8Hz, C-6, 1-H), 5.64 (d-
br, J=9.9Hz, C-7, -H), 5.08 (t-br, J=7.5Hz, C-24, 1-H), 4.51 (dd, J1 =4.8Hz,
J2=10.8Hz, C-3, 1-H), 4.17 (dd, Jl=1.6Hz, J2 =10.8Hz, C-32, 1-H), 3.43 (m-br, C-32,
1-H), 2.37 (din, 1-H), 2.06 (s, acetate, 3-H), 1.68 (s, C-26, 3-H), 1.60 (s, C-27, 3-H),
0.90 (s, C-19, 3-H), 0.87-0.86 (s-br, C-18, 30, 31 and 32, 12-H).
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A 8 -6a: 1 H-NMR (CDC13): 6 5.09 (t-br, J=6.9Hz, C-24, 1-H), 3.62 (d-br,
J=9.6Hz, C-32, 1-H), 3.2 (m, C-32 and C-3, 2-H), 2.04 (s, acetate, 3-H), 1.68 (s, C-26,
3-H), 1.60 (s, C-27, 3-H), 1.00 (s, C-19, 3-H), 0.91 (d, C-21, 3-H), 0.89 (s, 3-H),
0.83 (s, 3-H), 0.70 (s, C-18, 3-H).
A7 -6a: 1H-NMR (CDC13): 6 5.37 (m, C-7, -H), 5.09 (t-br, J=6.9Hz, C-24, 1-
H), 3.62 (d-br, J=9.6Hz, C-32, -H), 3.2 (m, C-32 and C-3, 2-H), 2.04 (s, acetate, 3-
H), 1.68 (s, C-26, 3-H), 1.60 (s, C-27, 3-H), 1.04 (s, C-19, 3-H), 0.98 (s, 3-H), 0.91
(d, C-21, 3-H), 0.90 (s, 3-H), 0.72 (s, C-18, 3-H).
A6 -6a: 1H-NMR (CDC13): 6 5.81 (dt, J=3Hz, J2 =10.8Hz, C-6, 1-H), 5.68 (dt,
Jl=2.4Hz, J2 =9.9Hz, C-7, 1-H), 5.08 (tt, Jl=3Hz, J2 =7.5Hz, C-24, 1-H), 4.17 (dd,
Jl=1.6Hz, J2 =10.8Hz, C-32, 1-H), 3.43 (d, J=11.7Hz, C-32, -H), 3.27 (dd, J=5.7Hz,
J2 =11.7Hz, C-3, 1-H), 2.37 (dm), 1.68 (s, C-26, 3-H), 1.60 (s, C-27, 3-H), 1.02 (s, C-
19, 3-H), 0.87 (d, J=4.8Hz, C-21, 3-H), 0.86 (s, 3-H), 0.84 (s, 3-H), 0.80 (s, C-18, 3-
H).
3P,32-dihydroxylanostadienyl-32-acetates (A 7 -6c, A 8 -6c). 3,32-
dihydroxylanostadienes (A 8-6a, A7-6a) were dissolved in pyridine and 2-5 equivalents of
acetic anhydride were added. The reaction was monitored by TLC until the starting
material was >90% consumed, generally less than 8 hours. The reaction was quenched by
pouring into water and worked up by extraction with ethyl acetate and 5% HC1, saturated
bicarbonate, saturated brine and distilled water washes. The products were separated by
chromatatron or silica flash chromatography. Yields of 32-acetates were >75%.
A8 -6c: 1H-NMR (CDC13): 6 5.08 (t-br, C-24, 1-H), 3.95 (dd, C-3, 1-H), 3.24
(dd, C-3, 1-H), 1.97 (s, acetate, 3-H), 1.68 (s, C-26, 3-H), 1.60 (s, C-27, 3-H), 0.99 (s,
C-19, 3-H), 0.90 (d, J=6.3Hz, C-21, 3-H), 0.87 (s, 3-H), 0.70 (s, C-18, 3-H).
A7 -6c: 1H-NMR (CDC13): 6 5.21 (m, C-7, I-H), 5.08 (t-br, C-24, 1-H), 4.59
(dd, C-32, 1-H), 3.67 (d, J=10.8Hz, C-32, 1-H), 3.24 (dd, C-3, -H), 2.03 (s, acetate,
3-H), 1.68 (s, C-26, 3-H), 1.60 (s, C-27, 3-H), 0.97 (s, C-19, 3-H), 0.87 (s, 3-H),
0.80 (s, 3-H), 0.70 (s, C-18, 3-H).
3P,32-dihydroxylanosta-7,24-dienyl-3f-acetate-32-mesylate (A 7 -7b).
A7-7b: 1H-NMR (CDC13): 6 5.30 (d-assym, C-7, 1-H), 5.08 (t-br, C-24, 1-H),
4.51 (dd, J=5.4Hz, J2 =10.8Hz, C-3, 1-H), 4.40 (dd, Jl=8.4Hz, J2=very small, C-32,
I-H), 4.02 (d, J=9.3Hz, C-32, -H), 2.93 (s, mesylate-CH3, 3-H), 2.05 (s, acetate, 3-
H), 1.68 (s, C-26, 3-H), 1.60 (s, C-27, 3-H), 0.96 (s, C-19, 3-H), 0.92 (s, 3-H), 0.86
(s, 3-H), 0.73 (s, C-18, 3-H).
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3P3,32-dihydroxylanostadienyl-33-TBDMS ether (A 8 -6e, A 7 -6e).
3Pf,32-dihydroxylanostadienyl-32-acetates were dissolved in dry methylene chloride in a
flame dried flask under argon and chilled to 0 C. To this was added 3.0 equivalents of
pyridine and 1.2 equivalents of t-butyldimethylsilyltriflate (TBDMS-Tf). The reaction was
essentially instantaneous. If TLC showed less than 95% conversion, another small aliquot
of reagent was added to finish the reaction. The reaction was worked up by ether/water
extraction and evaporated. The crude product was dissolved in tetrahydrofuran, methanol
and 1 N NaOH (2:1:1) and warmed to reflux. TLC showed complete cleavage of the ester
after 2 hours. The reaction was worked up by ether/water extraction, washed with water
and saturated brine and dried over magnesium sulfate. Yield, >95%. The double bond
isomers (A 8-6e and A7 -6e) were separated by flash chromatography in 4:1 hexane-
chloroform.
A8 -6e: 1H-NMR (CDC13): 6 5.09 (t-br, C-24, -H), 4.63 (d, J=9.6Hz, C-32, 1-
H), 3.20 (m, C-32 and C-3, 2-H), 1.68 (s, C-26, 3-H), 1.60 (s, C-27, 3-H), 1.04 (s, C-
19, 3-H), 0.91 (s, 3-H), 0.90 (s, 12-H), 0.70 (s, C-18, 3-H), 0.04 (s, SiCH3 , 3-H),
0.03 (s, SiCH 3, 3-H).
A7-6e: 1 H-NMR (CDC13): 6 5.36 (m, C-7, -H), 5.09 (t-br, C-24, l-H), 4.63 (d,
J=9.6Hz, C-32, -H), 3.20 (m, C-32 and C-3, 2-H), 1.69 (s, C-26, 3-H), 1.60 (s, C-27,
3-H), 1.57 (s, 3-H), 0.90 (s, C-19, 3-H), 0.89 (s, t-butyl, 9-H), 0.86 (s, 3-H), 0.72 (s,
C-18, 3-H), 0.04 (s, SiCH 3, 3-H), 0.03 (s, SiCH3 , 3-H).
Lanosterol-TBDMS ether. Same procedure as above on a 3:2 mixture of
lanosterol and 24,25-dihydrolanosterol. The products were separated by silica flash
chromatography in 100% heptane.
le: 1H-NMR (CDC13): 6 5.10 (t-br, C-24, I-H), 3.20 (dd, J1=4.5Hz, J2 =10.8Hz,
C-3, l-H), 1.68 (s, C-26, 3-H), 1.60 (s, C-27, 3-H), 0.98 (s, C-19, 3-H), 0.91 (d,
J=6.3Hz, C-21, 3-H), 0.91 (s, 3-H), 0.89 (s, 9-H), 0.87 (s, 3-H), 0.77 (s, 3-H), 0.69
(s, C-18, 3-H), 0.034 (s, SiCH3, 3-H), 0.029 (s, SiCH3, 3-H).
1 3 C-NMR (CDC13): 6 15.79 (C-18), 15.94 (C-30), 17.66 (C-27), 18.17 (C-6),
18.49 (CH3-Si), 18.67 (C-21), 19.21 (C-19), 21.07 (C-11), 24.26 (C-32), 24.95 (C-C-
23), 25.75 (C-26), 25.95 ((CH 3)3CSi), 26.56 (C-7), 28.24 (C-16), 28.30 (C-31?), 28.44
(CH3-Si), 30.90 (C-15), 31.11 (C-12), 35.62 (C-1), 36.28 (C-20), 36.42 (C-22), 36.95
(C-10), 39.52 (C-4), 44.53 (C-13), 49.86 (C-14), 50.43 (C-17) 50.49 (C-5), 79.48 (C-
3), 125.32 (C-24), 130.86 (C-25), 134.30 (C-9), 134.68 (C-8).
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MS (HP GC/MS): C3 6 H6 4OSi, M+ = 540.49 (calc.) 540.45 (obs.), M+-CH3 =
525, M+-(CH 3) 3C = 483, M+-TBDMSOH-H = 407, M+-TBDMSOH-CH 3 = 393
33-acetoxylanosta-8,24-dien-32-al (A 8 -9b). In a flame-dried 25 mL round
bottom flask with spin bar and rubber septum under argon and cooled to -60 C in a
chloroform dry-ice bath, was placed 700 gl of dry methylene chloride and 211 1 of 2.0 M
oxalyl chloride in methylene chloride (422 tmol, 1.15 equiv.). To this solution was added
a mixture of 62 l1 dry dimethylsulfoxide (891 gmol, 2.4 equiv.) and 180 gl of methylene
chloride dropwise via syringe. After 5 minutes, a solution of 303-acetoxylanosta-8,24-dien-
32-ol (A8-6b, 178 mg, 367 gmol, 1.0 equiv.) in 890 gl methylene chloride was added by
syringe. This was allowed to stir for 15 minutes and the reaction was then quenched by the
slow addition of 300 tl triethylamine. The reaction was allowed to warm to room
temperature and distilled water was added. The reaction was worked up by extraction of
the aqueous phase with methylene chloride followed by 1% HC1, saturated bicarbonate,
and saturated NaCl washes of the organic layer which was then dried over MgSO4, filtered
and evaporated to dryness. Yield: >95%.
A8 -9b: 1 H-NMR (CDC13): 6 9.43 (s, C-32, -H), 5.05 (tm, J=5.7Hz, C-24, 1-
H), 4.46 (dd, Jl=4.5Hz, J2=11.4Hz, C-3, l-H), 2.05 (s, acetate, 3-H), 1.67 (s, C-26, 3-
H), 1.58 (s, C-27, 3-H), 1.08 (s, C-19, 3-H), 0.90 (d, J=7.8Hz, C-21, 3-H), 0.89 (s, 3-
H), 0.85 (s, 3-H), 0.75 (s, C-18, 3-H)
31-t-butyldimethylsilyloxylanosta-7,24-dien-32-al (A 7 -9e). The same
procedure was used as above was used on 3,32-dihydroxylanosta-7,24-dienyl-3-
TBDMS ether (A 7-6e).
A7 -9e: 1 H-NMR (CDC13): 6 9.58 (s, C-32, -H), 5.42 (m, C-7, l-H), 5.06 (t-br,
C-24, I-H), 3.18 (dd, J=4.5Hz, J2 =11.lHz, C-3, l-H), 1.67 (s, C-26, 3-H), 1.59 (s,
C-27, 3-H), 1.25 (s, 3-H), 0.90 (d, J=6.3Hz, C-21, 3-H), 0.89 (s, 12-H), 0.85 (s, 3-
H), 0.72 (s, C-18, 3-H), 0.04 (s, SiCH3, 3-H), 0.03 (s, SiCH3 , 3-H).
[32-D]-3[,32-dihydroxylanosta-8,24dienyl-33-TBDMS ether (A 8 -D-
6e). 30 mg of 3j3-acetoxylanosta-8,24-dien-32-al (A8-9e) was dissolved in about 20 mL
of anhydrous ethanol with -2 mL benzene to aid dissolution of the relatively insoluble
aldehyde. Small aliquots of sodium borodeuteride (>98% D) were added; the solution was
refluxed and monitored by TLC. When all of the starting material had been consumed the
reaction was quenched by the addition of aqueous ammonium chloride and extracted with
ether.
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3[-acetoxylanosta-8,24-dienyl-32-tosylhydrazone (A 8-lOb). 25 mg of
3j3-acetoxylanosta-8,24-dien-32-al (A8 -9b, 1.0 equiv.) was added to a screw-capped vial
and dissolved in 2 mL of absolute ethanol. 11.1 mg of tolylsulfonhydrazide (1.2 equiv.)
was added to the flask which was then equipped with a reflux condenser. The solution
was heated to a vigorous reflux for several hours. The reaction was monitored by TLC.
Generally the reaction was completed by 5 hours; occasionally additional
toylsulfonhydrazide must be added to complete the reaction.
A8 -lOb: 1H-NMR (CDC13): 6 7.80 and 7.28 (dd, J=7.8Hz, aromatic, 4-H), 7.33
(m-br, =NNHS0 2Ar, I-H), 6.94 (s, C-32, l-H), 5.07 (tm, J=6.9Hz, C-24, 1-H), 4.49
(dd, Jl=4.2Hz, J2=11.4Hz, C-3, -H), 2.39 (s, -ArCH3, 3-H), 2.05 (s, acetate, 3-H),
1.69 (s, C-26, 3-H), 1.59 (s, C-27, 3-H), 0.99 (s, C-19, 3-H), 0.86 (s, 3-H), 0.84 (s, 3-
H), 0.80 (d, J=6.3Hz, C-21, 3-H), 0.68 (s, C-18, 3-H).
3[3-t-butyldimethylsilyloxylanosta-7,24-dienyl-32-tosylhydrazone
(A 7-10e).
A 7-0e: 1H-NMR (CDC13): 6 7.84 and 7.28 (dd, J=8.5Hz, aromatic, 4-H), 7.70
(m-br, =NNHS02Ar, -H), 7.51 (s, C-32, -H), 5.31 (s-br, C-7, I-H), 5.07 (tm,
J=6.9Hz, C-24, I-H), 3.19 (dd, J=4.5Hz, J 2=11.1Hz, C-3, -H), 2.40 (s, -ArCH3, 3-
H), 1.70 (s, C-26, 3-H), 1.59 (s, C-27, 3-H), 0.89 (s, 12-H), 0.85 (s, 3-H), 0.84 (s, 3-
H), 0.80 (d, J=6.3Hz, C-21, 3-H), 0.65 (s, C-18, 3-H), 0.042 (s, SiCH_3 , 3-H), 0.038
(s, SiCH3, 3-H).
3f3-t-butyldimethylsilyloxylanosta-7,24-dienyl-32-N,N,N ',N '-
tetramethylphosphorodiamidate (A 7 -lle, 3-TBDMS-lanosta-7,24-dienyl-
32-TMPDA). 3,32-dihydroxylanosta-7,24-dienyl-33-TBDMS ether (12b, 1.0 equiv.)
was dissolved in 4:1 freshly distilled (from CaH2) 1,2-dimethoxyethane and
tetramethylethylenediamine (TMEDA) in a dried flask under argon with magnetic stirring.
In a second dried flask under argon was added freshly distilled tetrahydrofuran and freshly
distilled diisopropylamine (1 mmols) and cooled to 0 C on ice. n-butyllithium (1 mmol of a
2.0 M solution in hexanes) was added slowly by syringe. 1.5 equiv. of the lithium
diisopropylamide, thus generated, was added to the initial reaction flask slowly by syringe
and allowed to stir 15 min. 5.0 equiv. of dimethylphosphoroamidodichloridate
(DMPADC) was added to the solution by syringe and allowed to stir for several hours.
When the reaction was complete by TLC (4-8 hours), the reaction flask was cooled to 0 C
and an excess of dimethylamine was added by pasteur pipette. (NOTE: dimethylamine is
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extremely volatile and must be stored and used on ice at all times.) After 5 minutes the
reaction was allowed to warm to room temperature and was worked up by ether-water
extraction with rinses with 1% HCl, saturated NaHCO 3, and saturated brine. The
combined organics were dried over magnesium sulfate and filtered. Yield, 79%.
A7 -lle: 1H-NMR (CDC13): 6 5.24 (d-br, J=5.4, C-7, l-H), 5.09 (t-br, C-24, 1-
H), 4.08 (dm, J=7.2Hz, C-32, -H), 3.60 (dd, J 1=3.3Hz, J2 =9.3Hz, C-32, -H), 3.17
(dd, J1=4.2Hz, J2=1 1.1Hz, C-3, l-H), 2.62 (dd, J1=9.6Hz, J2 =23.7Hz, P(N(CH 3)2) 2 ,
12-H), 1.68 (s, C-26, 3-H), 1.60 (s, C-27, 3-H), 0.89 (s, t-butyl and one steroid methyl,
12-H), 0.85 (s, 3-H), 0.83 (s, C-18, 3-H), 0.71 (s, C-18, 3-H), 0.045 (s, SiCH 3, 3-H),
0.031 (s, SiCH3, 3-H).
3 -t-butyldimethylsilyloxylanosta-8,24-dienyl-32-N,N,N',N'-
tetramethylphosphorodiamidate (A 8 -lle, 3-TBDMS-lanosta-8,24-dienyl-
32-TMPDA). Same procedure as above. With this isomer, however, the yield is poor
under these conditions (12%) apparently due to rearrangement/elimination of the TMPDA
(see Tactics section above).
A 8 -lle: 1 H-NMR (CDC13): 6 5.07 (t-br, C-24, 1-H), 3.84 (dd, J 1=3.4Hz,
J2 =9.2Hz, C-32, l-H), 3.67 (dd, J1 =2.2Hz, J2 =8.8Hz, C-32, l-H), 3.11 (dd,
J1=5.OHz, J2 =ll.OHz, C-3, I-H), 2.65 (dd, J 1=9.6Hz, J2 =23.7Hz, P(N(CH 3)2 )2 , 12-
H), 1.68 (s, C-26, 3-H), 1.60 (s, C-27, 3-H), 0.98 (s, 3-H), 0.89 (s, t-butyl, 9-H), 0.86
(s, 3-H), 0.77 (s, C-18, 3-H), 0.69 (s, C-18, 3-H), 0.040 (s, SiCH3 , 3-H), 0.028 (s,
SiCH 3, 3-H).
Lanosterol-TBDMS ether (le). Into a flame-dried 25ml three neck flask
cooled to 0 C, with a glass-sheathed spin bar, gas inlet and dewar condenser with dry
ice/acetone was condensed -5ml of anhydrous methylamine. To this was added a small
lump of lithium metal (large excess). This was allowed to stir until the solution turned deep
blue/black. 8.7 mg of 3-TBDMS-lanosta-8,24-dienyl-32-TMPDA (A 8-l1e) was
dissolved in freshly distilled THF and added to the reaction mixture by syringe. After
reacting at 0 C for 5 minutes the reaction was quenched by the addition of distilled water.
The mixture was extracted with diethyl ether, rinsed with water and saturated brine, dried
over magnesium sulfate and filtered. TLC shows >90% reaction to a product which co-
spots ( 0.05 Rf units) with authentic lanosterol-TBDMS ether in 100% pentane. 1H-
NMR, 13 C-NMR, GC retention time and mass spectroscopy are all identical with the
authentic standard.
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Proposals for future research
Syntheses of Hemi-lanosterols as building-blocks for structural probes
and drugs
In light of the need for drugs which specifically bind to the active site of lanosterol
14x-demethylase and other closely related enzymes (which bind lanosterol derivatives as
discussed in the main text), and considering the scientific need to develop probe molecules
which can be used to determine the amino acid residues lining the active site, we have
considered the utility of a modular design. Inhibitors and probes containing either the A
and B rings, or the C and D rings of lanosterol and other variable groups may have
particular advantage because of their built-in binding characteristics. These modular probes
have been dubbed "hemilanosterols," and several specific compounds based on them have
been imagined with various uses (Figure 13).
Two routes to these hemilanosterols are proposed. The first, based on some
degradative chemistry presented in the Mechanisms section of the introduction, above, (34 )
gives access simultaneously to the precursors of both the AB and CD hemilanosterol
(Figure 14). The second is based on the classic route of total steroid synthesis, the
Robinson annelation (Figure 15) and accesses only the AB hemilanosterol. Both of these
routes were briefly investigated by a graduate student in our labs who has since departed
(S. Lokey).
Preparation of lanosterol affinity column material
The purification of 14o-demethylase is, at present, rather tedious, and would be
streamlined considerably if an affinity method were available for specific adsorption of the
protein. It has been shown that the binding of lanosterol is mediated, in part, by a specific
interaction with the 3-hydroxyl group.(l3) Studies on altered side-chains of lanosterol
have shown that significantly shortened side-chains impair turnover of the enzyme,( 12 6) but
no studies have investigated the binding characteristics of unnaturally long side-chains.
These can be synthesized using a method based on Sato's work: ozonolysis of lanosterol
yields the tris-norlanosterol-24-aldehyde. (1 2 6 ) This could be elaborated by Wittig
condensation with the phosphorus ylide of a long-chain halo-amine such as -amino-7-
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bromooctane or -amino-8-bromooctane. Should this type of compound show affinity for
the enzyme, it could be tethered to sepharose column material via the amino group using
cyanogen bromide chemistry.
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Figure 13: Some potential photo-affinity probes,
mechanism-based inhibitors and radical clock probes
based on hemilanosterol skeletons.
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Figure 14: Proposal for synthesis of hemilanosterols AB and CD via degradation of
Lanosterol. Starting material, either dihydrolanosterol or suitably protected lanosterol. (a)
Pb(OAc) 4 followed by Os0 4 or modem equivalent (after Castells, 1956); (b) oa-oxidation by
MoO 5 or other oxidant; (c) CrO3, seperation of diacid products (all subsequent steps are
shown for AB-compounds only, but they are identical for the BC version); (d) SOC12 1 eq.;
(e) MeLi; SOC12; n-BuLi; (f) NaH; R 2Br; BF3, dithioethane; Raney nickel; (g) TsNNH 2;
n-BuLi, R Li.
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Figure 15: Proposal for synthesis of hemilanosterol AB via Robinson
annelation. (a) H 20, 24 h.; DMSO, L-proline, 5 days; (b) HOCH 2CH 2OH,
p-TsOH; Li-NH3; Mel; (c) LAH, TBDMSOTf, AcOH, H20; (d) LDA, R 2B r;
TsNHNH 2; n-BuLi, R Li.
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Appendix
Evidence supporting the assignment of structure of two Li-ammonia-
toluene reduction side-products as 3,8f-dihydroxy-7-oxolanost-24-
enol and its corresponding 3-acetate.
1. Ring A and the side-chain of the steroid are unchanged as evidenced by NMR,
the 31-alcohol and 3[3-acetate of the compound have both been isolated.
2. The compound is not oxidizable back to the starting material by chromium
trioxide-pyridine in methylene chloride, however, standing in chloroform for several days
does result in partial reversion to the conjugated ketone, probably through trace HC1
catalysis ( elimination of an alcohol?).
3. The compound contains a second alcohol group. This is supported by IR of the
31-acetate (broad peak at 3330 cm-1), and by the esterification of the 31-acetate to a less
polar product by acetic anhydride in pyridine.
4. The compound contains a ketone. IR of the 31-alcohol shows a carbonyl stretch
(1708 cm-1). However, there seemed to be no reaction of the compound with LAH in THF
after 10 minutes (perhaps this reduction is slow, this was not investigated further).
5. 1 3C-NMR shows a ketone resonance at 206 ppm and a resonance at 94 ppm
which is consistent with a hindered tertiary alcohol. The 35-alcohol and acetate appear in
their usual positions as do the vinyl carbons of the side-chain; no other double bonds are
present. Proton-coupled 13 C-NMR confirms that the 94 ppm resonance corresponds to a
carbon with no attached protons.
6. 1H-NMR is not consistent with a 9-hydroxy-7-ketone. This compound would
have a singlet due to the isolated proton at C-8. This singlet should be well down-field due
to the adjacent alcohol and ketone; no such singlet is observed. In contrast, what is
observed is a triplet at 2.85 ppm and a doublet at 2.25 ppm which may correspond to a 9c-
proton (coupled to two protons on C- 11) and one of the two C-6 protons (the other falling
closer to 2.0 ppm among some other unresolved resonances), respectively. This is
consistent with the assigned structure.
7. The 13C-NMR spectra of 7-oxolanosta-24-enol and its acetate (3a and 3b) were
completely assigned by comparison with published literature spectra of lanostane
derivatives, (4 9) H-coupled 13 C-NMR spectra and 2-D hetero-correlation (HetCor) and
COSY NMR, and comparison of typical acetate-shift correlations. Comparison of this
standard with the 13C spectrum of the unknown yielded unambiguous assignment of all of
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the unknown resonances ( 5 ppm, 22 carbons within 1 ppm) except for carbons 8 and 9.
Assignment of the compound as the 9-alcohol was inconsistent because the carbons alpha
to the alcohol-bearing carbon are only shifted by -0.35, -0.42 and -1.98 ppm (C-8, C-10
and C-ll, respectively), while the carbonyl at C-7 is shifted by +4.86 ppm and the C-6
carbon by +2.4 ppm compared to 3a and 3b. Assignment as the 8-alcohol yields more
realistic shifts of +4.86, -4.93 and -4.17 ppm (C-7, C-9 and C-14) as well as the +2.4
ppm shift of C-6.
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CHAPTER 3
PRELIMINARY STUDIES ON THE
ACTIVE SITE STRUCTURE OF P-4 50scc:
A REPORT ON RESEARCH IN PROGRESS
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Preface
The study of the cholesterol side-chain cleavage enzyme (P-450scc) has been an
active research area in the Orme-Johnson research lab for many years. My contribution to
this project has been brief, but I include this account here as a record for those who take on
this work after me. I am indebted to my predecessors, Subhendu Joardar, Emily Miao,
Atsushi Nagahisa and many others before them. The experiments described below are
quite preliminary and were done in an exploratory manner. The account given here serves
mainly to suggest a heretofore unappreciated complexity in the inhibition of SCC by certain
alkyne-containing compounds. For this reason little has been conclusively shown, but the
indications for future researchers are that certain assumptions cannot be made and
experiments must be designed with considerable caution to avoid false leads and
ambiguous results.
In the introduction to the thesis of Dr. Subhendu Joardar is found an extensive
discussion of the properties of this enzyme, its biological niche and research on its
inhibition along with a thorough list of references. My discussion here, then, will be brief
and I refer readers to his thesis and several other excellent reviews referenced therein.(9)
Previous Research on the Active Site Structure of P-450scc.
The side-chain cleavage enzyme is found in the adrenal cortex, testis, ovary and
placenta of mammals and is responsible for the conversion of cholesterol to pregnenolone
via a three-cycle (6 electron) oxidation in which the side chain of cholesterol is removed as
isocapraldehyde (Scheme 1). From pregnenolone all of the other steroid hormones are
synthesized (Scheme 2). Side chain cleavage is the rate limiting step in steroidogenesis and
is hormonally regulated. Thus, this step can serve as a point at which steroidogenesis can
be arrested by inhibition. This has been suggested as a desirable therapeutic regimen for
the treatment of prostate and other steroid hormone-dependent cancers and may have other
clinical utility.
Because of the membrane-bound nature of mammalian P-450's, these proteins have
resisted attempts to form crystals of suitable quality for the determination of x-ray crystal
structures. Due to this difficulty, indirect methods have been devised to illuminate the
three-dimensional structure of P-450 active sites. These techniques fall into three
categories; chemical, spectroscopic and computational; which, together, may provide
considerable insight into the matter.
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Chemical techniques encompass covalent modification of the active site residues
and the heme cofactor. Mechanism-based inhibitors (see below) and photoaffinity probes
are designed to bind specifically to the active site and either by enzymatic turnover or
activation by light, generate a highly reactive species there which will form a covalent link
with the surrounding active site components. Subsequent analysis of the peptide reveals
the location of the link and the identity of a segment of the protein which borders the active
site. Heme-directed probes which ligate to the iron atom can be made to rearrange and
modify the heme itself. Analysis of the modification pattern can reveal those areas of the
heme which are exposed, and which are blocked by the protein.( 2 3)
Spectroscopic techniques have been developed to determine the precise orientation
of a bound inhibitor or substrate with respect to the heme iron. EXAFS (Extended X-ray
Absorption Fine Structure) is used to determine the radial distance from the iron atom (the
X-ray absorber) to nearby surrounding atoms (the backscatterers of emitted photons). This
technique requires a strong source of polychromatic (white) X-rays such as that provided
by Brookhaven's National Synchrotron Light Source. ESEEM (Electron Spin Echo
Envelope Modulation) can be used to determine the distance between the iron atom (the
paramagnetic species) and nearby NMR-active nuclei. Use of an appropriate inhibitor
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Scheme 1: Conversion of cholesterol to pregnenolone by P-450scc
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Scheme 2: The biosynthesis of mammalian steroid hormones from pregnenolone
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strategically labeled with deuterium, one can use these techniques in tandem to define
parameters of the conformation and relative orientation of a bound inhibitor.
Since P-450's comprise a large group of related genes it is theoretically possible to
model the three dimensional structure of a particular P-450 protein by comparison with one
for which an accurate structure is known using computational methods. At this time, the
only structure available is that of the camphor hydroxylase (P-4 50cam) from Pseudomonas
putida. This P-450 is, unfortunately, only distantly related to the mammalian P-450's,
making accurate comparisons difficult. However, the active site regions of P-450's are
apparently more closely conserved than the protein in total including the surface and
membrane-binding regions, and thus, modeling of this region only can reasonably be
expected to yield meaningful results.(9)
In the previous ten years several effective competitive and mechanism-based
inhibitors of P-450scc have been developed in the Orme-Johnson labs (Figure 1).( 11' 14-16,
29) These have been used to help implement the above program of inquiry into the active
site structure of P-450scc. In particular, the mechanism-based inhibitor 20-(1,5-
hexadiynyl)-5-pregnen-3,20x-diol (5, 20-HDY), was notable because, along with time-
dependent inactivation of the enzyme, it was subsequently discovered that the steroid
becomes covalently linked to the protein.(l3) This was unexpected, because previous
examples of alkyne-containing inhibitors in the literature tended to covalently label the
heme.(20-22, 24) It is believed that this type of inhibitor is converted into an oxirene by
oxygen insertion into an acetylene ir-bond. This reactive species, which can be alternately
viewed as an oxygen-substituted vinyl cation, vinyl radical or an ux-oxocarbene, could trap
weak protein nucleophiles such as threonine, serine, aspartate, glutamate, lysine or tyrosine
or insert into carbon-carbon or carbon-nitrogen bonds (Scheme 3).(13)
The obvious next experiment, to determine the site of label incorporation, was not
performed at that time because of the absence of any model for the active site of SCC.
Instead, a program to develop such a model was begun.
The mechanism-based inhibitor (not an inactivator), (20S)-22-thiacholesterol (1)
has been shown to be oxidized by the action of SCC to give (20S,22R)-22-thiacholesterol-
S-oxide (2), a particularly tight-binding compound (Kd=0.14M). (11' 29) The resulting
enzyme-inhibitor is considered to be a model for the binding of the first oxidative
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Figure 1: P-450SCC inhibitors and inactivators studied in the Orme-Johnson
laboratories
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inactivation by alkynyl inhibitors
intermediate in side chain cleavage, (22R)-22-hydroxy-cholesterol. The presence of sulfur
atom in the place of a carbon in the natural substrate is fortuitous, because it allows for
detection of the Fe-S (3.01A) distance by EXAFS. Coupled with the Fe-O distance of this
complex (1.99A), and the crystallographically determined S=O bond length of the
sulfoxide (1.5A), it is possible to calculate the angle ZFe-O-S using the law of cosines
(118.5 ).(9' 10) The synthesis of (20R)-20-D-sulfoxide allowed for determination of the
distance between the iron and this deuterium atom as 4.2A using ESEEM. This distance
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serves to constrain the torsions about the S=O bond and the S-C20 bond somewhat (Figure
2).(9, 10) Further experiments with deuterium labels at different positions will continue to
refine the model for substrate binding at the SCC active site. Earlier work on C-22
deuterium-labeled (22R)-22-hydroxy-cholesterol showed a distance of 4.0A between that
deuterium and the heme iron.(8)
C21
Figure 2: One possible conformation of the bound sulfoxide inhibitor (2)
yielding a distance of 4.2A between the deuterium and the heme iron. T1
and T2 are the torsion angles defined by Fe-O=S-C2 0 and O=S-C20-C 21 ,
respectively. (0 = all in the same plane in cis conformation) The S=O and
S-C20 bonds have been set to the crystallographically determined lengths of
1.5A and 1.8A, respectively. The ZFe-O=S angle has been set to 118.5 .
The active site region of several steroidogenic active sites, including that of SCC,
have been modeled in this lab using multiple sequence alignments based on sequence
identity, conservative replacements and hydropathy-based secondary structure prediction.
These techniques were used to locate the helical regions lining the active site that
correspond to the analogous regions found in the crystal structure of P-4 50 cam. These
helices (helix I and helix L), and their neighboring stretches of peptide were then modeled
by computer into the crystal structure model of the active site of P- 4 50cam, first by
substituting the SCC regions for the CAM regions in a series of "point mutations". After
each amino acid change the side-chain torsions were modified to minimize steric clashes
with the rest of the sequence. After all of the residues were mutated, the entire structure
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was energy minimized. Finally, a model of (22R)-22-hydroxy-cholesterol was placed in
the active site using the constraints found from the EXAFS and ESEEM studies discussed
above, and the complex was minimized again.( 9)
From this model it has been predicted that a particular stretch of amino acids along
Helix I are the most likely to be covalently modified by the alkynyl mechanism-based
inhibitors. This region includes Thr290, Thr291 and Thr294 as possible nucleophiles to
attack any turnover-generated electrophile from the inactivator acetylene (see Scheme 3).
Research goals
The goals of this research project, then, are to lay the groundwork for the
determination of the site of labeling by the inhibitor, 20-(1,5-hexadiynyl)-5-pregnen-
3P,20c-diol (5, 20-HDY). Several points needed to be investigated to assess the
feasibility of this project:
1) Reconfirm the covalent nature of the adduct between 20-HDY and the protein.
2) Assess the stability of this adduct; will it hydrolyze or otherwise cleave during
the planned procedures.
3) The monoyne inhibitor 20-(1-hexynyl)-5-pregnen-33,20o-diol (3, 20-HY) has
been shown to be an inactivator, although a poorer one than 20-HDY. However, this
inhibitor was not assayed for its protein-labeling efficiency. The 20-(4-methyl-1-
pentynyl)-5-pregnen-3,200x-diol (4, 20-MPY), which more closely approximates the
natural cholesterol side chain has been synthesized but had not been evaluated as an
inhibitor or inactivator. The important point to evaluate here is whether the effectiveness of
20-HDY is due to steric factors which give it a better binding constant, and thus a higher
rate of inactivation, or rather the presence of the second triple bond is critical for the
labeling of the protein for chemical reasons.
4) Is the labeling by 20-HDY specific to a particular site on the protein or are there a
number of discrete peptide-steroid adducts.
5) Under what conditions can the protein be mildly unfolded without aggregation or
precipitation such that cleavage by proteases will be exhaustive and not yield overlapping or
overly large fragments.
6) What conditions are necessary to isolate the steroid-containing peptide fragment
after proteolysis (since the peptide-steroid conjugate is expected to be quite hydrophobic).
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Materials and Methods
Protein Purifications
P-450scc was purified from bovine adrenal glands via published procedures by
Orme-Johnson(18) and Tsubaki.(2 7 ) In brief, the cortices of the bovine adrenals were
separated from the internal medullar tissue, suspended in buffer, homogenized in a Waring
blender, and centrifuged to remove cellular debris. This supernatant is sonicated to break
the mitochondria, and ultracentrifugation yields the P-450-containing membrane fraction in
the pellet. The pellet is resuspended and homogenized in buffer and then potassium cholate
is added to solubilize the membranes. Centrifugation removes insoluble material, and the
supernatant is partitioned by ammonium sulfate precipitation. P-450scc is concentrated in
the 33-45% saturation fraction. This precipitate is resolubilized in buffer and batch
adsorbed onto DEAE-cellulose equilibrated in buffer containing the detergent Emulgen 913
at room temperature. This material is poured into a column and eluted with the detergent-
containing buffer. The P-450-containing fractions are pooled, concentrated using an
Amicon membrane cell, and loaded onto a column of hydroxyapatite in the same buffer.
The column is eluted with a step gradient of 10, 20, 40 and 80 mM potassium phosphate
buffer containing detergent. P-450-containing fractions are pooled, separated into 10 ml
portions, frozen in liquid nitrogen and stored for use at -80 C.
P-450 content is measured by the CO-binding difference spectrum of the dithionite
reduced protein at 450 nm by the method of Omura and Sato.(l7) UV/Visible spectra were
acquired using a Perkin-Elmer 557 double wavelength, double beam spectrophotometer.
Total protein content was measured with the Bradford dye-binding assay(2) using a kit
supplied by BioRad. Measurements were made using a Hewlett Packard 8452A diode
array spectrophotometer. The P-450 used for this project had a P-450 to protein ratio of
5.4 nmoles/mg, which was deemed sufficient for these studies (SDS gel electrophoresis
showed only minor impurities).
Adrenodoxin was purified by the method of Orme-Johnson(19) as follows. The
preparation is identical to that for SCC up to the stage of sonication. For adrenodoxin and
adrenodoxin reductase (see below), the supernatant following sonication was used. This
was fractionated by ammonium sulfate precipitation. The adrenodoxin is concentrated in
the 60-95% saturation fraction. This precipitate is resolubilized in and dialyzed against Tris
buffer and then concentrated on a column of DE-52 (DEAE cellulose) eluted with high salt
buffer. The proteins are then separated by size on a sephadex G-50 gel filtration column.
Column fractions were assayed spectrophotometrically; all fractions with A414/A280 ratios
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greater than 0.25 were pooled and frozen at -20 C until use. A complete spectrum showed
peaks at 258, 320, 414 and 454nm which matched published spectra.
Adrenodoxin reductase was purified by the method of Sugiyama(2 5) . The method
is identical to that for adrenodoxin up to the stage of ammonium sulfate precipitation.
Here, adrenodoxin reductase is concentrated in the 30-60% saturation fraction. The
precipitate is resuspended in buffer, dialyzed and applied to an affinity column constructed
of adrenodoxin covalently linked to sepharose. The bound adrenodoxin reductase is
washed free of contaminating proteins and then eluted with high salt. Fractions with low
280/450nm ratios are pooled and then dialyzed against low salt buffer. Again, full spectra
were identical to published standards.
Measurement of SCC Activity and Inhibition
P-450 catalysis of pregnenolone formation from cholesterol was assayed by the
method of Takikawa with modifications by Nagahisa.(1 3' 26) Typically assay constituents
were 2 tM adrenodoxin, 0.1 [gM Adrenodoxin reductase, 1 unit/mL catalase, 1 unit/mL
glucose-6-phosphate dehydrogenase, 10 mM magnesium chloride, 32 gM NADPH, 3 mM
glucose-6-phosphate, 50 mM MOPS, 0.2% Tween 20, 100 ptM cholesterol, and 20,000
cpm 7-[ 3 H]-cholesterol. The assay mixture was pH 7.2. For SCC specific activity
determination the P-450 content was varied from 0 to 0.25 gM. Incubations were carried
out at 37 C for 15 minutes. At 15 minutes the reaction was halted by the addition of 1 N
HCl and [14C]-pregnenolone was added as an internal standard. The mixture was passed
through a pipette column of C-18 reverse phase gel (from Sep-Pac cartridges, Waters Co.),
washed with distilled water and the steroids were eluted with methanol. The methanol was
evaporated to dryness and the steroids were chromatographed by analytical TLC versus
authentic standards. The pregnenolone bands were isolated, eluted with ethyl acetate and
counted by scintillation using a Beckman LS-2800 liquid scintillation counter, all
measurements were corrected for detector efficiency, sample quench and background, and
monitored for chemiluminescence.
The specific activity of the protein used in these studies was measured as 8.6
nmoles pregnenolone formed per nmole P-450 per minute. It was desirable for the P-450
steroid labeling studies to have as little other protein in the incubation mixture as possible.
Adrenodoxin reductase, glucose-6-phosphate dehydrogenase and catalase are only used in
small amounts. Adrenodoxin, on the other hand, is used in excess to insure a maximal rate
of turnover since the delivery of electrons to the P-450 by adrenodoxin is the rate limiting
131
step in the reaction. A study of the adrenodoxin dependence of the turnover rate showed
that anything less than a two-fold excess of adrenodoxin resulted in a reduced turnover rate
under our conditions.
For inhibition studies the cholesterol was replaced by inhibitor in the assay mixture
and the entire assay mixture was made three times more concentrated. The
SCC/adrenodoxin ratio was also increased to 0.5 (ranges from 0 to 0.125 were used in the
activity assays). The purpose of this modification was to expedite the further processing of
the inhibitor-labeled SCC.
Glucose-6-phosphate dehydrogenase, glucose-6-phosphate, cholesterol, MOPS,
NADPH and catalase were purchased from Sigma. Cholesterol was recrystallized two
times from methanol/ethanol prior to use. Radioactive cholesterol and pregnenolone were
purchased from New England Nuclear and purified by analytical thin-layer chromatography
versus authentic standards before use. Inhibitors were prepared as described below.
Synthesis and Characterization of Inhibitors
All three inhibitors used in this study were synthesized by the same method using
different alkynes (Scheme 4):(12 ' 13)
To a stirred solution of aLkyne (6 equiv.) in freshly distilled tetrahydrofuran under
nitrogen at -78 C was added dropwise a solution of n-butyl lithium in hexanes (5 equiv.).
The solution was stirred 10 min, followed by addition of pregnenolone (1 equiv.). in dry
tetrahydrofuran. The reaction was allowed to warm to room temperature and was
monitored by TLC. The reaction was generally complete after 40 minutes. The reaction
was quenched with water, extracted with ethyl acetate, dried over sodium sulfate and
evaporated to dryness. The crude product was recrystallized from ethyl acetate and
hexanes. 1H-NMR was used to prove structure and purity.
Larger excesses of alkyne and butyllithium were used when synthesizing the
radioactive inhibitors, but it is critical that an excess of alkyne is used over the butyllithium,
and sufficient time is allowed for the reaction between the two, otherwise residual
butyllithium can react with the pregnenolone leading to side products. The reaction is
otherwise the same except the crude product was purified by analytical TLC.
20-(1,5-hexadiynyl)-5-pregnen-3,20c-diol (5, 20-HDY) was synthesized by me.
NMR matched that reported by Nagahisa.(l3)
Two batches of tritium labeled 20-HDY were used in this study. The first was
synthesized by Nagahisa in 1983 and repurified by me using TLC. Specific activity was
determined using a microgram balance and scintillation counting to be 5.3 nCi/nmol. Later
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1. n-Butyl Lithium, 0.8 equiv.
a second batch was synthesized by me having a specific activity of 800 nCi/nmol, this was
diluted with cold inhibitor as needed for labeling studies.
20-(1-hexynyl)-5-pregnen-3f3,20x-diol (3, 20-HY) was synthesized by E. Miao in
1989. NMR of that material showed it to be pure and undegraded.
4-[ 14 C]-20-HY was synthesized by me and had a specific activity of 56 nCi/nmol.
20-(4-methyl-1-pentynyl)-5-pregnen-33,20-diol (4, 20-MPY) was synthesized
by S. Joardar in 1989. NMR of that material indicated it to be pure and undegraded. No
isotope-labeled version of this compound was used in these studies.
The alkynes (1,5-hexadiyne, 1-hexyne and 4-methyl-1-pentyne) were supplied by
Lancaster Synthesis Ltd. 7-[ 3H]-pregnenolone and 4-[14 C]-pregnenolone were purchased
by New England Nuclear. n-butyllithium was purchased from Aldrich.
Measurement of Covalent Attachment of Inhibitor to Protein
In order to show covalent attachment of inactivators to the protein three types of
experiments were performed:
1) Dialysis. Enzyme incubated with inhibtors was dialyzed against cholesterol-
containing buffer in a micro-dialysis cell. The cell was constructed from of a 500pIL
Eppendorf tube, in the cap of which had been bored a 5mm diameter hole. A small square
of dialysis tubing was placed over the mouth of the tube and the bored cap was closed over
it. The tube was then placed in a styrofoam block floating inverted in the dialysis buffer.
A pasteur pipette bent into a U-shape was used to remove any air bubbles obstructing the
dialysis fluid from the dialysis membrane. After several changes of buffer the residual
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Scheme 4: Synthesis of (20R)-(l-hexadiynyl)-pregn-5-en-3 P,20-diol
(20-HDY, 5) from pregnenolone and 1,5-hexadiyne
activity was measured by the turnover assay described above versus non-
inhibited(dialyzed) and inhibited(non-dialyzed) and non-inhibited(non-dialyzed) controls.
2) Hydroxyapatite chromatography. After incubations with radioactive inhibitor the
protein mixture was diluted with low-salt, detergent containing buffer and applied to small
(pasteur pipette) columns of hydroxyapatite equilibrated in that buffer. When the non-
bound inhibitor ceased eluting from the column with low-salt washes (scintillation counting
returned to baseline) the protein was eluted with high-salt buffer. The residual radioactivity
in the protein fraction was measured by scintillation.
3) Acetone/HCl protein precipitation. (A similar procedure has been used to
prepare apo-P- 4 50cam free of heme and steroid(13' 30)). An aliquot of SCC-inhibitor
incubation was quenched into a tube containing 1 mL of ice-cold acetone/HCl (500:1),
vortexed, and placed on ice for 15 min. The resulting precipitate was centrifuged and the
supernatant decanted. This was repeated until the supernatant showed no residual
radioactivity (usually 2-3 washes). Sometimes the resulting pellets were unable to be
resuspended by vortexing, so they were sonicated in a sonication bath. The final pellet was
dissolved in 6 M Guanidine/HCl buffer (pH 7.0) and counted by scintillation. Nagahisa
reported the protein recovery in this technique to be 78%.(13)
Cleavage of Inhibitor-labeled SCC into two Fragments, (1i and ()2, by
Trypsinolysis and Separation of these Fragments for Analysis
The following procedures are modifications of those reported by Chaschin.( 1' 6, 7)
Trypsin was added directly to the enzyme inhibition incubations after they had cooled from
37 C to 25 C. A 1:30 trypsin:SCC molar ratio was used, and the mixture was allowed to
react 15-20 minutes with occasional swirling of the reaction tube. The reaction was then
quenched by the addition of 2pL trypsin inhibitor on agarose beads for every lg of
trypsin used. The trypsinized mixture is centrifuged to remove the trypsin-trypsin
inhibitor-sepharose complex and the supernatant is diluted 4-fold with low-salt, detergent-
containing buffer and applied to a pipette column of hydroxyapatite. The column is washed
free of excess inhibitor with low salt buffer and then the proteins are eluted with high-salt
buffer. SDS-PAGE of an aliquot of the mixture at this time shows nearly quantitative
conversion of the SCC to two fragments at approximately 27 and 22 kilodaltons (1 and
02, respectively). The protein solution is adjusted to 1 M NaCl and 1 mM EDTA and then
applied to a column of "activated" thiopropylsepharose 6B at a flow rate of 1 mL/min.
After washing with high-salt buffer and then low-salt buffer, the 01 fragment is eluted from
the column using guanidine buffer (50 mM potassium phosphate, 0.1 mM EDTA, 7 M
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guanidine-HC1, pH 7.2) and then the remaining bound 02 fragment is released using the
same buffer containing 0.1 M 3-mercaptoethanol. SDS-PAGE shows only small cross-
contamination of the two fragments by each other. (This technique is based on the
convenient circumstance that SCC possesses only one surface cysteine which serves to
crosslink the protein to the thiopropyl sepharose. The guanidine unfolds the protein,
releasing fragment 1, which is not covalently attached to the column support)
Trypsin, trypsin inhibitor-sepharose and activated thiopropyl sepharose were
purchased from Sigma. SDS-PAGE was performed using the Phast system from
Pharmacia.
Results
Inactivation by Various Alkyne-Containing Steroids
Nagahisa reports a -60% loss of residual activity when the inhibitor 20-HY (3) is
incubated with SCC ([SCC]=1.3 [tM, [20-HY]=18 gM) under turnover conditions for 1
hour compared with SCC incubated for 1 hour without added steroid. Under the
conditions used here ([SCC]=4 gM, [20-HY]=100 gtM) for 2 hours compared to SCC
incubated for 2 hours in the presence of cholesterol followed by dialysis and then turnover
assay, only a 39% loss of activity is observed. The inhibitor 20-MPY (4) results in a 50%
loss of activity under these conditions. However, this experiment was only done once,
and it was noted at the time that the recovery of steroid from the incubations was quite low,
probably due to excessive warming of the extracts while evaporating the methanol, and
thus the reliability of these numbers is questionable.
Since the 20-MPY inhibitor had not been evaluated before, we performed the
following experiment to prove that the inactivation of the enzyme was turnover dependent
and covalent. Pre-incubation was carried out with cholesterol or with the inhibitor and each
was divided into two incubations, one with NADPH the four ancillary enzymes of the
turnover mixture and one without these. All of these were incubated for 2 hours, dialyzed
against cholesterol-containing buffer and assayed for residual activity. The results showed
clearly (see Table 1) that the inhibition by 20-MPY is dependent on the turnover of the
enzyme. The somewhat lowered activity of the incubation with inhibitor but without the
electron-supplying system (NADPH, etc.) suggests that some inhibitor remained bound to
the enzyme even after dialysis and was able to subsequently inhibit the enzyme. In stark
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contrast to the earlier results , these results suggest an 89% loss of activity due to this
inhibitor (compared to 50% earlier, see previous paragraph).
The 86% labeling of SCC by the diyne inhibitor 20-HDY (5) after 2 hours (10-fold
excess of inhibitor over enzyme) reported by Nagahisa in his thesis(l3) was confirmed by
repetition of his experiment. Here, a 46-fold excess of inhibitor was used in a two-hour
incubation. After the incubation the mixture was subjected to the acetone-HCl precipitation
experiment (see above) and the resulting guanidine extract indicated roughly 95% labeling
of the protein. (This experiment was carried out using the sample of tritium-labeled 20-
HDY synthesized in 1983 which was repurified and whose specific activity was measured
manually. Thus the accuracy of this determination depends on the accuracy with which that
number was determined, which is estimated at only 20%.) In a separate experiment it
was confirmed that this labeling is dependent on turnover; incubations lacking NADPH in
the turnover mixture resulted in no label incorporated into the protein phase as tested by the
acetone-HCl precipitation experiment.
In contrast to this result, incubation with 1 4C-labeled 20-HY (3), the linear side-
chain monoyne inhibitor, yielded only 9.6% protein labeling.
Localization of the Site of Labeling to one of the Two Tryptic
Fragments, 41 or 2
The experiments to localize the site of labeling on the protein to either the 71 or 42
tryptic fragments proved to be considerably less straightforward that was initially projected.
Two methods were used to estimate the amount of radioactivity in each of these fragments;
thiopropyl-sepharose covalent chromatography and SDS gel electrophoresis. In these
experiments a freshly synthesized sample of tritium-labeled 20-HDY (5) was used.
Unexpectedly, the radioactivity incorporated into SCC was about 10-fold lower using this
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Table 1
Activity (nmol / Std. Dev. ofTrial Steroid NADPH, etc.
nmol min-1) mean (Sn)
A Cholesterol Present 6.11 0.27
B Cholesterol Absent 6.42 0.39
C 20-MPY (5) Present 0.66 0.16
D 20-MPY (5) Absent 4.49 0.43
batch of inhibitor. Several possibilities present themselves to account for this discrepancy.
The most likely is a factor-of-ten error in the amount of cold carrier that was added during
the synthesis. Other possibilities are that some component of the turnover mixture had
degraded or that the inhibitor is contaminated with another compound which inhibits but
does not covalently label the enzyme. We pressed on with these experiments because the
amount of label that was incorporated into the protein was sufficient to answer the relevant
questions. Considering these circumstances, these experiments should be reconfirmed by
future researchers.
SCC was incubated with 20-HDY (5) and the resulting mixture was applied to a
hydroxyapatite column after 10 times dilution with low salt buffer. The excess steroid was
washed off, and the protein was eluted with high salt buffer. As a control, this sample was
applied to thiopropyl sepharose without trypsinolysis. The solution was diluted with high
salt thiopropyl sepharose buffer and applied to the column at a low flow rate.
Nevertheless, approximately one-third of the- radioactivity flowed through the column
unbound. The possibilities for explanation of this unbound fraction include: lability of the
steroid adduct, chemical modification of the lone surface cysteine of some of the protein
molecules, a sub-population of protein which is abnormally folded such that the surface
cysteine is buried or shielded from reaction, disulfide formation between SCC molecules
resulting in an inaccessible disulfide, the flow rate was too high for the disulfide exchange
rate or residual aggregation of SCC molecules even in 1M salt. Lack of sufficient
thiopropyl sepharose was ruled out as a possibility. Elution with guanidine released
another 30% of the total radioactivity while elution with [-mercaptoethanol released 37%.
Since the sample was not trypsinized the radioactivity released in the guanidine fraction
must result from either steroid which had been labilized but not yet released from the
enzyme active site, or the aggregation of unbound SCC molecules with bound SCC
molecules. When the same experiment was repeated with sample which had been
trypsinized (as described above), the same distribution of label in the three fractions was
observed. The only way this is possible (besides the failure of the trypsinolysis to cleave
the protein at all), is if the label is localized to the 02 fragment, the one which is released in
the 3-mercaptoethanol fraction. It had been originally planned to use the
thiopropylsepharose technique as a purification step to remove nearly half of the SCC
molecule prior to exhaustive proteolysis and HPLC purification of the labeled fragment (see
below). The results discussed above were discouraging because of the partitioning of the
label into three different fractions. Additional study is required on the cause of this
inefficiency.
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In the SDS-PAGE experiments it was found that it was extremely difficult to count
any tritium from a slice of polyacrylamide in scintillation cocktail. After several trails it was
found that boiling the gel slices in 3.33 N NaOH followed by boiling in an SDS and 3-
mercaptoethanol solution and neutralization of the solution with HC1, that a small amount
of the radioactivity could be labilized (-15%). Thus, SCC was incubated with 20-HDY
(5), trypsinized, rinsed free of excess steroid by hydroxyapatite chromatography,
concentrated to a small volume using a mini-centrifugal membrane concentrator cell
(Ultrafree-MC from Waters), mixed with Laemmli buffer concentrate and boiled briefly.
This solution was loaded onto a Phast-system mini gel and the proteins were separated by
electrophoresis. The molecular weights were marked by pre-stained standards which had
been previously calibrated with the 27 and 22 kilodalton tryptic fragments. Without
staining of the gel, regions of the protein-loaded lanes corresponding to the two fragments
were excised and subjected to the extraction treatment outlined above. Results indicate that,
after subtracting a background radioactivity level on the gel, that the radioactivity in
fragment 02 (22 kDa) is greater than that in fragment 01 (27 kDa) by a factor of roughly 6
to 18. This is in qualitative agreement with the results from thipropylsepharose
chromatography.
Although both of these methods are far from decisive, they both tend towards the
conclusion that the label is solely associated with the 02 fragment. This fragment has been
identified by sequencing to be the C-terminal portion of the molecule, the site of the heme-
binding region and, according to modeling based on the P-4 50cam structure by
Vijayakumar(28) and Joardar,(9) the location of helix I which Joardar predicts to be the
likely site of alkynyl inhibitor covalent labeling (see above).
Experiments towards the Identification of the Precise Location of the
Steroid Adduct
The possible lability of the steroid adduct continued to be a concern throughout
these experiments. Various conditions were assayed for their ability to labilize the adduct,
but none could be pinpointed as particularly detrimental. Nevertheless, there seemed to be
a constant, slow decline in the amount of radioactivity associated with the protein fraction
with time and experimental manipulations. This point also requires further study.
In order to break the protein into pieces of moderate size the endoproteinase (Glu-
C, Protease Type XXXV) from Staphylococcus aureus V8 has been used by Chashchin
and coworkers. (4' 5) This treatment results in the formation of 18 peptide fragments from
fragment 2 (and another 24 from fragment 1 if it has not been separated first). This
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reference suggests that prior maleylation of the lysine groups of the peptide improves the
production of non-overlapping peptides by the endoproteinase by unfolding the protein and
exposing the entire peptide to digestion.
An initial experiment on [3H]-steroid-labeled 02 fragment purified by thiopropyl
sepharose used the maleylation conditions suggested by Butler and Hartley.(3) This
required the concentration of the guanidine and P-mercaptoethanol-containing solution
using a centrifugal membrane concentrator. This concentrate was diluted with carbonate
buffer and maleic anhydride was added. The reaction mixture was again concentrated in
preparation for proteolysis. Counting of an aliquot of this solution, however, indicated that
less than 10% of the original radioactivity remained in the concentrate. About half of the
radioactivity was found in the final concentration filtrate. The remaining 40% was
unaccounted for, although the first filtrate was not examined. Explanations include
cleavage of the label by the f3-mercaptoethanol, or adsorption of the hydrophobic steroid-
peptide conjugate to the concentration membrane. Previous control experiments had shown
that the maleylation conditions did not promote label cleavage, and during the SDS-PAGE
experiments (see above), it was found that brief boiling with -mercaptoethanol-containing
solutions similarly had no effect. This seems to be the last major hurdle to overcome
before the proteolysis and HPLC separation of the label-containing peptide can be
accomplished.
In order to optimize the conditions for the maleylation of SCC several spectroscopic
experiments were carried out. The focus of these experiments was to find conditions
which were suitable for maleylation, proteolysis with the endoproteinase and HPLC and
which would not cause precipitation of the protein. In this way it was hoped to minimize
the number of manipulations required prior to the HPLC analysis. To monitor the progress
of the maleylation the Soret band of the heme in P-450 at 418 nm was monitored. Buffers
containing 250 mM potassium phosphate, 0.25% cholate and various concentrations of
acetonitrile were found to be particularly effective. The endoproteinase is effective up to
10% acetonitrile without a decrease in activity. 250 mM phosphate is sufficient to buffer
the maleic acid formed by the hydrolysis of maleic anhydride, in this way there is no need
to change buffers from carbonate to phosphate when moving from the maleylation to the
proteolysis. As the maleylation progresses the Soret band shifts towards shorter
wavelengths indicating that the heme is being exposed to a less hydrophobic environment.
Increasing the amount of acetonitrile in the solution accentuates this shift and speeds up the
transition. To further assay whether the heme pocket of the protein has been completely
unfolded, the circular dichroism (CD) spectrum of the protein was measured during the
course of the reaction (using a Jasco J-500C spectrophotometer). Prior to addition of the
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maleic anhydride the CD spectrum of P-450scc in 250mM phosphate and 0.25% cholate (no
acetonitrile, so that the reaction will be slow enough to monitor) was measured between
330 and 440 nm. Two peaks, one at -346 nm, another at -410 nm were observed. The
molar ellipticity calculated from the more intense band at 410nm was found to be 58,300.
After addition of the maleic anhydride the peak begins to disappear, and is undetectable by
one hour. Thus, after maleic anhydride treatment the heme is not only in a less
hydrophobic environment (shifted to shorter wavelengths), but is in an achiral environment
as well, i.e. it has been extruded into the bulk solution.
Discussion: Future Studies
Interspersed throughout the text of this chapter have been inserted notes as to where
certain experiments are in need of repetition or elaboration. The nature of the problem with
the poor labeling by the freshly synthesized diynyl inhibitor is most bothersome and must
be resolved before any of the conclusions discussed here can be found anything more than
tentative. The most conservative course here is probably warranted, these experiments
should be repeated with proteins of the highest purity available and all radio-labeled
inhibitors should be purified by HPLC methods. A technique that was never applied to
these experiments, but should have been, is the addition of cold carrier inhibitor after the
conclusion of every radio-incubation to assist in the stripping of non-covalently bound
inhibitor. A thorough kinetic analysis of the three inhibitors should be carried out under
identical conditions to those reported earlier for comparison, and the observation that the
mono-yne inhibitors do not label the protein efficiently needs to be confirmed and
correlated with their inactivation rates to determine a partition ratio (number of inactivation
events over number of covalent attachment events). The possible covalent attachment of
these inhibitors to the heme group needs to be investigated.
The observation that the monoyne inhibitors do not result in covalent protein
labeling while the diynes do is cause for speculation. The possibility exists that the
modification of the protein may be mediated by an intramolecular activation of the terminal
alkyne by the P-450-activated internal (disubstituted) alkyne of the diyne. All evidence
from the literature suggests that terminal alkynes and alkenes cause modification of the
heme group by N-alkylation, while internal alkynes and alkenes result in isolable oxidized
products without covalent attachment.( 20 22' 24) Intramolecular chemistry requires that the
diynyl side-chain be bound in the active site in a recurved orientation indicating a transoid
torsion about the 3'-4' single bond in the side chain. This conformation and several
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Scheme 5: a) a conformation of the inactivator 20-HDY (5) bringing the two alkyne groups in
close proximity. b) Some possible reaction pathways involving covalent labelling of the enzyme,
the iron-ligated enols of the products are shown, each has a corresponding unsaturated ketone
form. Other pathways based on radical or carbene mechanisms are possible, as well. c) The two
proposed enediyne inhibitors discussed in the text.
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possibilities for the relevant chemistry are shown in Scheme 5a and b. Through these
mechanisms the chemically reactive species is moved several angstroms away from the iron
atom towards, presumably, the active site residues of the protein. The question of the
conformation of the bound side chain of cholesterol derivatives in the active site of SCC
should be answerable via the synthesis of inhibitors with conformationally restricted
groups such as, for instance, cis- and trans- enediynes (Scheme 5c, (9) and (8),
respectively). One would expect that the trans enediyne would have a stronger binding
interaction if this type of intramolecular mechanism is in effect. In addition, these enediyne
inhibitors may prove to be excellent mechanism-based inhibitors.
142
References
1. Akhrem, A.A., et al., Structural Organization of the 20S,22-Cholesterol-
hydroxylating Cytochrome P-450 from the Mitochondria of the Adrenal Cortex. I.
Globular Structure of Cytochrome P-450 and its Spectrally Differing Forms by Limited
Proteolysis. Bioorganic Chemistry (english edition), 1980. 6(2): p. 148-156.
2. Bradford, M., Anal. Biochem., 1976. 72: p. 248.
3. Butler, P.J.G. and B.S. Hartley, Maleylation of Amino Groups. Meth. Enz.,
1972. 25: p. 191-199.
4. Chashchin, V.L., et al., Primary structure of 20S,22R-Cholesterol-hydroxylating
Cytochrome P-450 from the Mitochondria of the Bovine Adrenal Cortex. III. An
investigation of the structures of the peptides obtained on the hydrolysis offragment 02 by
Staphylococcus aureus Proteinase. 1986..
5. Chashchin, V.L., et al., Primary structure of 20S,22R-Cholesterol-hydroxylating
Cytochrome P-450 from the Mitochondria of the Bovine Adrenal Cortex. II. A study of
the structure of the peptides obtained on the hydrolysis offragment 1 by Staphylococcus
aureus Proteinase. Bioorganic Chemistry (english edition), 1986. 11(4): p. 244-257.
6. Chashchin, V.L., et al., The Domain Structure of the Cholesterol Side-Chain
Cleavage Cytochrome P-450 from Bovine Adrenocortical Mitochondria. Bioch. Biop.
Acta, 1984. 787: p. 27-38.
7. Chashchin, V.L., et al., The Domain Structure of the Cholesterol Side-Chain
Cleavage Cytochrome P-450 from Bovine Adrenocortical Mitochondria: Localization of
the Haem Group and Domains in the Polypeptide Chain. Bioch. Biop. Acta, 1984. 791: p.
375-383.
8. Groh, S.E., et al., Electron Spin Echo Modulation Demonstrates P-450sCc
Complexation. J. Am. Chem. Soc., 1983. 105: p. 7445-7446.
143
9. Joardar, Mapping the Active Sites of Steroidogenic Cytochromes P-4501993,
Massachusetts Institute of Technology:
10. Joardar, S., et al., Mapping the Active Sites of Steroidogenic Cytochromes P-450:
I. Use of EXAFS and ESEEM Spectroscopy in tandem on P-450sec complexed with a
deuterated steroidal sulfoxide to secure distance and orientation information about an
intermediate analog relative to the heme Fe atom. J. Am. Chem. Soc. (submitted), 1994..
11. Miao, E., et al., Cytochrome P-450scc-Mediated Oxidation of (20S)-22-
Thiacholesterol: Characterization of Mechanism-Based Inhibition. J. Am. Chem. Soc.
(submitted), 1994..
12. Midland, M.M., J. Org. Chem., 1975. 40: p. 2250-2252.
13. Nagahisa, A., Mechanism and Inhibition of Cytochrome P-450scc Catalyzed
Production of Pregnenolone from Cholesteroll984, Massachusetts Institute of Technology:
14. Nagahisa, A., et al., Competitive Inhibition of Cytochrome P-4 50 scc by (22R)-
and (22S)-22-Aminocholesterol. J. Biol. Chem., 1985. 260(2): p. 846-851.
15. Nagahisa, A. and W.H. Orme-Johnson, Silicon-mediated suicide inhibition: An
efficient mechanism-based inhibitor of cytochrome P-4 50 scc oxidation of cholesterol. J.
Amer. Chem. Soc., 1984. 106: p. 1166-1167.
16. Nagahisa, A., R.W. Spencer, and W.H. Orme-Johnson, Acetylenic Mechanism-
based Inhibitors of Cholesterol Side Chain Cleavage by Cytochrome P-450scc. J. Biol.
Chem., 1983. 258(11): p. 6721-6723.
17. Omura, T. and R. Sato, The Carbon Monoxide-binding pigment of liver
microsomes. J. Biol. Chem., 1964. 239(7): p. 2370-2378.
18. Orme-Johnson, N.R., et al., J. Biol. Chem., 1979. 254: p. 2103-2111.
19. Orme-Johnson, W.H. and H. Beinert, J. Biol. Chem., 1969. 244: p. 6143-6148.
20. Ortiz de Montellano, P. and K.L. Kunze, Biochem. J., 1981. 20: p. 7266-7271.
144
21. Ortiz de Montellano, P., B.A. Mico, and G.S. Yost, Bioch. Biop. Res. Commun.,
1978. 83: p. 132-137.
22. Ortiz de Montellano, P.R., et al., J. Biol. Chem., 1981. 256(4395-4399).
23. Ortiz de Montellano, P.R., et al., Mechanism-based probes of the topology and
function offatty acid hydroxylases. FASEB Journal, 1992. 6(January): p. 695-699.
24. Ortiz de Montellano, P.R. and K.L. Kunze, Arch. Bioch. Biop., 1981. 209(710-
712).
25. Sugiyama, T. and T. Yamano, FEBS Letters, 1978. 52: p. 145-148.
26. Takikawa, O., et al., Arch. Bioch. Biop., 1978. 190: p. 300-306.
27. Tsubaki, M., et al., Characterization of two cysteine residues in cytochrome P-
450scc: Chemical identification of the heme-binding cystein residue. Bioch. Biop. Acta,
1986. 870: p. 564-574.
28. Vijayakumar, S. and J.C. Salerno, Molecular Modelling of the 3-D structure of
Cytochrome P-450Scc. Bioch. Biop. Acta, 1992. 1160: p. 281-286.
29. Wilson, S.R., et al., (20S)-22-Thiacholesterol: The Design of an Inhibitor for
Cytochrome P-4 50Sc c. J. Am. Chem. Soc. (submitted), 1994..
30. Yu, C.-A., et al., J. Biol. Chem., 1974. 249: p. 94-110.
145
CHAPTER 4
THE DISCOVERY AND SIGNIFICANCE OF
CALPROTECTIN IN RENAL STONES
ASSOCIATED WITH URINARY TRACT INFECTION
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Preface
In the spring of 1991 William Orme-Johnson ("Bill"), a man well known for his
infectious smile, began to frown. At first one might have mistaken it for consternation,
perhaps, or concern about some private matter, but soon there was no mistaking it (even
his graduate students noticed), Bill was not well. Sitting at his place at the head of the
conference table, the frown became a teeth-clenched grimace, and that was promptly topped
with glazed eyes and a bead or two of sweat. The day's speaker spoke nervously on.
Later, so I am told (and by a fairly reliable source), Bill finds his way to the Medical Center
and, bent over like a ski jumper and knees buckling, says, "I'm {gasp fine, {groan) it's
nothing, just..." To which the nurse on duty replies, without much emotion, "Kidney
stone...call the ambulance."
In this way Professor Orme-Johnson found his way into the capable hands of one
Dr. Steven Dretler, M.D., who, after much prodding, poking, irradiating and ultrasonic
shocking declared him to be cured, for now, thank you very much. Ignoring, for the
moment, the jokes by the Harvard Medical School residents when confronted with the
immobilized MIT professor, the ever curious O.J. began to discuss the biochemistry of
kidney stones with the equally curious doctor. The rest, as they say, is history.
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Introduction
Kidney stones (renal calculi) are concretions of inorganic and organic salts that
form in the renal pelvis. Having very much the appearance and consistency of stones or
corals, the condition becomes symptomatic when they reach a size which precludes their
exit from the kidney via the ureter. Blockage of the ureter by a kidney stone causes
extreme pain and, if not passed into the bladder by the peristaltic (spasmodic) action of the
surrounding musculature will result in interruption of the flow of urine from that kidney
resulting in renal damage. If not treated these conditions would result in renal failure and
death. A recent review of the disease and its treatment has been published by Coe, Parks
and Asplin. (14 )
Urinary calculi have been afflicting mankind since recorded history and have been
identified in 7000 year old mummies in the Sudan.(3 6 ) Calculi occur in 2.7% of
Americans, with the highest incidence in the 30-50 year age group, and results in the
hospitalization of 1.6 individuals per thousand yearly.(3 9) The chances of an individual
having a recurrence of the disease are estimated to be as high as 67%. With over 250,000
patients in the United States requiring an interventional treatment for urinary lithiasis yearly
and each treatment costing over seven thousand dollars, the minimum cost for
interventional treatment is 1.7 billion dollars per year. This figure does not include the
100,000+ patients who have a stone episode which requires supportive treatment but no
intervention nor does it take into account lost productive labor. The international incidence
of stone disease, especially in underdeveloped countries, is estimated to be considerably
higher.(l8, 43) However, in the third world countries, if medical care is available, the
clinical stone episode often means an open operation, prolonged illness and, sometimes,
death.
There are not sufficient financial resources worldwide to treat the disease. The only
realistic possibility for the care of these patients is stone prevention. The present
understanding of the processes responsible for stone formation is not sufficient for any
type of reliable preventative regimen to be developed. For years, for instance, medicine
has suggested that patients having suffered from a calcium-containing stone reduce the
amount of calcium in their diet. Recently, however, a thorough study of stone patients has
revealed that, among calcium oxalate stone sufferers, those with lower calcium intake had a
slightly higher incidence of stone episodes.
The ionic species that make up kidney stones are common to normal urine: calcium,
magnesium, phosphate, oxalate, ammonium, carbonate, uric acid and occasionally
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cysteine. Often urine is supersaturated with respect to combinations of these salts,
especially calcium oxalate which is normally four times more concentrated than its
solubility.(l3) Kidney stones are classified by their mineralogical composition.(14) The
most common type (27%) and the physically hardest are stones composed of pure calcium
oxalate. Calcium phosphate is found in several crystal forms such as hydroxyapatite and
brushite as well as amorphous phases and makes up 8% of all stones. These two minerals
are often found together in the same stone (33%). Thus, calcium oxalate is found in 60%
of all stones. Somewhat rarer are stones consisting of uric acid in whole or in part and
cysteine (4% and 4.5%, respectively).
The other major classification of stones is called "infection stones." These consist
of struvite (magnesium ammonium phosphate) often mixed with either hydroxyapatite or
carbonate apatite, and account for 23.5% of all stones.( 2 3) Infection stones are so named
because they are very often associated with infections of the urinary tract. Although
infection stones account for only about one-fifth of all kidney stones, they are responsible
for a disproportionate amount of the number of clinical procedures performed, and these
procedures are generally characterized by a greater number of complications and the
associated mortality and morbidity of affected patients. The reasons for this discrepancy
are two-fold. First, infection stones are often quite large and display a staghorn (multi-
lobed) morphology that fills the convoluted interior space of the renal pelvis. This makes
the treatment and removal of these stones a painstaking process that often requires multiple
techniques to break up and remove the stone fragments from all of the lobes of the pelvis.
This is accompanied by a greater rate of damage to the renal epithelium due to the close fit
between the available space and the stone. Second, since the infection stones often harbor
colonies of the bacteria which initially caused the condition, (4 4 ) if any fragments of the
stone remain behind the stone will generally reform and require additional treatments.(2 1 )
Antibiotic treatment of infected stones is sometimes ineffective because the microorganisms
are so well shielded within the structure of the stone. (9' 19) Furthermore, electron
microscopy studies have indicated that the bacteria themselves may be the source of much
struvite stone material in the form of a "biofilm" of exopolysaccharide and other
constituents which may further protect the microbial colonies.( 33)
The final and rarest type of stone are called "matrix" stones and are characterized by
their softness and very low mineral content compared to other stones. Although this type
of stone has been only occasionally studied, it has been proposed that matrix stones are
very poorly mineralized infection stones since they tend to have similar shapes and internal
structure as other stone types and tend to be associated with struvite and hydroxyapatite.(5)
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A question that comes to mind when one considers the composition of urine is not,
why do stones form, but rather what keeps them from forming with much greater
frequency? Like blood, which is supersaturated with respect to calcium phosphate, urine is
a concentrated solution because of the great selective advantage that is gained by organisms
by minimizing the need for water. Mammals can go far longer without food than water.
Recognizing this need for water conservation, and thus the benefit of giving up as little
water as possible in the passage of wastes, we would expect that, over the course of
evolution, mechanisms will have evolved to specifically handle the possibility of stone
formation in these concentrated urines since such a condition leads to death.
It is reasonable to hypothesize then, that some factor or factors must be released in
the urine which inhibit the formation of stones. These factors should be small molecules or
proteins which have the ability to sequester calculogenic salts as soluble complexes and
thus reduce the free concentration of these salts to below saturation, or alternatively, the
ability to coat the surfaces of forming crystals in such a way that the growth and
aggregation processes are slowed to such an extent that these micro-crystals can be passed
in the urine without incident. It has been long known that urine concentrates have just this
property when assayed for crystal growth under controlled conditions. (2 2 ' 37) Several
proteins have been identified in the last ten years which posses calcium oxalate crystal
growth inhibition activity. These include nephrocalcin, (2' 32) uropontin,(38) "uronic acid-
rich protein" (UAP)(3) and Tamm-Horsfall mucoprotein.( 25) It seems quite clear that the
management of supersaturated salt solutions in humans is multifactorial.
Considering the existence of these various protective mechanisms, kidney stone
formation can be considered to be, at least in some cases, a disorder resulting from the
degradation of one or more of these systems. This might be due to genetic factors (stone
disease does seem to run in some families), secondary to other disease or metabolic
disorder, or due to the interference of some factor with the protective system, something
like a compound in the diet or natural product of a microbe. Thus stone formation would
be due to either the lack of some factor in the urine, or perhaps caused by the presence of a
mutant or altered form of the factor. In the case of calcium oxalate stones, for instance,
nephrocalcin from stone-former urine has been found to be deficient in the modified amino
acid gamma-carboxyglutamate which is believed to be responsible for calcium ion binding
at the surface of growing crystals. A deficiency in the production of an unaltered factor, or
a metabolic condition causing the salts in question to be excreted in amounts too
voluminous to effectively inhibit would result in the factors bound at the crystal surface to
be included in the growing structure of the stone.
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Another class of explanation for stone formation encompasses the possibility of
crystallization promoters in the urine. Clearly, crystallization promoters will not be
proteins selected for this property, but those which posses it as an unfortunate side effect of
some other function. For instance, a protein which is released into the urine to fight a
urinary tract infection might also have the unfortunate property of promoting certain types
of crystal growth (this possibility will be discussed further below in regard to the
experimental work reported in this chapter). Additionally, the mutation or other
modification of a crystallization inhibitor might result in the generation of a crystallization
promoter, especially considering the likelihood that any functional inhibitor would posses
the property of binding to the surface of growing crystals. The dimerization of such an
inhibitor, for instance, might promote the aggregation of crystals to which it bound.
For these reasons, some researchers have followed a program in parallel to the
investigations of urinary proteins possessing crystal growth inhibition properties. In these
explorations, the stones themselves are the source of protein or other factors potentially
responsible for the stone's formation and growth. The difficulty in this type of work is the
tenacious insolubility of these samples and techniques for the extraction of these materials
vary considerably.
All kidney stones contain some proportion of protein. This material was first
observed in 1684 by Anton von Hyde who showed that after all of the crystalline
components of a stone had been dissolved, the gross structure of the stone remained
unchanged. This material was later termed the "matrix" and was first hypothesized to be
composed of protein in 1884 by Meckel von Hemsbach.(1l) Generally this matrix protein
accounts for only 2-5% of the dry weight of a stone, but there is slightly more in struvite
stones and matrix stones average 65% matrix.
Studies have identified proteins that are selectively concentrated in the matrix of
stones relative to the amounts found in urine,(2 6' 30, 35) and that the type of protein found
in the matrix is dependent on the mineralogical type of the stone.(6) This should not be
surprising considering the common biochemical technique of adsorption of proteins onto
hydroxyapatite in order to perform chromatography.
We report below our initial isolation and identification, by N-terminal peptide
sequencing and immunochemical methods, of the anti-microbial, calcium-binding protein
known as calprotectin from a single matrix stone and three struvite infection stones (of the
three that we have investigated thus far). The protein is known by several names and in
several contexts. Although recent convention has assigned the name calprotectin , it is
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perhaps most widely known in medicine as the cystic fibrosis-associated antigen
(CF Ag).(1 0 ) In other contexts it has been known as the leukocyte antigen L1, 1 5)
calgranulin (46 ) and migration inhibitory factor-related protein (MRP).2 7) This protein is
found to be elevated in the serum of cystic fibrosis homozygotes and obligate
heterozygotes,(l0) in the macrophages of rheumatoid arthritis sufferers, (3 4) in the epidermal
scales of psoriasis patients,(8) associated with neoplastic skin diseases,( 2 0 ) inflammatory
disorders and microbial infections as well as in virtually all circulating blood neutrophils
and monocytes in healthy humans,(7) The protein appears to be released at the time of
granulocyte death and thus is concentrated at sites of inflammation and infection where
neutrophil turnover is high. (28 )
The functional protein is believed to be a hetero-dimer that binds two calcium ions
per subunit,( 34) although there have been reports of alternative subunit ratios. Of the two
subunits, the smaller one corresponds to the protein we have N-terminally sequenced. The
larger subunit has been reported to be N-terminally blocked. ( l ) Monoclonal antibodies
have been raised to this protein, and the gene coding for it has been identified in a cDNA
library from human chronic myeloid leukemia (CML) cells.(l6) The primary site of
expression of this protein appears to be in the granulocytes. Evidence has been gathered
showing calgranulin to be an inhibitor of some protein kinases (31) as well as an
antimicrobial agent when released by neutrophils at a site of tissue infection. (4 0)
Significantly, calgranulin has been shown to comprise approximately 45% of the cytosolic
protein in these neutrophils.(17)
The properties of the protein are strongly affected by the local calcium
concentration. (4 5 ) Calprotectin has been reported to associate strongly with the cell
membrane(4) pancreatic elastase( 2 9) and the keratinocyte cytoskeleton.(l2) Further, the C-
terminal section of both subunits of calprotectin have strong homology with small proteins
known as neutrophil-immobilizing factors. It has been suggested that calprotectin may also
posses the ability to direct neutrophils to sites where the protein is bound. These properties
suggest that calprotectin has distinct binding properties which may explain its association
with matrix and struvite stones and lead us to an understanding of its function in the urinary
tract and possible role in renal lithogenesis.
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The Identification of Calprotectin in Renal Stones
Studies on a "Matrix" stone
In October of 1991 an unusual case came to the attention of Dr. Steven Dretler in
his practice at the Department of Urology, Massachusetts General Hospital. This patient
was suffering from a "large-volume, amorphous renal concretion," a matrix stone.
Because of the soft and adherent nature of this material, uroscopic techniques for the
physical removal of the material were unsuccessful as would have been lithotripsy. The
large volume of the stone, present in only one kidney, but nearly occluding passage of
urine from that one, required the intervention of major surgery to remove the material from
the renal pelvis. Unfortunately, even after this procedure, the material began to form again
and eventually it was necessary to remove the patient's kidney entirely. This condition was
rare both in the fact that it involved a matrix stone and in the excessive quantity of material
that was formed.
During the treatment of the patient, however, thanks to the scientific relationship
that had developed between Dr. Dretler and Professor Orme-Johnson, samples of the
matrix material that had been passed in the urine and that which had been surgically
removed were sent to our labs at M.I.T. for analysis. Our initial goal was to identify
conditions which might be applied in vivo to promote the dissolution of this material. Our
rudimentary analysis of the problem was based on the observation that matrix stones
posses a larger proportion of protein than other, harder, stones. Thus, we hoped, with this
particularly soft and apparently fast-growing sample, that basic biochemical knowledge
about the solubilization of proteins could be applied to some good effect. The protein-
protein interactions thus interrupted, the diffuse inorganic phase of the material could be
rinsed from the renal pelvis by irrigation.
The matrix material was prepared as follows. The samples were centrifuged and
the supernatants were decanted away. The pellets were washed twice with distilled water
and lyophilized to dryness in order to get accurate weights of the material.
In order to determine what mechanisms were responsible for the insolubility of the
protein phase of the matrix material we first tried harsh conditions for solubilization,
looking for unambiguous results which we could then modify into a milder regime once we
knew what principles to apply. The various reasons for protein insolubility that we
hypothesized were; 1) disulfide-based crosslinking, 2) aggregation due to hydrophobic
effects, 3) aggregation mediated by the chelation of cations and 4) aggregation by unfolding
and deranged refolding. To attempt to interfere with these mechanisms the solutions listed
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in Table 1 were used with the accompanying results. 1 mL of each solution was added to
10 mg of dried matrix stone material and was warmed to 65° C for one hour. The resulting
solutions were clarified by centrifugation and the resulting supernatants assayed for total
protein by the Bradford dye-binding method (BioRad kit). It is quite apparent that none of
these methods was particularly successful in solubilizing large amounts of protein, in fact,
visual inspection of the pellets after these experiments showed no change in appearance at
all. The best method was the combination of urea (to unfold the protein), P-
mercaptoethanol (to break disulfides), EDTA (to remove cations) and acetic acid.
TABLE 1
Solution Protein (g/mL) % of total weight
6.6gtM EDTA pH 4.5 16 0.02
0.5 M EDTA pH 8.0 54 0.05
0.2 M -mercaptoethanol (ME) 31 0.03
10M Urea 171 0.17
10% acetic acid 127 0.13
50% acetic acid 148 0.14
0.1% SDS, 0.2 M 3ME 76 0.08
0.2 M 3ME, 6.6gM EDTA 32 0.03
0.2 M ME, 8 M urea 154 0.15
6.6gM EDTA, 8.7M urea 146 0.15
10% acetic acid, 0.1M EDTA 60 0.06
10% acetic acid, 18M urea 152 0.15
6.6gM EDTA, 0.2 M 3ME, 6.7M Urea 215 0.22
0.1M EDTA, 0.2 M ME, 10M Urea, 239 0.24
10% acetic acid
The relative ineffectiveness of these treatments suggested that our assumptions
about the protein content of this material might be unfounded. To test this assumption the
solids were incubated with proteinase K (Sigma) in buffer containing 100 mM NaCl, 10
mM Tris (pH 8), 25 mM EDTA and 0.5% SDS at 500 C overnight. After this treatment
centrifugation yielded only trace insoluble material. Thus it appears that in the absence of
protein, the matrix material would be solubilized. What then is holding the proteins
together and causing their insolubility? One possibility is crosslinking via transamidation,
sugar linkages or other covalent modification.
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- 106 Phosphorylase B
- 80 Bovine Serum Albumin
-49.5 Ovalbumin
- 32.5 Carbonic Anhydrase
- 27.5 Soybean Trypsin Inhibitor
- 18.5 Lysozyme
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Figure 1: SDS-PAGE of proteins extracted from struvite and matrix
stone samples using the Phast electrophoresis system on a homogeneous
20% acrylamide gel and stained with coomassie blue (Pharmacia).
Molecular weight markers are Bio-Rad prestained SDS-PAGE standards,
low range; reported molecular weights are approximate due to shifts
caused by the attached dye molecules. Bands a have been identified as the
small subunit of calprotectin by N-terminal peptide sequencing. Band b of
lane 4 (matrix sample) has similarly been identified as lysozyme.
154
The protein that had been solubilized was further analyzed by electrophoresis in
search of clues concerning the composition of the matrix material. The protein-containing
supernatant from the EDTA-3ME-urea extraction was concentrated by trichloroacetic acid
precipitation and separated by SDS polyacrylamide gel electrophoresis using the Phast
mini-electrophoresis system (Pharmacia). Protein bands were visualized with silver nitrate
stain. The most prominent bands on the gel by far were a triplet of low-molecular weight
proteins (apparent molecular weights 6-16 kilodaltons, see Figure. 1, lane 4).
These proteins were not evident in concentrates of the urine passed with the matrix
stone material; that is they were essentially insoluble in urine under the conditions existing
in this patient. Although the protein assays indicated otherwise, it was subsequently found
that the SDS buffer used to dissolve the protein precipitates prior to electrophoresis was
quite effective in solubilizing the proteins directly from the matrix material. This provided a
one-step procedure for electrophoresis of these proteins. The reason for the discrepancy
between the protein assay and the evidence of the stained gels has not yet been determined.
In order to identify these three proteins by amino acid sequencing, a sample of
matrix solid was solubilized in SDS, subjected to electrophoresis, electroblotted onto Pro-
Blott membranes and visualized with Coomassie blue stain. The triplet of protein bands
were excised and subjected to Edman degradation to determine their N-terminal sequences
(analysis performed by the MIT Biopolymers Lab, via standard techniques.) The
degradation failed to yield sequence information with the protein in the first (-16 kDa)
band, most likely due to N-terminal blockage of that protein. The second (middle) band
yielded an N-terminal amino acid sequence identical to that of human lysozyme except for
one leucine residue (amino acid #2) which is reported to be a valine in the human protein
and isoleucine in the baboon protein (Figure 2a). These three amino acids are very similar
in terms of hydrophobicity as well as the nucleotides which code for them and probably
represent a site of allelic variation. This assignment is curious in that human lysozyme has
a molecular weight of 18.5 kDa and this band has an apparent molecular weight of around
10 kDa. The reason for this anomalous electrophoretic behavior has not yet been
determined.
The third (-6 kDa) protein yielded an eighteen amino acid sequence that was exactly
matched by two sequences in the Nbrf database of protein sequences. The first match was
to the protein known as the cystic fibrosis antigen (CFAg), a peptide isolated from the
blood of cystic fibrosis patients and obligate heterozygotes, although this is not the (as of
yet unidentified) product of the defective gene in cystic fibrosis. The second match is to a
protein known as MRP-8 or MIF-related protein (MIF=migration inhibitory factor). A
search of the relevant literature (see introduction) shows that these two proteins have been
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proven to be one in the same. Furthermore, this protein has been known be a number of
other names including leukocyte antigen Ll-light chain, p8, calgranulin B and, as it is now
most commonly called, calprotectin. This protein is reported to consist of 93 amino acids
and have an apparent molecular weight on SDS-PAGE of 8 kDa which is consistent with
Figure 2: Edman degradation N-terminal amino acid sequences of two proteins
extracted from a matrix stone and matching sequences extracted from the Nbrf
database of protein sequences. a) 10 kDa band. xxx stands for unclear
assignments, residues in bold show mismatches. b) 6 kDa band. C. F. Antigen =
cystic fibrosis antigen, CaBP MRP-8 = calcium binding-protein migration
inhibitory factor related protein.
our rough estimates. The protein is almost always associated with a second subunit of -14
kDa (MRP-14, LI-heavy chain, p14, calgranulin A) which is reported to be N-terminally
blocked and thus resistant to Edman degradation. This is consistent with our observation
that the largest band of the triplet, -16 kDa, is also N-terminally blocked and suggests that
this is the larger subunit of calprotectin.
Commercially available monoclonal antibodies to calgranulin (DAKO, Carpenteria
California) were used in an ELISA (Enzyme-Linked ImmunoSorbant Assay) to confirm the
identification of calprotectin in these solids. The assay was performed as follows:
A lyophilized powder of matrix material was added to a plastic vial and blocked
with bovine serum albumin (BSA) in phosphate-buffered saline (PBS). The primary
antibody (mouse anti-calprotectin, 50:1 diluted) was allowed to bind, followed by the
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a)
-10 kDa Band: Lys-Leu-Phe-Glu-Arg-xxx-Glu-Leu-Ala-Arg-xxx-Leu-Lys-Arg-Leu
Human Lysozyme: Lys-Val-Phe-Glu-Arg-Cys-Glu-Leu-Ala-Arg-Thr-Leu-Lys-Arg-Leu
Baboon Lysozyme: Lys-Ile-Phe-Glu-Arg-Cys-Glu-Leu-Ala-Arg-Thr-Leu-Lys-Arg-Leu
b)
-6 kDa Band: Met-Leu-Glu-Leu-Glu-Lys-Ala-Leu-Asn-Ser-Ile-Ile-Asp-Val-Tyr-His-Lys
C. F. Antigen: Met-Leu-Glu-Leu-Glu-Lys-Ala-Leu-Asn-Ser-Ile-ne-Asp-Val-Tyr-His-Lys
CaBP MRP-8: Met-Leu-Glu-Leu-Glu-Lys-Ala-Leu-Asn-Ser-Ile-Ile-Asp-Val-Tyr-His-Lys
secondary antibody, biotinylated goat anti-mouse (cross-reactivity with human serum
eliminated by affinity chromatography, purchased from Pierce). Then a complex of avidin
and biotinylated horseradish peroxidase was allowed to bind to the biotinylated antibody
(Pierce ABC peroxidase kit). Each of these steps was followed by several washes with
BSA in PBS. The amount of calgranulin originally on the surface of the matrix powder
was measured by reacting the reagent ortho-phenylenediamine (OPD) with the bound
peroxidase and hydrogen peroxide. The enzyme catalyzes the conversion of the weakly
colored OPD into a strongly colored product. The amount of colored product produced
was measured spectrophotometrically (A492).
The ELISA clearly shows a positive test versus stringent controls (Table 2). When
the lyophilized matrix powder is serially diluted with an inert carrier (ground glass)
calgranulin can still be detected in one part matrix powder per 100,000. When the primary
antibody is substituted with a blank wash (or extra secondary antibody) there is a low
background response. In the absence of any matrix material (but with the primary
antibody) there is almost no response at all. This study confirms our identification of
calprotectin as a component of these samples.
TABLE 2
Sample Dilution 10 Antibody Response (A 49 2)
Matrix owder - Mouse anti-caprotectin >3
,, 1:10 ," >3
,, 1:100 ,, >3
",, 1:1000 ,, -3
", 1:10,000 ,, 2.6
,, 1:100,000 ,, 2.2
,, 1:1000 None 1.7
Ground Glass - Mouse anti-calprotectin 0.4
The Identification of Calprotectin in Struvite Infection Stones
The notable association of calprotectin with the immune system and especially anti-
microbial defenses (see Background and Significance section, above) as well as our
observation of lysozyme (a granulocyte protein) in the matrix stone material suggested that
calprotectin might be released into the urinary tract as a common defense against urinary
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tract infections. An inquiry into the medical history of the patient who supplied the matrix
material confirmed that the patient had suffered from recurrent Candida infection of the
urinary tract at various times prior to the collection of our samples. Thus, calprotectin
might be expected to be associated with "infection" stones.
Infection stones are composed of struvite (magnesium ammonium phosphate) and
carbonate-apatite which are believed to be undersaturated in normal urine.(2 3 ) In this case
urinary tract infection by urea-splitting bacteria have been widely recognized as a primary
cause of supersaturation. The splitting of urea into ammonium and bicarbonate by the
enzyme urease in these organisms results in the alkalinization of the urine which promotes
both the formation of carbonate from bicarbonate and the relatively insoluble P0 43- from
HP04 2-.(24 ) This rationale has gained general support although notable exceptions exist.
The largest correlation of struvite/carbonate-apatite stones and bacterial infection is only
77%, and in 20% of these stones no urea-splitting organisms could be cultured.(')
Escherichia coli, which does not express urease, has been reported to promote infection
stone formation,(9) and quite often urinary tract infections with urea-splitting organisms do
not result in infection stone formation. These results suggest that the formation of infection
stones is a complex process and that, like the metabolic stones, somatic proteins may play
an important role.
Samples of three struvite stones from three different patients (thanks to Dr. Dretler
and the Massachusetts General Hospital Kidney Stone Center) were analyzed by the
techniques described above. The results were quite similar (but not identical) to those
observed for the matrix stone, except only two low molecular-weight bands were observed
(Figure 1, lane 3). The same pattern of bands was observed in all three samples. In
addition, we considered the possibility of surface contamination of the stones with white
blood cells. All stones were thoroughly washed with distilled water prior to crushing, and
one stone was carefully dissected into "core" and "surface" fractions, both samples showed
the same amounts of protein bands (Figure 1, lanes 2 and 3).
N-terminal sequencing of all three stone samples shows the upper band to be N-
terminally blocked, and the lower one to be the lower molecular weight subunit of
calprotectin. The sequence of the low-molecular weight subunit of calprotectin was found
to be identical in all three samples. Unlike the matrix stone, no lysozyme was observed.
Also differing from the matrix stone sample we were able to completely dissolve the
struvite stones (including the protein matrix) in our urea, EDTA and -mercaptoethanol
solutions. Because of this, we are able to estimate from the optical density of the stained
bands, that approximately 40% of the protein content of these stones consists of
calprotectin. The slight difference in mobility of the calprotectin band (compare bands 3
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and 4 of Figure 1) is presently unexplained but may indicate differences in calcium ion
content of the sample solutions. Presently we have no sequence information for the other
prominant bands observed in these gels, perhaps due to N-terminal blockage.
EDTA, -mercaptoethanol and urea extracts of these struvite stones were serially
diluted and blotted onto nitrocellulose paper which was then probed by the ELISA in much
the same way as described above except the insoluble peroxidase-activated dye 4-chloro- 1-
naphthol (4-CN) was used instead of OPD. The stained nitrocellulose blots were
quantitated by scanning desitometry. The response of this assay under these conditions is
shown in Figure 4. In the absence of a pure standard of calgranulin we cannot calibrate
this assay, although this will be remedied in the near future (see below).
One calcium oxalate monohydrate stone was demineralized by dialysis versus
several changes of 0.025M EDTA over the course of two weeks. The remaining
solids were further extracted by dialysis versus 10% acetic acid and then by boiling
with the EDTA, 3-mercaptoethanol and urea solutions used for the struvite samples
above. Concentrates of all of these extracts were blotted onto nitrocellulose and
assayed by the ELISA method but showed no response above background.
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Figure 4: Standard curve showing linear response range of ELISA for calprotectin by
dot-blot and densitometry with 4-chloro- 1-naphthol peroxidase stain.
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Proposals for Continued Research
Having identified calprotectin as a component of a single matrix stone and three
struvite "infection" stones (of three tested), and having found calgranulin to comprise
approximately 40% of the protein content of these struvite stones, the following
experiments are proposed to further investigate the clinical relevance of this protein to
disorders of the urinary tract. As discussed above, calprotectin has been found to be an
effective bacteriocide and fungicide at physiological concentrations in human serum versus
Candida species, Cryptococcus neoformans, Escherischia coli, Klebsiella species,
Staphlococcus aureus, and Staphlococcus epidermis.(4 2 ) It is believed that the protein,
which comprises up to half of the cytosolic protein of granulocytes but lacks signal
sequences for export, is released at the time of granulocyte lysis. Considering the range of
inflammatory and infectious conditions with which calprotectin has been associated, it
seems likely that this protein finds its way into the renal pelvis as a specific response to
irritation due to the early stages of stone formation at the renal tubules, or as a response to
urinary tract infection. The possibility must also be considered, however, that a protein
such as this which has a high circulating concentration in the serum and is relatively low-
molecular weight may be cleared from the serum at a relatively constant rate by filtration
through the renal glomerulae.
Considering the inflammatory or constant filtration modes of calprotectin release
into the renal pelvis, the possibility exists that calprotectin may yet be found as a
component of the matrix of non-infection stones such as calcium oxalate, calcium
phosphate or other varieties. The reported (above) investigation of a single calcium oxalate
monohydrate stone showed no calprotectin, but presently we are only able to detect down
to about 1/500 of the amount of calprotectin found in a standard sample of struvite after
extraction with EDTA, [-mercaptoethanol and urea. This is in contrast to the 100,000-fold
dilution that was achieved when the solid matrix stone was assayed without extraction.
Very likely the harsh conditions used for the extraction have so denatured or otherwise
altered the protein that it is no longer efficiently recognized by the antibody. Alteration of
the extraction techniques, and use of spectroscopic detection in microtiter plates instead of
the rather crude densitometric quantitation should significantly increase the sensitivity of
this assay. It is expected that stones not associated with urinary tract infections would have
significantly less calprotectin (if any), so this added sensitivity is crucial.
The association of urinary calprotectin levels with urinary tract infection must be
investigated. Using ELISA techniques the urine of patients suffering from various
infection will be compared with normal controls. The effect of calprotectin on several
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common bacteria and fungal species has been investigated in growing cultures under
laboratory conditions. We will extend these investigations to include species common to
the urinary tract in standard culture and growing in urine (it has been reported that the
antimicrobial activity of calprotectin is strongly dependent on the nature of the culture
medium(4 2 )). These results will be correlated with the observed levels of calprotectin in
infected urines. The antimicrobial effect of calprotectin has been found to be reversible by
added zinc. (41 ) and this has prompted the speculation that the protein acts by sequestering
zinc from the growing microbes. Why, in the case of struvite stone-associated infection, is
calprotectin ineffective? The status of trace zinc in infected urines will be investigated as
well as other possibilities for the mechanism of antimicrobial action for calprotectin.
In order to determine whether calprotectin is relevant to the process of renal
lithogenesis, purified calprotectin (either recombinant, or from human blood granulocytes)
will be added to urines supersaturated with respect to the various common stone forming
salts. Many studies have been published detailing the effects, inhibitory and promotive, of
various urinary proteins, and these techniques will be applied to our future work. We will
focus in particular on the process of struvite formation in infected urines.
Often stones are found to be mixtures of different mineral types. Our investigations
of primarily struvite stones will be extended to stones with varying amounts of struvite to
determine the correlation between struvite deposition in particular and calprotectin
incorporation into growing stones.
Finally, we will revisit the original matrix stone sample. The persistent insolubility
of this material continues to be perplexing and, in this way, may be a relevant model for the
equally insoluble matrix of the non-infection stones. The possibility of intermolecular
covalent linkage as the basis for insolubility will be investigated by limited proteolysis and
other chemical digestion methods. Proteolytic fragments will be sequenced in order to
identify some of the component proteins of this material.
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EPIGRAPH
Cytochrome
(with apologies to Simon and Garfunkel)
When I think back on all the crap I learned in Grad school,
It's a wonder I'm still sane at all,
Though the excess of education hasn't hurt me none,
I can read the writing on the cell:
Cytochrome,
They give us those deep red colors,
Give us the greens of summer,
Makes you think all the world's made of heme, oh yeah.
I got an NIH grant,
I'd love to take a spectrograph,
Mamma don't take my cytochrome away.
If you took all the hours I've spent in my lab,
Working without windows day and night,
I know they'd never match my sweet appreciation,
For the healing powers of real sunlight.
Cytochromes,
The give hydroxylations,
Give us respiration,
Makes you think all the world's made of heme, oh yeah.
I've got a touch of frost bite,
From summers in the cold room, So mamma don't take my
cytochrome away!
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